GRAPEVINE LEAFROLL VIRUS PROTEINS AND THEIR USES

Abstract: The present invention relates to an isolated protein or polypeptide corresponding to a coat protein or other polypeptide of a grapevine leafroll virus. The encoding DNA molecule either alone in isolated form or in an expression system, a host cell, or a transgenic grape plant is also disclosed. Another aspect of the present invention relates to a method of imparting grapevine leafroll resistance to grape plants by transforming them with the DNA molecule of the present invention. A method for imparting tristeza virus resistance in citrus plants using the DNA molecule of the present invention is also disclosed.

Description: CTA KVTNE LEAFROLL VTRUS PROTEINS AND THEIR USES This work was supported by United States-Israel Binational Agricultural Research and Development Fund Grant No. US-1737-89 and by the United States Department of Agriculture Cooperative Agreement No. 58-2349-9-01. The Federal Government may have certain rights in the invention. FIELD OF THE INVENTION The present invention relates to grapevine leafroll virus proteins, DNA molecules encoding these proteins, and their uses BACKGROUND OF THE INVENTION The world's most widely grown fruit crop, the grape (Vitis sp. ) , is cultivated on all continents except Antarctica. Major grape production centers are in European countries (including Italy, Spain, and France) , which constitute about 70% of the world grape production (Mullins et al., Bioloσγ of the Grapevine. Cambridge, U.K., University Press (1992) ) . The United States is the eighth largest grape grower in the world. Although grapes have many uses, a major portion of grape production (-80%) is used for wine production. Unlike cereal crops, most of the world's vineyards are planted with traditional grapevine cultivars, which have been perpetuated for centuries by vegetative propagation. Several important grapevine virus and virus-like diseases, such as grapevine leafroll, corky bark, and Rupestris stem pitting, are transmitted and spread through the use of infected vegetatively propagated materials . Thus, propagation of certified, virus-free materials is one of the most important disease control measures. Traditional breeding for disease resistance is difficult due to the highly heterozygous nature and outcrossing behavior of grapevines, and due to polygenic patterns of inheritance. Moreover, introduction of a new cultivar may be prohibited by custom or law. Recent biotechnology developments have made possible the introduction of special traits, such as disease resistance, into an established cultivar without altering its horticultural characteristics. Many plant pathogens, such as fungi, bacteria, phytoplasmas, viruses, and nematodes can infect grapes, and the resultant diseases can cause substantial losses in production (Pearson et al. , Compendium of Gra p niseaπps, American Phytopathological Society Press (1988) ) . Among these, viral diseases constitute a major hindrance to profitable growing of grapevines. About 34 viruses have been isolated and characterized from grapevines. The major virus diseases are grouped into: (1) the grapevine degeneration caused by the fanleaf nepovirus, other European nepoviruses, and American nepoviruses, (2) the leafroll complex, and (3) the rugose wood complex (Martelli, ed. , Graft Traπsmi sπihl Diseasps nf Grapevines. Handbook for Detection and niaqnn < ■■ , FAO, UN, Rome, Italy (1993)) . Grapevine leafroll complex is the most widely distributed of the major diseases of grapes. According to Goheen (Goheen, "Grape Leafroll," in Frazier et al. , eds., Virus Diseases of Small Fruits and Grapevines (A Handbook) , University of California, Division of Agricultural Sciences, Berkeley, Calif, USA, pp. 209-212 (1970) , grapevine leafroll-like disease was described as early as the 1850s in German and French literature. The viral nature of the disease and graft transmission were first demonstrated by Scheu (Scheu, D. D. W inba,u 14:222-358 (1935) . In 1946, Harmon and Snyder (Harmon et al., Prnr. Am. Snr. Hort . Sci. 74:190-194 (1946)) determined the virus nature of White Emperor disease in California. It was later proven by Goheen et al. (Goheen et al., Phytopathology. 48:51-54 (1958)) that both leafroll and "White Emperor" diseases were the same, and only the name "leafroll" was retained. Leafroll is a serious virus disease of grapes and occurs wherever grapes are grown. This wide distribution of the disease has come abouz. through the propagation of diseased vines. It affects almost all cultivated and rootstock varieties of Vi tis . Although the disease is not lethal, it causes yield losses and reduced sugar content. Scheu estimated in 1936 that 80 per cent of all grapevines planted in Germany were infected (Scheu, Mein Winzerb ch. Berlin, Reichsnahrstand-Verlags (1936) ) . In many California wine grape vineyards, the incidence of leafroll (based on a 1959 survey of field symptoms) agrees with Scheu*s initial observation in German vineyards (Goheen et al. , Amer. J. Bnol . Vitic .. 10:78-84 (1959)) . The current situation on leafroll disease appears similar (Goheen, The American PhytopathologiesT Society. St. Paul, Minnesota:APS Press, 1:47-54 (1988) . Goheen estimated that the disease causes an annual loss of about 5-20 per cent of the total grape production (Goheen (1970); Goheen (1988)) . The amount of sugar in individual berries of infected vines is only about 1/2 to 2/3 that of berries from noninfected vines (Goheen (1958) ) . Symptoms of leafroll disease vary considerably depending upon the cultivar, environment, and time of the year. On red or dark-colored fruit varieties, the typical downward rolling and interveinal reddening of basal, mature leaves is prevalent in autumn and is less apparent in spring or early summer. On light-colored fruit varieties, symptoms are less conspicuous, usually downward rolling accompanied by interveinal chlorosis. Moreover, many infected rootstock cultivars do not develop symptoms. In these cases, the disease is usually diagnosed with a woody indicator indexing assay using Vitis vivifera cv. Carbemet Franc (Goheen (1988)) . Ever since Scheu demonstrated that leafroll was graft transmissible, a virus etiology has been suspected (Scheu (1935) ) . Several virus particle types have been isolated from leafrcll diseased vines. These include potyvirus-like (Tanne et al., Phytopathology. 67:442-447 (1977)) , isometric virus- like (Castellano et al. , Vi is. 22:23-39 (1983)) and Namba et al., Ann. Phytnpathol . Snπ. Japan. 45:70-73 (1979)) , and closterovirus-like (Namba, Ar.r.■ Phytopathol . Soc. iTa an . 45:497-502 (1979)) particles. In recent years, however, long flexuous closteroviruses ranging from 1,400 to 2,200 nm in length have been most consistently associated with leafroll disease (Castellano (1983) , Faoro et al. , Riv. Patol . Veg.. Ser TV. 17:183-189 (1981); Gugerli et al. , Rev. SUΪSSP Viticnlt. Arboricult. Hort .. 16:299-304 (1984); Hu et al. , J_ ^ Phytopatho .. 128:1-14 (1990) ; Milne et al . , Phytopathol . y;, r 110:360-368 (1984); Zee et al. , Phytopathology. 77:1427-1434 (1987) ; Zimmermann et al. , J. Phytopathol .. 130:205-218 (1990) . These closteroviruses are referred to as grapevine leafroll associated viruses (GLRaV) . At least six serologically distinct types of GLRaV s (GLRaV-1 to -6) have been detected from leafroll diseased vines (Table 1) (Boscia et al., Vitis. 34:171-175 (1995); (Martelli, "Leafroll," pp. 37-44 in Martelli, ed. , Gra t Transmissible Diseases of Grapevines. Handbook for Detection and Diagnosis. FAO, Rome Italy, (1993)) . The first five of these were confirmed in the 10th Meeting of the International Council for the Study of Virus and Virus Diseases of the Grapevine (ICVG) (Volos, Greece, 1990) . Through the use of monoclonal antibodies, however, the original GLRaV II described in Gugerli (1984) has been shown to be an apparent mixture of at least two components, Ila and lib (Gugerli et al., "Grapevine Leafroll Associated Virus II Analyzed by Monoclonal Antibodies," 11th Meeting of the International Council for the Study nf VTΠIRPR and vims Diseases of the Grapevine, Montreux, Switzerland, pp. 23-24 (1993)) . Recent investigation with comparative serological assays (Boscia (1995) ) demonstrated that the lib component of cv. Chasselas 8/22 is the same as the GLRaV-2 isolate from France (Zimmermann (1990) ) which also include the isolates of grapevine corky bark associated closteroviruses from Italy (GCBaV-BA) (Boscia (1995)) and from the United States (GCBaV-NY) (Namba et al. , Phytopa holo g y. 31:964-970 (1991) ) . The Ila component of cv. Chasselas 6/22 was given the provisional name of grapevine leafroll associated virus 6 (GLRaV-6) . Furthermore, the antiserum to the CA-5 isolate of GLRaV-2 produced by Boscia et ai. (Boscia et al. , Phytopathology. 80:117 (1990)) was shown to contain antibodies to both GLRaV-2 and GLRaV-1, with a prevalence of the latter (Boscia (1995)) . Several shorter closteroviruses (particle length 800 nm long) have also been isolated from grapevines. One of these, called grapevine virus A (GVA) has also been found associated, though inconsistently, with the leafroll disease (Agran et al., Vitis. 29:43-48 (1990) ; Conti, et al. , Phytopathol . Mediterr.. 24:110-113 (1985); Conti et al. , Phvtona ho ogy. 70:394-399 (1980)) . The etiology of GVA is not really known; however, it appears to be more consistently associated with rugose wood sensu lato (Rosciglione at al., Rev. Suisse V t c Arboric. Hortic.. 18:207-211 (1986) ; and Zimmermann (1990) ) . Another short closterovirus (800 nm long) named grapevine virus B (GVB) has been isolated and characterized from corky bark-affected vines (Boscia et al. , Arch. Virol.. 130:109-120 (1993) ; Namba (1991)) . As suggested by Martelli, leafroll symptoms may be induced by more than one virus or they may be simply a general plant physiological response to invasion by an array of phloem-inhabiting viruses. Grapevine leafroll is induced by one (or a complex) of long closteroviruses (particle length 1,400 to 2,200 nm) . Grapevine leafroll is transmitted primarily by contaminated scions and rootstocks. However, under field conditions, several species of mealybugs have been shown vectors of leafroll (Engelbrecht et al., Phytophylactica . 22:341-346 (1990); Engelbrecht et al. , Phvtophylac ca . 22:347-354 (1990) ; Rosciglione, et al. , (Abstract), Phvtoparasi i.ca. 17:63-63 (1989) ; and Tanne, Phytpparasitica, 16:288 (1988)) . Natural spread of leafroll by insect vectors is rapid in various parts of the world. In New Zealand, observations of three vineyards showed that the number of infected vines nearly doubled in a single year (Jordan et al . , llth Meeting cf the International Council for thp Study nf Viruses an Virus Diseases of the Grapevine. Montreux, Switzerland, pp. 113-114 (1993)) . One vineyard became 90% infected 5 years after GLRaV-3 was first observed. Prevalence of leafroll worldwide may increase as chemical control of mealybugs becomes more difficult due to the unavailability of effective insecticides. In view of the serious risk grapevine leafroll virus poses to vineyards and the absence of an effective treatment, there is a need to prevent this disease and the resulting economic losses. The present invention overcomes this deficiency in the art. SUMMARY OF INVENTION The present invention relates to an isolated protein or polypeptide corresponding to a protein or polypeptide of a grapevine leafroll virus. The encoding RNA and DNA molecules, in either isolated form or incorporated in an expression system, vectors, host cells, and transgenic Vi tis or citrus scions or rootstock cultivars, are also disclosed. Another aspect of the present invention relates to a method of imparting grapevine leafroll virus resistance to Vitis scion or rootstock cultivars by transforming them with a DNA molecule encoding a protein or polypeptide of a grapevine leafroll virus. These DNA molecules can also be used in transformation of citrus scion or rootstock cultivar to impart tristeza virus resistance to such cultivars. The present invention also relates to an antibody or binding portion thereof or probe which recognizes the protein or polypeptide or the nucleic acid encoding same. Grapevine leafroll virus resistant transgenic variants of the current commercial grape cultivars and rootstocks allows for improved control of the virus while retaining the varietal characteristics of specific cultivars. Furthermore, these variants permit control of GLRaV transmitted by contaminated scions or rootstocks or by GLRaV-carrying mealybugs or other insect pests. With respect to the latter mode of transmission, the present invention circumvents increasingly restricted pesticide use, which has made chemical control of mealybug infestations increasingly difficult. Thus, the interests of the environment and the economics of grape cultivation and wine making are benefited by the present invention. BRIEF DESCRIPTION OF THE DRAWINGS Figures 1A-1B, illustrates the results of Northern blot hybridization. Figure IB shows that probe made from a clone insert gave positive reaction with itself (lane 3) and to dsRNA from leafroll infected tissues (lane 1) , but not with nucleic acids extracted from healthy grapevines (lane 2) . Lane M contains molecular weight markers (HindiII digested lambda DNA) . Figure 1A depicts an ethidium bromide stained agarose gel before transfer to a membrane. Figure 2 presents an analysis of GLRaV-3 dsRNA by electrophoresis on an ethidium bromide stained agarose gel. P. dsRNA of ca. 16 kb was readily isolated from diseased grapevine (lane 6) , but not from the healthy control (lane 5) . Other samples that were used for control were tobacco mosaic virus dsRNA (lane 1) ; cucumber mosaic virus dsRNA (lane 2) ; pBluescript vector (lane 3) and an insert of clone pC4. λ HindiII digested lambda DNA was used as molecular weight markers (lane M) . Figure 3 is a Western blot of antibodies to GLRaV-3 that reacted to proteins produced by cDNA clones after IPTG induction in E. coli . Similar banding patterns were observed whether a polyclonal (panel A) or a monoclonal antibody (panel B) was used. Lane 1 shows clone pCPlO-1; lane 2, pCP5 ; lane 3, pCP8-4; and lane 4, the native coat protein from GLRaV-3 infected tissue. Lane M is a prestained protein molecular weight marker. Figure 6 shows the cDNA clones containing the coding region for the coat protein of the NY1 isolate of GLRaV-3. Three clones (pCP8-4, pCP5, pC?lC-l) were identified by immunoscreening a cDNA library prepared in lambda ZAP II. Two other clones were aligned after plaque hybridization and nucleocide sequencing. The coat protein ORF is shown bv an arrow in an open rectangle. Figure 5 is the phylogenetic tree generated using results obtained using the Clustal Method of MegAlign program in DNASTAR for the coat protein of GLRaV-3. The coat protein of GLRaV-3 was incorporated into a previously described alignment (Dolja et al. , Ann. Rev. Ph y topathol .. 32:261-285 (1994)) for comparison. The other virus sequences were obtained from current databases: apple chlorotic leafspot virus (ACLSV) ; apple stem grooving virus (ASGV) ; apple stem pitting virus (ASPV) ; barley yellow mosaic virus (BaMV) ; beet yellows closterovirus (BYV) ; diverged copies of BYV and CTV coat proteins (BYV p24 and CTV p27, respectively) ; citrus tristeza virus (CTV) ; grapevine virus A (GVA) ; grapevine virus B (GVB) ; lily symptomless virus (LSV) ; lily virus X (LVX) ; narcissus mosaic virus (NMV) ; pepper mottle virus (PeMV) ; papaya mosaic virus (PMV) ; potato virus T (PVT) ; potato virus S (PVS) ; potato virus M (PVM) ; potato virus X (PVX) ; tobacco etch virus (TEV) ; tobacco vein mottle virus (TVMV) ; and white clover mosaic virus (WcMV) . Figure 6 depicts an analysis of reverse transcription polymerase chain reaction (RT-PCR) to detect GLRaV-3 in a partially purified virus preparation. The original sample concentration is equivalent to 50 mg/μl of phloem tissue (lane 1) which was diluted by 10-fold series as 10 "1 (lane 2) , 10" 2 (lane 3) , 10 "3 (lane 4) , 10 "4 (lane 5), and 10 "5 (lane 6), respectively. The expected 219 bp PCR product was clearly observed up to lane 4, which is equivalent to a detection limit of 10 μg of phloem tissue. Lane 7 was a healthy control. Lane 8 was dsRNA for positive control. Lanes 9-11 were also used for positive controls of purified viral RNA (lane 9) , dsRNA (lane 10) , and piasmid DNA (pC4) (lane 11) as templates, respectively. Lane M contains molecular weight markers (Haelll digested fX 174 DNA) . Figures 7A-7B depicts comparative analysis of Nested PCR with immuno-capture preparations on field collected samples. Using a polyclonal antibcdy to GLRaV-3 for immune-capture, th expected 648 bp PCR product was not consistently observed in the first round of PCR amplification with external primers over a range of samples (lanes 1-7, Figure 7A) . However, the expected 219 bp PCR product amplified by internal primers was consistently observed over all seven samples (lanes 1-7, Figure 7B) . A similar inconsistency is also shown in a sample prepared by proteinase K-treated crude extract (compare panels A to B on lane 8) . With dsRNA as template, the expected PCR products were readily observed in both reactions (compare lane 10 in Figure 7A and 7B) . No such products were observed on a healthy sample (lane 9) . Lane M contained molecular weight markers (Haelll digested fX 174 DNA) . Figures 8A-8B depict comparative studies on the sensitivity of Nested PCR with samples prepared using proteinase K-treated crude extract (Figure 8A, PK Nested PCR) and by immuno-capture preparation (Figure 8B, IC Nested PCR) . Nested PCR was performed on samples with serial 10-fold dilutions of up to 10 "6 in a proteinase K-treated and 10 "β in an immuno-capture preparation. The expected 219 bp PCR product was observed up to 10 "5 in PK Nested PCR and over 10 "8 (the highest dilution used in this test) in IC Nested PCR. A similar PCR product was also observed with dsRNA template but not healthy grape tissues (H. CK) . Lane M contained molecular weight markers (Haelll digested fX 174 DNA) . Figure 9 shows partial genome organization for GLRaV-3 and the cDNA clones used to determine nucleotide sequence. Numbered lines represent nucleotide coordinates in kilobases (kb) . Figure 10 depicts the proposed genome organization of the GLRaV-3 in comparison with three other closterovirus genomes, BYV, CTV, and LIYV (Dolja (1994)) . Homologous proteins are shown by identical patterns. Papain-like proteinase (P-PRO) ; methyltransferase of type 1 (MTR1) ; RNA helicase of superfamily 1 (HELD ; RNA polymerase of supergroup 3 (PL03) ; HSP70-related protein (HSP70r) ; and capsid protein forming filamentous virus particle (CPf) . Figure 11 is the phylogenetic tree showing the amino acid sequence relationship of the helicase of alphaviruses. The helicase domain of GLRaV-3 (291 aa) from the present study is used. The other virus sequences were obtained from current databases (Swiss-Prot and GenBank, release 84.0) . Apple chlorotic leafspot virus (ACLSV) ; broad bean mottle virus (BbMV) ; brome mosaic virus (BMV) ; beet yellow closterovirus (BYV) ; cowpea chlorotic mottle virus (CcMV) ; cucumber mosaic virus (CMV) ,* fox mosaic virus (FxMV) ; lily symptomless virus (LSV) ; lily virus X (LXV) ; narcissus mosaic virus (NMV) ; pea early browning virus (PeBV) ; papaya mosaic virus (PMV) ; poplar mosaic virus (PopMV) ; peanut stunt virus (PSV) ; potato virus S (PVS) ; potato virus M (PVM) ; potato virus X (PVX) ,* strawberry mild yellow edge-associated virus (S Yea V) ; tomato aspermy virus (TAV) ; tobacco mosaic virus (TMV) ; tobacco rattle virus (TRV) ; and white clover mosaic virus (WcMV) . Figure 12 shows the phylogenetic tree for the RNA dependent RNA polymerases (RdRp) of the alpha-like supergroup of positive strand RNA viruses. The deduced amino acid sequence of the RdRp of GLRaV-3 was incorporated into a previously described alignment (Dolja (1994)) for comparison. The other virus sequences were obtained from current databases: Apple chlorotic leafspot virus (ACLSV) ; alfalfa mosaic virus (AlMV) ; apple stem grooving virus (ASGV) ; brome mosaic virus (BMV) ; beet necrotic yellow vein virus (BNYW) ; beet yellow virus (BYV) ; barley stripe mosaic virus (BSMV) ; beet yellow stunt virus (BYSV) ; cucumber mosaic virus (CMV) ; citrus tristeza virus (CTV) ; hepatitis E virus (HEV) ; potato virus M (PVM) ,* potato virus X (PVX) ; raspberry bushy dwarf virus (RBDV) ,- shallot virus X (SHVX) ; Sinbis virus (SNBV) ; tobacco mosaic virus (TMV) ; tobacco rattle virus (TRV) ; and turnip yellow mosaic virus (TYMV) . Figure 13 is the predicted phylogenetic relationship for viral and cellular HSP70 proteins. HSP70-related protein of GLRaV-3 (p59) was incorporated into a previously described alignment (Dolja (1994)) for comparison. The sequences of BYV, CTV, and LIYV proteins were from Agranovsky et al. , J. Gen. Virol.. 217:603-610 (1991), Pappu et al., Virology. 199:35-46 (1994), and Klaassen et al. , Virology. 208:99-110 (1995) , respectively. Only the N-terminal half of beet yellow stunt virus HSP70-related protein (Karasev et al., J. Gen. Virol .. 75:1415-1422 (1994)) is used. Other sequences were obtained from the Swiss-Prot database; their accession numbers are as follows: DNA1_BACSU, Bacillus subtilis (P13343) ; DNAK_ECOLI, Escherichia coli (P04475) ; HS70_CHICK (P08106) ; HS70_ONCMY, Oncorhynchus mykiss (P08108) ; HS70_PLACB, Plasmodium cynomolgi (Q05746) ; HS70_SCHMA, Schiεtosoma mansoni (P08418) ; HS70_XENLA, Xenopus laevis (P02827) ; HS71_DR0ME, Drosophila melanogaster (P02825) ; HS71_HUMAN (P08107) ; HS71_M0USE (P17879); HS71_PIG (P34930); HS74_PARLI, Paracentrotus lividus (Q06248) ; HS74_TRYBB, Trypanosoma brucei (P11145) ; and ZMHSP702, maize gene for heat shock protein 70 exon 2 (X03697) . Figure 14 summarizes the strategies employed in the construction of the plant transformation vector pBinl9GLRaV- 3hsp90-12-3. A plant expression cassette, in the Hindlll- EcoRI fragment containing CaMV 35S-35S promoters-AMV 5' untranslated sequence-43K ORF-Nos 3' untranslated region, was excised from pBI525GLRaV-3hsp90 and cloned into the similarly (restriction enzyme) treated plant transformation vector pBinl9. The resulting clone, pBinl9GLRaV-3hsp90-12-3, is shown. Locations of important genetic elements within the binary piasmid are indicated: BR, right border; BL, left border; Nos-NPT II, plant expressible neomycin phosphotransferase gene; Lac-LAC Z, plant expressible Lac Z gene; and Bacterial Kan, bacterial kanamycin resistance gene. Figure 15 shows the Agro-bacterium-binary vector pGA482G/cpGLRaV-3 , which was constructed by cloning the HindiII fragment of pEPT8cpGLRaV-3 into a derivative of pGA482 and used for transformation via Agrobacterium or Biolistic approach. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to isolated DNA molecules encoding the proteins or polypeptides of a grapevine leafroll virus. A substantial portion of the grapevine leafroll virus genome, within which are a plurality of open reading frames, has been sequenced by the present inventors. One such DNA molecule contains an open reading frame encoding grapevine leafroll virus helicase and comprising the nucleotide sequence corresponding to SEQ ID NO:l. The helicase has an amino acid sequence corresponding to SEQ ID NO:2 and a molecular weight from about 146 to about 151 kDa, preferably about 148.5 kDa. Another such DNA molecule comprises an open reading frame which codes for a grapevine leafroll virus RNA-dependent RNA polymerase and comprises the nucleotide sequence corresponding to SEQ ID NO:3. The RNA-dependent RNA polymerase has an amino acid sequence as given in SEQ ID NO:4 and a molecular weight from about 59 to about 63 kDa, preferably about 61 kDa. Another such DNA molecule comprises an open reading frame which codes for a grapevine leafroll virus hsp70-related protein or polypeptide and comprises the nucleotide sequence corresponding to SEQ ID NO:5. The hsp70-related protein has an amino acid sequence corresponding to SEQ ID NO: 6 and a molecular weight from about 57 to about 61 kDa, preferably about 59 kDa. Another such DNA molecule comprises an open reading frame which codes for a grapevine leafroll virus hsp90-related protein and comprises the nucleotide sequence corresponding to SEQ ID NO:7. The hsp90-related protein has an amino acid sequence corresponding to SEQ ID NO:8 and a molecular weight from about 53 to about 57 kDa, preferably about 55 kDa. Another such DNA molecule comprises an open reading frame which codes for a grapevine leafroll virus coat protein or polypeptide. The DNA molecule comprises the nucleotide sequence corresponding to SEQ ID NO:9. The coat protein has an amino acid sequence as given in SEQ ID NO:10 and a molecular weight from about 33 to about 43 kDa, preferably about 35 kDa. Alternatively, the DNA molecule of the present invention can constitute an open reading frame which codes for a first undefined pro ein or polypeptide. This DNA molecule comprises the nucleotide sequence corresponding to SEQ ID NO:11. The first undefined protein or polypeptide has an amino acid sequence corresponding to that in SEQ ID NO:12 and a molecular weight from about 5 to about 7 kDa, preferably about 6 kDa. Another such DNA molecule constitutes an open reading frame which codes for a second undefined grapevine leafroll virus protein or polypeptide and comprises the nucleotide sequence corresponding to SEQ ID NO:13. The second undefined protein or polypeptide has an amino acid sequence as given in SEQ ID NO:14 and a molecular weight from about 4 to about 6 kDa, preferably about 5 kDa. Another such DNA molecule constitutes an open reading frame which codes for a grapevine leafroll virus coat protein repeat and comprises the nucleotide sequence corresponding to SEQ ID NO:15. The coat protein repeat has an amino acid sequence as given in SEQ ID NO:16 and a molecular weight from about 51 to about 55 kDa, preferably about 53 kDa. Yet another such DNA molecule constitutes an open reading frame which codes for a third undefined grapevine leafroll virus protein or polypeptide and comprises the nucleotide sequence corresponding to SEQ ID NO:17. The third undefined protein or polypeptide has an amino acid sequence as given in SEQ ID NO:18 and a molecular weight from about 33 to about 39 kDa, preferably about 36 kDa. Yet another DNA molecule which constitutes an open reading frame for a fourth undefined grapevine leafroll virus protein or polypeptide comprises the nucleotide seuqence corresponding to SEQ ID NO:19. The fourth undefined protein or polypeptide has an amino acid sequence as given in SEQ ID NO:20 and a molecular weight from about 17 to about 23 kDa, preferably about 20 kDa. Yet another DNA molecule constitutes an open reading frame for a fifth undefined grapevine leafroll virus protein or polypeptide and comprises the nucleotide sequence corresponding to SEQ ID NO:21. The fifth undεfine protein or polypeptide has an amino acid sequence as given in SEQ ID NO:22 and a molecular weight from about 17 to about 23 kDa, preferably about 20 kDa. Yet another DNA molecule of the present invention consitutes an open reading frame for a sixth undefined protein or polypeptide and comprises the nucleotide sequence corresponding to SEQ ID NO:23. The sixth undefined protein or polypeptide has an amino acid sequence as given in SEQ ID NO:24 and a molecular weight from about 5 to about 9 kDa, preferably about 7 kDa. Also encompassed by the present invention are fragments of the DNA molecules of the present invention. Suitable fragments capable of imparting grapevine leafroll resistance to grape plants are constructed by using appropriate restriction sites, revealed by inspection of the DNA molecule's sequence, to: (i) insert an interposon (Felley et al., ize ., 52:147-15 (1987), which is hereby incorporated by reference) such that truncated forms of the grapevine leafroll virus coat polypeptide or protein, that lack various amounts of the C-terminus, can be produced or (ii) delete various internal portions of the protein. Alternatively, the sequence can be used to amplify any portion of the coding region, such that it can be cloned into a vector supplying both transcription and translation start signals suitable for the desired host cell. Variants may also (or alternatively) be modified by, for example, the deletion or addition of nucleotides that have minimal influence on the properties, secondary structure and hydropathic nature of the encoded polypeptide. For example, the nucleotides encoding a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The nucleotide sequence may also be altered so that the encoded polypeptide is conjugated to a linker or other sequence for ease of synthesis, purification, or identification of the polypeptide. The protein or polypeptide of the present invention is preferably produced in purified form (preferably, at least about 80%, more preferably 90%, pure) by conventional techniques. Typically, the protein or polypeptide of the present invention is isolated after lysing or sonication. After washing, the lysate pellet is resuspended in buffer containing Tris-HCl. During dialysis, a precipitate forms from this protein solution. The solution is centrifuged, and the pellet is washed and resuspended in the buffer containing Tris-HCl. Proteins are resolved by electrophoresis through an SDS 12% polyacrylamide gel. The DNA molecule encoding the grapevine leafroll virus protein or polypeptide of the present invention can be incorporated in cells using conventional recombinant DNA technology. Generally, this involves inserting the coding sequence into an expression system to which the DNA molecule is heterologous (i.e. not normally present) . The heterologous DNA molecule is inserted into the expression system or vector in proper sense orientation and correct reading frame. The vector contains the necessary elements for the transcription and translation of the inserted protein-coding sequences as well known in the art. U.S. Patent No. 4,237,224 (Cohen and Boyer) , hereby incorporated by reference, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced, e.g., by transformation, and replicated in unicellular cultures including procaryotes and eucaryotic cells grown in culture. Recombinant genes may also be introduced into virus vectors, such as vaccinia virus. Recombinant viruses can be generated by transfection of plasmids into cells infected with virus. Suitable vectors include, but are not limited to, the following viral vectors such as lambda vector system gtll, gt ES.tB, Charon 4, and piasmid vectors such as P3R322, pBR3 5, PACYC177, pACYC184, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pKC37, pKClOl, SV 40, pBluescript II SK +/- or KS +/- (see Stratagene Cloning Systems Catalog (1993) from Stratagene, La Joila, CA, hereby incorporated by reference) , pQE, pIH821, pGEX, pET series (see Studier et . al . , Gene E pr ssion Technology, vol. 185 (1990) , hereby incorporated by reference) , and any derivatives thereof. Recombinant molecules can be introduced into cells via transformation, transduction, conjugation, mobilization, or electroporation. The DNA sequences are cloned into the vector using standard cloning procedures in the art, as described by Maniatis et al., Molecular Cloning: A Laboratory Manual. Cold Springs Laboratory, Cold Springs Harbor, New York (1982) , which is hereby incorporated by reference. A variety of host-vector systems may be utilized to express the protein-encoding sequence (s) . Primarily, the vector system must be compatible with the host cell used. Host-vector systems include but are not limited to the following: bacteria transformed with bacteriophage DNA, piasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus) ,* and plant cells infected by bacteria or transformed via particle bombardment (i.e. biolistics) . The expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable and well known transcription and translation elements can be used. Different genetic signals and processing events control many levels of gene expression (e.g., transcription and messenger RNA (mRNA) translation) . Transcription of DNA is dependent upon the presence of a promotor, a DNA sequence that directs the binding of RNA polymerase and thereby promotes mRNA synthesis. The DNA sequences of eucaryotic promotors differ from those of procaryotic promotors. Furthermore, eucaryotic promotors and accompanying genetic signals, including enhancer-like sequences and inducible regulatory sequences, may not be recognized in or may not function in a procaryotic system, and, further, procaryotic promotors are usually not recognized and do not function in eucaryotic cells. Similarly, translation of mRNA in procaryotes depends upon the presence of the proper procaryotic signals, which differ from those of eucaryotes. Efficient translation of mRNA in procaryotes requires a ribosome binding site (Shine- Dalgarno (SD) sequence) on the mRNA. This sequence is a short nucleotide sequence that is located before the start codon, usually AUG, which encodes the N-terminal methionine of the protein. The SD sequences are complementary to the 3 ' -end of the 16S rRNA (ribosomal RNA) and promote binding of mRNA to ribosomes by duplexing with rRNA to allow correct positioning of the ribosome. For a review on maximizing gene expression, see Roberts and Lauer, Methods in Enzymology, 68:473 (1979), which is hereby incorporated by reference. Promotors vary in their "strength" (i.e. their ability to promote transcription) . It is generally desirable to use strong promotors in order to obtain a high level of transcription and, hence, expression of the cloned gene of interest. Depending upon the host cell system utilized, any one of a number of suitable promotors may be used. For instance, when cloning in E. coli , its bacteriophages, or plasmids, promotors such as the T7 phage promoter, lac promotor, trp promotor, recA promotor, ribosomal RNA promotor, the P R and P L promotors of coliphage lambda and others, including but not limited, to 2acUV5, oiηpF, Jbla, Ipp, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lacUV5 ( tac) promotor or other E. coli promotors produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted coding seσuence or other inserted nucleic acid. Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promotor unless specifically induced. In certain operons, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D- galactoside) . A variety of other operons, such as trp, pro, etc., have different under regulatory mechanisms. Specific initiation signals are also required for efficient gene transcription and translation in procaryotic cells. These transcription and translation initiation signals may vary in "strength" as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promotor, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in E. coli requires a SD sequence about 7-9 bases 5' to the initiation codon (ATG) to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include, but are not limited to, the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli trp E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used. Once the isolated DNA molecules encoding the various grapevine leafroll virus proteins or polypeptides, as described above, have been cloned into an expression system, they are ready to be incorporated in a host cell. Such incorporation can be carried out by the various forms of transformation noted above, depending upon the vector/host cell system. Suitable host cells include, but are not limited to, bacteria, yeast, mammalian cells, insect, plant, and the like. The present invention also relates to RNA molecules which encode the various grapevine leafroll virus proteins or polypeptides described above. The transcripts can be synthesized using the host cells of the present invention by any of the conventional techniques . The mRNA can be translated either in vi tro or in vivo . Cell-free systems typically include wheat-germ or reticulocyte extracts. One aspect of the present invention involves using one or more of the above DNA molecules encoding the various proteins or polypeptides of a grapevine leafroll virus to transform grape plants in order to impart grapevine leafroll resistance to the plants. The mechanism by which resistance is imparted is not known. As hypothesized, the transformed plant can express the coat protein or polypeptide, and, when the transformed plant is inoculated by a grapevine leafroll virus, such as GLRaV-1, GLRaV-2, GLRav-3, GLRaV-4, GLRaV-5, or GLRaV-6, or combinations of these, the recombinantly expressed coat protein or polypeptide surrounds the virus, thereby preventing translation of the viral DNA. In this aspect of the present invention the subject coding sequence incorporated in the plant can be constitutively expressed. Alternatively, expression can be regulated by a promoter which is activated by the presence of grapevine leafroll virus. Suitable promoters for these purposes include those from genes expressed in response to grapevine leafroll virus infiltration. Additional suitable plant promoters include those which induce downstream gene expression in response to wounding, in response to elicitors and in response to virus infection. In the alternative, a constitutive plant-expressible promoter can be used; it is preferred that the level of gene expression is sufficiently high to provide virus resistance but not so high as to be detrimental to the normal functioning of the cell and tissues in which it is expressed. Immediately upstream of the start of a coding sequence for a GLRaV-3 protein or polypeptide in an expression system (expression vector, for use in plants) it is desired that there be a Kozak consensus for translation intiation (AAXXATGG, where X is any of the four nucleotides) Downstream of the end of the coding sequence for the virus protein or polypeptide, it is preferred that there be a polyadenylation signal functional in plants, such as that from the nopaiine synthase gene, the octopine synthase gene or from the CaMV 35S gene. These sequences are well known in the plant biotechnology ar . The DNA coding sequences and/or molecules of the present invention can be utilized to impart grapevine leafroll resistance for a wide variety of grapevine plants. The DNA molecules are particularly well suited to imparting resistance to Vitis scion or rootstock cultivars. Scion cultivars which can be protected include those commonly referred to as Table or Raisin Grapes, such as Alden, Almeria, Anab-Ξ-Shahi, Autumn Black, Beauty Seedless, Black Corinth, Black Damascus, Elack Malvoisie, Black Prince, Blackrose, Bronx Seedless, Burgrave, Calmeria, Campbell Early, Canner, Cardinal, Catawba, Christmas, Concord, Dattier, Delight, Diamond, Dizmar, Duchess, Early Muscat, Emerald Seedless, Emperor, Exotic, Ferdinand de Lesseps, Fiesta, Flame seedless, Flame Tokay, Gasconade, Gold, Himrod, Hunisa, Hussiene, Isabella, Italia, July Muscat, Khandahar, Katta, Kourgane, Kishmishi, Loose Perlette, Malaga, Monukka, Muscat of Alexandria, Muscat Flame, Muscat Hamburg, New York Muscat, Niabell, Niagara, Olivette blanche, Ontario, Pierce, Queen, Red Malaga, Ribier, Rish Baba, Romulus, Ruby Seedless, Schuyler, Seneca, Suavis (IP 365) , Thompson seedless,, and Thomuscat. They also include those used in wine production, such as Aleatico, Alicante Bouschet, Aligote, Alvarelhao, Aramon, Baco blanc (22A) , Burger, Cabernet franc, Cabernet, Sauvignon, Calzin, Carignane, Charbono, Chardonnay, Chasselas dore, Chenin blanc, Clairette blanche, Early Burgundy, Emerald Riesling, Feher Szagos, Fernao Pires, Flora, French Colombard, Fresia, Furmint, Gamay, Gewurztraminer, Grand noir, Gray Riesling, Green Hungarian, Green Veltliner, Grenache, Grillo, Helena, Inzolia, Lagrein, Lambrusco de Salamino, Malbec, Malvasia bianca, Mataro, Melon, Merlot, Meunier, Mission, Montua de 97/22700 21 Pilas, Muscadelle du Bordelais, Muscat blanc, Muscat Ottonel, Muscat Saint-Vallier, Nebbiolo, Nebbiolo fino, Nebbiolo Lampia, Orange Muscat, Palomino, Pedro Ximenes, Petit Bouschet, Petite Sirah, Peverella, Pinot noir, Pinot Saint- George, Primitivo di Gioa, Red Veltliner, Refosco, Rkatsiteli, Royalty, Rubired, Ruby Cabernet, Saint-Emilion, Saint Macaire, Salvador, Sangiovese, Sauvignon blanc, Sauvignon gris, Sauvignon vert, Scarlet, Seibel 5279, Seibel 9110, Seibel 13053, Se illon, Servant, Shiraz, Souzao, Sultana Crimson, Sylvaner, Tannat, Teroldico, -Tinta Madeira, Tinto cao, Touriga, Traminer, Trebbiano Toscano, Trousseau, Valdepenas, Viognier, Walschriesling, White Riesling, and Zinfandel. Rootstock cultivars which can be protected include Couderc 1202, Couderc 1613, Couderc 1616, Couderc 3309, Dog Ridge, Foex 33 EM, Freedom, Ganzin 1 (A x R #1) , Harmony, Kober 5BB, LN33, Millardet & de Grasset 41B, Millardet & de Grasset 420A, Millardet & de Grasset 101-14, Oppenheim 4 (S04) , Paulsen 775, Paulsen 1045, Paulsen 1103, Richter 99,_Richter 110, Riparia Gloire, Ruggeri 225, Saint-George, Salt Creek, Teleki 5A, Vitis rupestris Constantia, Vi tis California, and Vitis girdiana. There is extensive similarity in the hsp70-related sequence regions of GLRaV-3 and other closteroviruses, such as tristeza virus. Consequently, the GLRaV-3 hsp70-related gene can also be used to produce transgenic cultivars other than grape, such as. citrus, which are resistant to closteroviruses other than grapevine leafroll, including tristeza virus. These include cultivars of lemon, lime, orange, grapefruit, pineapple, tangerine, and the like, such as Joppa, Maltaise Ovale, Parson (Parson Brown) , Pera, Pineapple, Queen, Shamouti, Valencia, Tenerife, Imperial Doblefina, Washington Sanguine, Moro, Sanguinello Moscato, Spanish Sanguinelli, Tarocco, Atwood, Australian, Bahia, Baiana, Cram, Dal au, Eddy, Fisher, Frost Washington, Gillette, LengNavelina, Washington, Satεuma Mandarin, Dancy, Robinson, Ponkan, Duncan, Marsh, Pink Marsh, Ruby Red, Red Seedless, Smooth Seville, Orlando Tangeic, Eureka, Lisbon, Meyer Lemon', Rough Lemon, Sour Orange, Persian Lime, West Indian Lime, Bearss, Sweet Lime, Troyer Citrange, and Citrus trifoliata. Plant tissue suitable for transformation include leaf tissue, root tissue, meristems, zygotic and somatic embryos, and anthers. It is particularly preferred to utilize embryos obtained from anther cultures. The expression systems of the present invention can be used to transform virtually any plant tissue under suitable conditions. Tissue transformed in accordance with the present invention can be grown in vi tro in a suitable medium to impart grapevine leafroll virus resistance. Transformed cells can be regenerated into whole plants such that the protein or polypeptide imparts resistance to grapevine leafroll virus in the intact transgenic plants. In either case, the plant cells transformed with the recombinant DNA expression system of the present invention are grown and express one of the above- described grapevine leafroll virus proteins or polypeptides and, thus, grapevine leafroll resistance. One technique of transforming plants with the DNA molecules of the present invention is by contacting the tissue of such plants with an inoculum of a bacterium transformed with a vector comprising a gene of the present invention which imparts grapevine leafroll resistance. Generally, this procedure involves inoculating the plant tissue with a suspension of bacteria and incubating the tissue for 48 to 72 hours on regeneration medium without antibiotics at 25- 28°C. Cells of the genus Agrobacteriuiπ can be used to transform plant cells and/or plant tissue. Suitable species include Agrobacterium tumefaciens and Agrobacterium rhizogeneε . A. tumefaciens (e.g., strains C58, LBA4404, or EHA105) is particularly useful due to its well-known ability to transform plants, plant tissue and plant cells. Another approach to transforming plant cells with a gene which imparts resistance to pathogens is particle bombardment (also known as biolistic transformation) of the host cell. This can be accomplished in one of several ways. This technique is disclosed in U.S. Patent Nos. 4,945,050, 5,036,006, and 5,100,792, all to Sanford et al. , and in Emerschad et al., P ant Cf>11 Reports. 14:6-12 (1995)) , all hereby incorporated by reference. Generally, this procedure involves propelling inert or biologically active particles at the cells under conditions effective to penetrate the outer surface of the cell and to be incorporated within the interior thereof. When inert particles are utilized, the vector can be introduced into the cell by coating the particles with the vector containing the heterologous DNA. Alternatively, the target cell can be surrounded by the vector so that the vector is carried into the cell by the wake of the particle. Biologically active particles (e.g., dried bacterial cells containing the vector and heterologous DNA) can also be propelled into plant cells. Once grape plant tissue is transformed in accordance with the present invention, it is regenerated to form a transgenic grape plant. Generally, regeneration is accomplished by culturing transformed tissue on medium containing the appropriate growth regulators and nutrients to allow for the initiation of shoot meristems. Appropriate antibiotics are added to the regeneration medium to inhibit the growth of AgroJbacteriuiπ and to select for the development of transformed cells. Following shoot initiation, shoots are allowed to develop in tissue culture and are screened for marker gene activity. The DNA molecules of the present invention can be transcribed into mRNA, which, although encoding a grapevine leafroll virus protein or polypeptide, is not translated to the corresponding protein. This is known as RNA-mediated resistance. When a Vitis scion or rootstock cultivar is transformed with such a DNA molecule, the DNA molecule can be transcribed under conditions effective to maintain the mRNA in the plant cell at low level density readings . Density readings of between 15 and 50 using a Hewlet ScanJet and Image Analysis Program are preferred. The grapevine leafroll virus protein or polypeptide can also be used to raise antibodies or binding portions thereof or probes. The antibodies can be monoclonal or polyclonal. Monoclonal antibody production may be effected by techniques which are well-known in the art. Basically, the process involves first obtaining immune cells (lymphocytes) from the spleen of a mammal (e.g., mouse) which has been previously immunized with the antigen of interest either in vivo or in vitro. The antibody-secreting lymphocytes are then fused with (mouse) myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line. The resulting fused cells, or hybridomas, are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies . Colonies producing such antibodies are cloned, and grown either in vivo or in vi tro to produce large quantities of antibody. A description of the theoretical basis and practical methodology of fusing such cells is set forth in Kσhler and Milstein, Nature. 256:495 (1975) , incorporated by reference. Mammalian lymphocytes are immunized by in vivo immunization of the animal (e.g., a mouse) with the protein or polypeptide of the present invention. Such immunizations are repeated as necessary at intervals of up to several weeks to obtain a sufficient titer of antibodies. Following the last antigen boost, the animals are sacrificed and spleen cells removed. Fusion with mammalian myeloma cells or other fusion partners capable of replicating indefinitely in cell culture is effected by standard and well-known techniques, for example, by using polyethylene glycol (PEG) or other fusing agents. (See Milstein and Kohler, Eur. J. Immunol .. 6:511 (1976) , incorporated by reference.) This immortal cell line, preferably murine, but may also be derived from cells of other mammalian species, including but not limited to rats and humans, is selected to be deficient in enzymes necessary for the utilization of certain nutrients, capable of rapid growth, and having good fusion capability. Many such cell lines are known to those skilled in the art, and others are regularly described. Procedures for raising polyclonal antibodies are also well known. Typically, such antibodies can be raised by administering the protein or polypeptide of the present invention subcutaneously to New Zealand white rabbits which have first been bled to obtain pre-immune serum. The antigens can be injected at a total volume of 100 μl per site at six different sites. Each injected material will contain synthetic surfactant adjuvant pluronic polyols, or pulverized acrylamide gel containing the protein or polypeptide after SDS-polyacrylamide gel electrophoresis. The rabbits are then bled two weeks after the first injection and periodically boosted with the same antigen three times every six weeks. A sample of serum is then collected 10 days after each boost. Polyclonal antibodies are then recovered from the serum by affinity chromatography using the corresponding antigen to capture the antibody. Ultimately, the rabbits are euthanized with pentobarbital 150 mg/Kg IV. This and other procedures for raising polyclonal antibodies are disclosed in Harlow et . al., editors, An bodie<=; ■ A Laboratory Manual (1988) , which is hereby incorporated by reference. In addition to utilizing whole antibodies, binding portions of such antibodies can be used. Such binding portions include Fab fragments, F(ab') 2 fragments, and Fv fragments. These antibody fragments can be made by conventional procedures, such as proteolytic ^ fragmentation procedures, as described in Goding, Monoclonal Antibodies: Pri-nc-iplec- ari Practice. New YorkrAcademic Press, pp. 98-118 (1983) , hereby incorporated by reference. The present invention also relates to probes found either in nature or prepared synthetically by recombinant DNA procedures or other biological procedures . Nucleic acid probes can also be synthesized by manual chemical synthesis (see, e.g., Beaucage and Caruthers (1981) Tetra . T-° t- . 22:1859-1862; MAtteuci et al. (1981) ~, Am. rherr- . ςor- , 103:3185) or by automated chemical synthesis using commercially available equipment (e.g., Applied Biosysterns, Foster City, CA) . Suitable probes are molecules which bind to grapevine leafroll viral antigens identified by the monoclonal antibodies of the present invention. Such probes can be, for example, proteins, peptides, lectins, or nucleic acid probes. The antibodies or binding portions thereof or probes can be administered to grapevine leafroll virus infected scion cultivars or rootstock cultivars . Alternatively, at least the binding portions of these antibodies can be sequenced, and the encoding DNA synthesized. The encoding DNA molecule can be used to transform plants together with a promoter which causes expression of the encoded antibody or binding portion thereof when the plant is infected by grapevine leafroll virus. In either case, the antibody or binding portion thereof or probe will bind to the virus and help prevent the usual leafroll response. Antibodies raised against the proteins or polypeptides of the present invention or binding portions of these antibodies can be utilized in a method for detection of grapevine leafroll virus in a sample of tissue, such as tissue from a grape scion or rootstock. Antibodies or binding portions thereof suitable for use in the detection method include those raised against a helicase, an RNA-dependent RNA polymerase, an hsp70-related, an hsp90-related, or a coat protein or polypeptide in accordance with the present invention. Any reaction of the sample with the antibody is detected using a reporter or other assay system which indicates the presence of grapevine leafroll virus in the sample. A variety of assay systems can be employed, such as enzyme-linked immunosorbent assays, radioimmunoassays, gel diffusion precipitin reaction assays, immunodiffusion assays, agglutination assays, fluorescent immunoassays, protein A immunoassays, or immunoelectrophoresis assays. Alternatively, grapevine leafroll virus can be detected in such a sample using a nucleotide sequence of the DNA molecule, or a fragment thereof, encoding for a protein or polypeptide (or a portion thereof) of the present invention. The nucleotide sequence is provided as a probe in a nucleic acid hybridization assay or a specific gene amplification detection procedure (e.g., using a polymerase chain reaction procedure) . Any reaction with the probe is detected so that the presence of grapevine leafroll virus in the sample is indicated. The following examples are provided to illustrate embodiments of the present invention but are by no means intended to limit its scope. References cited in the Examples are incorporated by reference herein. EXAMPLES Example 1 - Materials and Methods Virus purification and dsRNA isolation. The NY1 isolate, also referred to as isolate GLRaV 109 by Golino, A er. t T. Fπol . V c. 43:200-205 (1992) , a member of GLRaV-3 (Hu et al., J. Phytopathol . fB r . ) . 128:1-14 (1990)) ; Zee et al. , Phytopathology. 77:1427-1434 (1987)) was used throughout this work. Leafroll-diseased canes and mature leaves were collected from a vineyard in central New York State, and kept at -20°C until used. GLRaV-3 virus particles were purified according to the method described by Zee (1987) , and modified later by Hu (1990) . After two cycles of Cs 2 S0 4 gradient purification, virus particles were observed from virus- enriched fractions by negative staining on an electron microscope. The dsRNA was extracted from scraped bark/phloem tissue of canes as described in Hu (1990) . Briefly, total nucleic acid was extracted with phenol/chloroform; dsRNA was absorbed on a CF-11 cellulose column under 17% ethanol and eluted without ethanol. After two cycles of ethanol precipitation, dsRNA was analyzed by electrophoresis on a 6% polyacrylamide or 1% agarose gel. A high Mr dsRNA (-16 kb) along with several smaller Mr dsRNAs was consistently identified in leafroll diseased but not in healthy samples (Hu (1990) . The 16 kb dsRNA, which was presumably a replicative form of the virus, was purified further following separation on a low melting temperature-agarose gel (Sambrook et al., Molecu1 a Clπninα. A τ.ahn-*-atorv Manual . ?nri v. . Cold Spring Harbor Laboratory Press (1989) . The double-stranded nature of the dsRNA was confirmed by its resistance to DNase and RNase in high salt and sensitivity to RNase in water (Hu (1990) . cDNA synthesis and molecular cloning. Complementary DNA (cDNA) was prepared by the procedure of Gubler et al. , Gene r 25:263 (1983) , and modified for dsRNA by Jelkmann et al. , Phytopathology, 79:1250-1253 (1989) . Briefly, following denaturation of about 2 μg of dsRNA in 20 mM methylmercuric hydroxide (MeHg) for 10 min, the first-strand cDNA was synthesized by avian myeloblastosis virus (AMV) -reverse transcriptase using random primers (Boehringer Mannheim, Indianapolis, IN) . The second-strand cDNA was synthesized with DNA polymerase I while RNA templates were treated with RNase H. The cDNA was size-fractionated on a CL-4B Sepharose column and peak fractions, which contained larger molecular weight cDNA, were pooled and used for cloning. Complementary DNA ends were blunted with T4 DNA polymerase, and EcoRI adapters were ligated onto a portion of the blunt-ended cDNA. After treatment with T4 polynucleotide kinase and removal of unligated adapters by spin column chromatography, the cDNA was ligated with lambda ZAPII/EcoRI prepared arms (Stratagene, La Jolla, CA) . These recombinant DNAs were packaged in vi tro with GIGAPACK II GOLD™ packaging extract according to the manufacturer's instruction (Stratagene) . The packaged phage particles were used to infect bacteria, E. coli XLl-blue cells. Screening the cDNA library. To select GLRaV-3 dsRNA specific cDNA clones, probes were prepared from UNI-AMP™ (Clontech, Palo Alto, CA) PCR-amplified cDNA. PCR-amplified GLRaV-3 cDNA was labeled with 32 P [a-dATP] by Klenow fragment of E. coli DNA polymerase I with random primers and used as a probe for screening the library (Feinberg et al., Analy c Ri orhetn.. 132:6-13 (1983)) . Library screening was carried out by transferring plaques grown overnight onto GENESCREEN PLUS™ filters, following the manufacturer's instructions for denaturation, prehybridization, and hybridization (Dupont, Boston, MA) . After washing, an autoradiograph was developed after exposing Kodak X-OMAT film to the washed filters overnight at -80°C. Bacteriophage recombinants were converted into plasmids (in vivo excision) following the manufacturer's instruction, (Stratagene) . Identification of the coat protein gene was done by immunoscreening the cDNA library with GLRaV-3 specific polyclonal (Zee (1987) ) and monoclonal (Hu (1990) ) , antibodies. Degenerate primer (5'GGNGGNGGNACNTTYGAYGTNTCN (SEQ. ID. No. 19) , I=inosine, Y=T or C) generated from a conserved amino acid sequence in Motif C of the BYV HSP70 gene (p65) was used to select HSP70 positive clones. Further sequence extension was made possible by the clone walking strategy, which used sequences that flanked the sequence to probe the library_ for a clone that contained an insert extending farther in either 5' or 3 ' direction. Northern blot hybridization. Inserts from selected clones were labeled with 32 P[a-dATP] by Klenow fragment of E. coli DNA polymerase I (Feinberg (1983) ) , and used as probes to test their specific reactions to dsRNAs isolated from leafroll infected tissues. Double-stranded RNA isolated from GLRaV-3 infected vines was separated by electrophoresis on a 1% agarose gel (nondenatured condition) , denatured with 50 mM NaOH, 0.6 M NaCl for 30 min at room temperature, and neutralized with 1.5 M NaCl, 0.5 M Tris-HCl, pH 7.5 for another 30 min. Denatured dsRNA was sandwich-blotted onto a GENESCREEN PLUS™ membrane. Prehybridization and hybridization were carried out in a manner similar to that described above. The membrane was washed and exposed to Kodak X-OMAT film, and an autoradiograph was developed. Identification of iπmunopositive clones. For immunoscreening, plates with plaques appearing after 8-12 h incubation at 37°C were overlaid with a 10 mM isopropyl-β-D- thio-galactopyranoside (IPTG) impregnated Nylon filters (GENESCREEN PLUS™) and incubated for an additional 3-4 h. After blocking with 3% bovine serum albumin (BSA), the blotted filter was incubated in a 1:1000 dilution of alkaline phosphatase-conjugated GLRaV-3 polyclonal antibody for 3 h at 37°C. Positive signals (purple dots) were developed by incubation of washed filters in a freshly prepared nitroblue tetrazolium (NET) and 5-bromo-4-chloro-3- indolyl phosphate (BCIP) solution. To further confirm whether or not a true GLRaV-3 coat protein expression plaque was selected, a secondary immunoscreening was carried out by reinfection of bacterial XL1 Blue cells with an earlier selected plaque. Western blot analysis. After secondary immunoscreening, GLRaV-3 antibody positive plaques were converted into piasmid, the pBluescript, by in vivo excision. Single colonies were picked up and cultured in LB medium with 100 μg/ml of ampicillin until mid-log growth. Fusion protein expression was induced by addition of 10 mM IPTG with an additional 3 h of incubation at 37°C. Bacteria was pelleted and denatured by boiling in protein denaturation buffer (Sambrook (1989)) . An aliquot of 5 μl denatured sample was loaded and separated by electrophoresis on a 12% SDS-polyacrylamide gel along with a prestained protein molecular weight marker (Bio-Rad, Hercules, CA) . The separated proteins were transferred onto an Immobulon membrane (Millipore) with an electroblotting apparatus (Bio-Rad) . After blocking with 3% BSA, the transferred membrane was incubated with 1:1,000 dilution of either GLRaV-3 polyclonal or monoclonal antibody/alkaline phosphatase conjugate. A positive signal was developed after incubation of the washed membrane in NBT and BCIP. PCR analysis. To analyze a cloned insert, an aliquot of a bacterial culture was used directly in PCR amplification with common vector primers (SK and KS) . PCR-amplified product was analyzed by electrophoresis on an agarose gel. Nucleotide sequencing and computer sequence analysis. Piasmid DNA, purified by either a CsCl method (Sambrook (1989) ) or a modified mini alkaline-iysis/PEG precipitation O 97/22700 31 procedure (Applied Biosystems' Instruction) , was sequenced either with Sequenase version 2 kit following the manufacturer's instruction (US Biochemical, Cleveland, Ohio) or with Taq DYEDΞOXY™ terminator cycle sequencing kit (Applied Biosystems, Inc.) . Automated sequencing was conducted on an ABI373 automated sequencer. Nucleotide sequences were analyzed using a Genetics Computer Group (GCG) sequence analysis software package (Madison, WI) . Sequence fragments were assembled using Newgelstart to initiate the GCG fragment assembly system and to support automated fragment assembly in GCG Version 7.2. Computer-assisted analysis of phylogenetic relationships. Amino acid sequences were either obtained from database Swiss- Prot or translated from nucleotide sequences obtained from GenBank. A phylogenetic tree depicting a predicted relationship in the evolution of the GLRaV-3 coat protein sequence with those of other filamentous plant viruses was generated using the Clustal Method of the DNASTAR's MegAlign program (Madison, WI) . With the Clustal method, a preliminary phylogeny is derived from the distances between pairs of input sequences and the application of the UPGMA algorithm (Sneath et al., Numer cal Taxonomy - The Principles a d Prar-r-ire nf Numerical Taxonomy. Freeman Press (1973)), which guides the alignment of ancestral sequences. The final phylogeny is produced by applying the neighborhood joining method of Saitou et al., Mol . P o . Evol .. 4:406-425 (1987) , to the distance and alignment data. Nucleotide sequence and primer selection. The sequence fragment (Table 16) selected for PCR has now been identified to be from nucleotides 9364 to 10,011 of the incomplete GLRaV- 3 genome (Table 4) . This sequence region encodes a short peptide which shares sequence similarity to HSP90 homologues of other closteroviruses (Figure 1) . Selected primers and their designations are shown in Table 16, which shows the nucleotide and amino acid sequences of a PCR amplified fragment cf the GLRaV-3 genome. The external and internal primers used for PCR are underlined and their orientations are indicated by arrows. Sample preparation. These include 1) dsRNA, 2) purified virus, 3) partially purified virus, 4) proteinase K treated crude extract, and 5) immuno-capture preparation. Isolation of dsRNA from leafroll infected grapevine tissues followed the procedure developed by Hu (1990) . Virus purification was effected by the following procedure. An aliquot of 500 μl GLRaV-3-enriched fractions after two cycles of Cs 2 S0 4 gradient was diluted with two volumes of TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) and incubated on ice for 5 min. The reaction was then adjusted to a final concentration of 200 mM NaAc, pH 5.0, C.5% SDS, and 200 μg/ml proteinase K and incubated at 37°C for 3 h. Viral RNA was extracted with phenol and chloroform, ethanol- precipitated, and resuspended in 50 μl of diethyl pyrocarbonate (DEPC) -treated H 2 0. For each 100 μl PCR reaction mixture, 1 μl of purified viral RNA was used as template. Partially purified virus was prepared according to the virus purification procedure described in Hu (1990) , but only to the high speed centrifugation (27,000 rpm, 2 h) step without further Cs 2 S0 4 gradient centrifugation. The pellet was resuspended in TE buffer and subjected to proteinase K treatment as described above. Viral RNA was extracted with phenol/chloroform and precipitated using ethanol. From 10 g of starting material, the pellet was resuspended in 200 μl of DEPC treated H 2 0. A 1 μl aliquot of extracted RNA or its 10- fold dilution series (up to 10 "s ) was used for reverse transcription-PCR (RT-PCR) . Crude extract was treated with Proteinase K as follows. Liquid nitrogen powdered grapevine bark/phloem tissue (100 mg) was macerated in 1 ml of virus extraction buffer (0.5 M Tris- HCl, pH 9.0, 0.01 M MgS0 4 , 4% water insoluble polyvinyl pyrrolidone (PVP40) , 0.5% bentonite, 0.2% 2-mercaptoethanol, and 5% Triton X-100) (Zee (1987)) . After a brief centrifugation (5,000 rpm, 2 min) , 500 μl of supernatant was transferred into a new tube, adjusted to 100 μg/ml proteinase K, and incubated for 1 h at 55°C (Kawasaki, "Sample Preparation from Blood, Cells, and Other Fluids," in Innis et al., eds, PCR Protocols: A Guide to Methods and Appl i oati one* , Academic Press, Inc. (1990)) . Following incubation, the preparation was boiled for 10 min to inactivate proteinase K and to denature the viral RNA. The upper clear phase was transferred into a new tube after a brief centrifugation. The viral RNA was precipitated with ethanol and resuspended in 100 μl of DEPC-treated H 2 0. An aliquot of 1 μl proteinase K- treated crude extract or its 10-fold dilution series (up to 10 "s ) was used. The immuno-capture procedure was adapted from the method described by Wetzel at al., J. Virol. Meth. 39:27-37 (1992)) . A 0.5 ml thin wall PCR tube was coated directly with 100 μl of 10 μg/ml purified gamma-globulin from GLRaV-3 antiserum (Zee (1987)) in ELISA coating buffer (15 mM Na 2 C0 3 , 35 mM NaHC0 3 , pH 9 . 6 , and 0.02% NaN 3 ) and incubated for 4 h at 30°C. After washing 3 times with PBS-Tween-20, the antibody coated tube was loaded with 100 μl of crude extract (1:10 or its 10-fold dilution series, up to 10 "β ) prepared in ELISA extraction buffer (50 mM sodium citrate, pH 8.3, 20 mM sodium diethyldithiocarbonate (DIECA) , 2% PVP OK) and incubated at 30°C for 4 h. After washing, a 25 μl aliquot of transfer buffer (10 mM Tris, pH 8.0, 1% Triton X-100) was added to the tube and vortexed thoroughly to release viral RNA. RT-PCR. Initially, reverse transcription (RT) and polymerase chain reaction (PCR) were performed in two separate reactions. An aliquot of 20 μl of reverse transcription reaction mixture was prepared to contain 2 μl of 10X PCR buffer (Promega, Madison, WI) (10 mM Tris-HCl, pH 8.3, 500 mM KCl, and 0.01% gelatin), 50 mM MgCl 2 , 2 μl of 10 mM dNTP, 150 J ng of 5' and 3' primers, 16 units of RNasin, 25 units of avian myeloblastosis virus (AMV) reverse transcriptase, and 1 μl of a denatured sample preparation. The reverse transcription reaction was carried out at 37°C for 30 min. After denaturation by heating at 95°C for 5 min, an aliquot of PCR reaction mixture was added. This PCR reaction mixture (80 μl) contained 8 μl of 10X PCR buffer (Promega) , 150 mM MgCl 2 , 250 ng of each 5' and 3' primer, 1 μl of 10 mM dNTP, and 2.5 units of Taq DNA polymerase. The thermal cycling program was set as follows: a precycle at 92°C for 3 min; followed by 35 cycles of denaturation at 92°C, 1 min; annealing at 50°C, 1 min; and extension at 72°C, 2.5 min. The final extension cycle was set at 72°C for 5 min. Because reverse transcriptase functions in the PCR buffer system, RT and PCR can be combined (RT-PCR) in a single reaction (Ali et al., Biotechniψies . 15:40-42 (1993) ; Goblet et al., Nucleic Acids Research. 17:2144 (1989)) . The RT-PCR reaction mixture of 100 μl contains 10 μl of 10X PCR amplification buffer (Promega) , 200 mM MgCl 2 , 250 ng each of primers, 3 μl of 10 mM dNTPs, 40 units of RNasin, 25 units of AMV or moloney-murine leukemia virus (M-MLV) reverse transcriptase, 2.5 units of Taq DNA polymerase, and 1 μl of denatured sample preparation. The thermal cycling program was set as follows: one cycle of cDNA synthesis step at 37°C for 30 min, immediately followed by PCR cycling as described above. Nested PCR. Inconsistent results obtained from a single round of PCR amplification prompted an investigation into the feasibility of Nested PCR. Initial PCR amplification was performed with an external primer set (93-110 & 92-98) (Table 15) . A PCR product of 648 bp was consistently observed from dsRNA as template, but the expected PCR product was not consistently observed in samples prepared from proteinase K- treated crude extract or immuno-capture sample preparation. Consequently, additional PCR amplification with an internal primer set (93-25 &. 93-40) was carried out by adding 5 μl of the first external primer-amplified PCR product into a freshly prepared 100 μl PCR reaction mixture. The PCR cycling parameters were as described above. Example ? - imπ Purification and dsRNA Isolation. GLRaV-3 virus particles were purified directly from field collected samples of infected grapevines. Attempts to use genomic RNA for cDNA cloning failed due to low yield of virus particles with only partial purity. However, virus particles were shown to be decorated by GLRaV-3 antibody using electron microscopy. The estimated coat protein molecular weight of 41K agreed with an earlier study (Hu (1990) . Because of low yield in virus purification, dsRNA isolation was further pursued. Based on the assumption that high Mr dsRNA (16 kb) is the replicative form of the GLRaV-3 genomic RNA, this high Mr dsRNA was separated from other smaller ones by electrophoresis (Figure 2) , purified from a low melting temperature agarose gel, and used for cDNA synthesis. Example 3 - cDNA Synthesis. Molecular Cloninσ. and Analysis of cDNA Clones. First-strand cDNA was synthesized with AMV reverse transcriptase using purified 16 kb dsRNA which had been denatured with 10 mM MeHg as template. Only random primers were used to prime the denatured dsRNA because several other closteroviruses (BYV, CTV, and LIYV) have been shown to have no polyadenylated tail on the 3' end (Agranovsky et al. , J. Gen. Virol.. 72:15-24 (1991)) ; Agranovsky et al. , Virolocry. 198:311-324 (1994) ; Karasev et al. , Virology. 208:511-520 (1995) ; Klaassen et al. , V ology. 208:99-110 (1995) ; Pappu et al., Virology. 199:35-46 (1994)) . After second-strand cDNA synthesis, the cDNA was size-fractionated on a CL-4B Sepharose column, and peak fractions which contained larger molecular weight cDNA were pooled and used for cloning. An autoradiograph of this pooled cDNA revealed cDNA molecules up to 4 kb in size. A lambda ZAPII library was prepared from cDNA that was synthesized with random primed, reverse transcription of GLRaV-3 specific dsRNA. Initially, white/blue color selection in IPTG/X-gal containing plates was used to estimate the ratio of recombination. There were 15.7% white plaques, and an estimated 7 X 10 4 GLRaV-3 specific recombinants in this cDNA library. The library was screened with probes prepared from UNI-AMP™ PCR-amplified GLRaV-3 cDNA. More than 300 clones with inserts of up to 3 kb were selected after screening the cDNA library with probe prepared from UNI-AMP™ PCR-amplified GLRaV-3 cDNA. In Northern blot hybridization, a probe prepared from a clone insert, pC4, reacted strongly to the 16 kb dsRNA as well as to several other smaller Mr dsRNAs. Such a reaction was not observed with nucleic acids from healthy grape or with dsRNA of CTV (Figure 1) . Example 4 - Selection and Characterization of Imrrmnopoπit-jv ft Clones A total of 6 X 10 4 plaques were immunoscreened with GLRaV- 3 specific polyclonal antibody. Three cDNA clones, designated pCP5, pCP8-4, and pCPlO-1, produced proteins that reacted to the polyclonal antibody to GLRaV-3. GLRaV-3 antibody specificity of the clones was further confirmed by their reaction to GLRaV-3 monoclonal antibody. PCR analysis of cloned inserts showed that a similar size of PCR product (1.0- 1.1 kb) was cloned in each immunopositive clone using primers corresponding to flanking vector seuqences (SK and KS) . However, various sizes of antibody-reacting protein were produced from these clones, which suggested that individual clones were independent and contained different segments of the coat protein gene. The Mr of immunopositive fusion protein from clone pCPlO-l was estimated to be 50K in SDS- PAGE, which was greater than the native coat protein of 41K (compare lanes 1 to 4 in Figure 3) . Immunopositive proteins produced in clone pCP5 (Figure 3, lane 2) and pCP8 (Figure 3, lane 3) were different in size and smaller than the native coat protein. Clone pCP5 produced a GLRaV-3 antibody-reacting protein of 29K. Clone pCP8-4, however, produced an antibody- reacted protein of 27K. Similar banding patterns were observed when either polyclonal (Figure 3A) or monoclonal (Figure 3B) antibodies were used in Western blots. These results indicated that these cDNA clones contained coding sequences for the GLRaV-3 coat protein gene. 37 Example <=, - Nucleotide Sequencing and Identification of the Coat Protein Gene Both strands of the three immunopositive clones were sequenced at least twice. A multiple sequence alignment of these three clones overlapped and contained an incomplete ORF lacking the 3' terminal sequence region. The complete sequence of this ORF was obtained by sequencing an additional clone, pA6-8, which was selected using the clone walking strategy. The complete ORF potentially encoded a protein of 313 amino acids with a calculated Mr of 34,866 (p35) (Figure 4 and Tables 2-3) . Table 2 shows the nucleotide and amino acid sequences of the coat protein gene of grapevine leafroll associated closterovirus-3 , isolate NY1. Nucleotide sequencing was conducted by the procedure described in Example 1. The translated amino acid sequence is shown below the nucleotide sequence. Table 3 compares the alignment of the coat protein of GLRaV-3 with respect to BYV, CTV, and LIYV. Consensus amino acid residues are shown. Uppercase letters indicate identical amino acids, and lowercase letters indicate at least three identical or functionally similar amino acids. The three conserved amino acid residues (S, R, and D) identified in all filamentous plant virus coat proteins are in bold (Dolja et al. , Virology. 184:79-86 (1991)) . Because this ORF was derived from three independent clones after screening with GLRaV-3 coat protein specific antibody, it was identified as the coat protein gene of GLRaV- 3. A multiple amino acid sequence alignment of p35 with the coat proteins of other closteroviruses, including BYV, CTV, and LIYV, is presented in Table 3. The typical consensus amino acid residues (S, R, and D) of the coat proteins of the filamentous plant viruses (Dolja et al., Virology. 184:79-86 (1991) ) , which may be involved in salt bridge formation and the proper folding of the most conserved core region (Boyko et al., Proc. Natl . Αcad. Sci. USA. 89:9156-9160 (1992)), were also preserved in the p35. Phylogenetic analysis of the GLRaV-3 coat protein amino acid sequence with respect to the other filamentous plant viruses placed GLRaV-3 into a separate but closely related branch of the closterovirus (Figure 5) . Direct sequence comparison of GLRaV-3 coat protein with respect to other closterovirus coat proteins or their diverged copies by the GCG Pileup program demonstrated that at the nucleotide level, GLRaV-3 had its highest homology to BYV (41.5%) and CTV (40.3%) . At the amino acid level, however, the highest percentage similarity were to the diverged copies of coat protein, with 23.5% identity (46.5% similarity) to CTV p26 and 22.6% (44.3% similarity) to BYV p24. Example 6 - Identification of a Coat Protein Translation Initiation Site Various sizes of GLRaV-3 specific antibody-reactive proteins were produced by three immunopositive clones in E. coli (Figure 3) . Sequences of these clones overlapped and represented a common ORF that was identified as the coat protein gene (Figure 4) . In searching for possible translation regulatory elements, sequence analysis beyond the coat protein coding region revealed a purine rich sequence, - uGAGuGAAcgcgAUG- (SEQ ID NO:26) , which was similar to the Shine-Dalgarno sequence (uppercase letters) (Shine et al., Proc. Natl . Acad. Sci. USA. 71:1342-1346 (1974) ,) , upstream from the coat protein initiation site (AUG) . This purine rich sequence can serve as an alternative ribosome entry site for the translation of the GLRaV-3 coat protein gene in E. coli . If this first AUG in the ORF serves for coat protein translation, the ribosomal entry site must be located in this purine rich region because an in-frame translation stop codon (UGA) was only nine nucleotides upstream from the coat protein gene translation initiation site (AUG) . Analysis of nucleotide sequence beyond the cloned insert into the vector sequence of clone pCP8-4 and pCPlO-1 provided direct evidence that the fusion protein was made from the N-terminal portion of coat protein and C-terminal portion of β-galactosidase (16.5K) . Further analysis of sequence around the selected AUG initiation codon of the coat protein gene revealed a consensus sequence (-GnnAUGG-) that favored the expression of eucaryotic RNAs (Kozak, Mi rob ological Reviews. 47:1-45 (1983) ; Kozak, Cell. 44:283-292 (1986) ) . Nucleotide sequence analysis of three immunopositive clones revealed overlapping sequences and an ORF that covers about 96% of the estimated coat protein gene (Figure 4) . The complete ORF was obtained after sequencing of an additional clone (pA6-8) that was selected by the clone walking strategy. Identification of this ORF as the coat protein gene was based upon its immunoreactivity to GLRaV-3 polyclonal and monoclonal antibodies, the presence of filamentous virus coat protein consensus amino acid residues (S, R, and D) , and the identification of a potential translation initiation site. The calculated coat protein molecular weight (35K) is smaller than what was estimated on SDS-PAGE (41K) . This discrepancy in molecular weight between computer-calculated and SDS-PAGE estimated falls in the expected range. The estimated coat protein Mr of GLRaV-3 and another grape closterovirus-like designated GLRaV-1 are larger than the 22-28K coat protein range reported for other well characterized closteroviruses such as BYV, CTV, and LIYV (Agranovsky (1991) ; Bar-Joseph et al., "Closteroviruses," CMI/AAB. No. 260 (1982), Klaassen et al. , J. Gen. V rol .. 75:1525-1533 (1994); (Martelli et al. , "Closterovirus, Classification and Nomenclature of Viruses, Fifth Report of the International Committee on Taxonomy of Viruses," in Archives of Virology Supplementum 2. Martelli et al. , eds., New York: Springer-Verlag Wein, pp. 345-347 (1991) ; Sekiya et al., .T. Gen. Virol.. 72:1013-1020 (1991)) . Hu (1990) suggested a possible coat protein dimer. The present sequence data, however, do not support this suggestion. First, the size of the coat protein is 35K, which is smaller than what would be expected of a coat protein dimer. Second, a multiple sequence alignment of N-terminal half and C-terminal half of GLRaV-3 coat protein with the coat proteins of other closteroviruses showed that the filamentous virus coat protein consensus amino acid residues (S, R, and D) are only present 40 in the C-terminal portion, but not in the N-terminal portion of the coat protein. Examp 7 - Primer Selection. Primers were selected based on the nucleotide sequence of clone pC4 which had been shown to hybridize to GLRaV-3 dsRNAs on a Northern hybridization (Figure 1) . The 648 bp sequence amplified by PCR was identified as nucleotides 9,364 to 10,011 of the incomplete GLRaV-3 genome (Table 4) . This sequence fragment encodes a short peptide which shows some degree of amino acid sequence similarity to heat shock protein 90 (HSP90) homologues of other closteroviruses, BYV, CTV, and LIYV (Table 5) . Two sets of primer sequences and their designations (external, 93-110 & 92-98, and internal, 93-25 & 93-40) are shown in Table 15. Effectiveness of synthesized primers to amplify the expected PCR product was first evaluated on its respective cDNA clone, pC4 (Figure 6, lane 11) . Example 8 - Development of a Simple and Effective PCR Sample Preparation. Initially purified dsRNA was used in a RT-PCR reaction. The expected 219 bp PCR product was consistently observed with the internal set of primers (Figure 6, lane 10) . To test whether or not these primers derived from GLRaV-3 specific dsRNA sequence is in fact the GLRaV-3 genome sequence, RNA extracted from a highly purified virus preparation was included in an assay. As expected, PCR products with similar size (219 bp) were observed in cloned piasmid DNA (ρC4) (Figure 6, lane 11), dsRNA (Figure 6, lane 10) as well as purified viral RNA (Figure 6, lane 9) . This PCR result was the first evidence that dsRNA isolated from leafroll-infected tissue was derived from the GLRaV-3 genome. However, PCR sample preparations from the purified virus procedure are too complicated to be used for leafroll diagnosis. Simplification sample preparations used viral RNA extracted from a partially purified virus preparation. This partially purified virus preparation was again shown to be effective in RT-PCR (Figure 6) . Sensitivity of RT-PCR was further evaluated with 10-fold serial dilution (up to 10 "5 ) of a sample. The expected PCR product of 219 bp in a partially purified virus preparation was observable up to the 10 "3 dilution (Figure 6, lane 4) . Although RT-PCR was shown again to work with partially purified virus preparations, this method of sample preparation was still too complicated to be used in a routine disease diagnosis. Over 10 attempts to directly use crude extract for RT-PCR were unsuccessful. Proteinase K-treated crude extract was by far the most simple and still effective pretreat ent for RT-PCR. Therefore, the proteinase K-treated crude extract was used to evaluate RT-PCR for its ability to detect GLRaV-3. Example 9 - RT-PCP With proteinase K-treated crude extract prepared from scraped phloem tissue collected from a typical leafroll infected vine (Doolittle's vineyard, New York) , a PCR product of 219 bp was readily observed. However, application of this sample preparation method to other field collected samples (USDA, PGRU, Geneva, NY) was disappointing. With different batches of sample preparations, a range of 3 to 10 out of 12 ELISA positive samples were shown to have the expected PCR products. To determine whether these inconsistent results were due to some kind of enzyme (reverse transcriptase or Taq DNA polymerase) inhibition present in the proteinase K-treated crude extract, increasing amounts of a sample were added into an aliquot of 100 μl PCR reaction mixture. PCR products of 219 bp were readily observed from samples of 0.1 μl (lane 1) and 1 μl (lane 2) but not from 10 μl. Presumably, sufficient amount of enzyme inhibitors was present in the .10 μl of this sample. Example 10 - Tmrrmno-capture PT-PCR The immuno-capture method further simplified sample preparation by directly using crude extracts that were prepared in the standard ELISA extraction buffer. Immuno- capture RT-PCR (IC RT-PCR) tests were initially performed with the internal primer set, and the expected PCR product of 219 bp was observed from a typical leafroll infected sample. However, this PCR method to test a range of field collected ELISA positive samples gave inconsistent results. In a PCR test performed with the external primer set, only five out of seven field collected ELISA positive samples were shown to amplify the expected PCR product (648 bp) (Figure 7A) . Meanwhile, the expected PCR product was consistently observed in dsRNA (Figure 7A, lane 10) , but such product was never observed in the healthy control (Figure 7A, lane 9) . In this case, however, the expected PCR product was not observed in a sample prepared using proteinase K-treated crude extract (Figure 7A, lane 8) . Example 11 - Nested PCR As described above, inconsistency of RT-PCR was experienced with samples prepared either by the proteinase K- treated or by the immuno-capture methods. If this PCR technique is to be used in disease diagnosis, a consistent and reproducible result is needed. Thus, the Nested PCR method was introduced. Although an expected PCR product of 648 bp from the first PCR amplification with the external primer set was not always observable (Figure 7A) , in a Nested PCR amplification with the internal primer set, the expected 219 bp PCR product was consistently observed from all seven ELISA positive samples (Figure 7B) . These products were observed in dsRNA (Figure 7B, lane 10) and in the proteinase K-treated crude extract (Figure 7B, lane 8) but not in a healthy control (Figure 7B, lane 9) . To determine the sensitivity of Nested PCR with samples prepared either by proteinase K-treated or by immuno-capture methods, Nested PCR and ELISA were performed simultaneously with samples prepared from a 10-fold dilution series. The sensitivity of Nested PCR was shown to be 10 "5 in proteinase K-treated crude extract (Figure 8A) , and was more than 10" β (the highest dilution point in this test) in an immuno-capture preparation (Figure 8B) . With similar sample preparations, sensitivity for ELISA was only 10 "2 . Example 13 - Validation of PCR with ELISA and indexing To determine whether the PCR-based GLRaV-3 detection method described in this study has a practical application in grapevine leafroll disease diagnosis, a validation experiment with plants characterized thoroughly by ELISA and indexing is necessary. Several grapevines collected at USDA-PGRU at Geneva, New York, which have been well characterized by 3-year biological indexing and by ELISA were selected for validation tests . A perfect correlation was observed between ELISA positive and PCR positive samples, although there was some discrepancy over indexing which suggested that other types of closteroviruses may also be involved in the grapevine leafroll disease (Table 7) . PCR technology has been applied to detect viruses, viroids and phytoplasmas in the field of plant pathology (Levy et al., .Tmirnal of Virological Methods. 49:295-304 (1994)) . Because of the presence of enzyme inhibitors (reverse transcriptase and/or Taq DNA polymerase) in many plant tissues, a lengthy and complicated procedure is usually required to prepare a sample for PCR. In studies of PCR detection of grapevine fanleaf virus, Rowhani et al. , Ph y topathology. 83:749-753 (1993), have already observed an enzyme inhibitory phenomenon. Substances including phenolic compounds and polysaccharides in grapevine tissues were suggested to be involved in enzyme inhibition. One of the objectives in the present study was to develop a sound practical procedure for sample preparation to eliminate this inhibitory problem for PCR detection of GLRaV-3 in grapevine tissues. Although the expected PCR product was consistently observed from samples of dsRNA, purified virus and partial purified virus, proteinase K-treated crude extract and immuno-capture methods were the simplest and were still effective. Samples prepared with proteinase K-treated crude extract have an advantage over others in that hazardous 44 organic solvents, such as phenol and chloroform, are avoided. However, care must be taken in the sample concentration because the reaction can be inhibited by adding too much grapevine tissue. Minafra et al., J. Virol. Methods. 47:175- 188 (1994) , reported the successful PCR detection of grapevine virus A, grapevine virus B, and GLRaV-3 with crude saps prepared from infected grapevine tissues, this method of sample preparation was, however, not effective in the present study. The similar primers used by Minafra (1994) , were, however, able to amplify the expected size of PCR products from dsRNA of the NY1 isolate of GLRaV-3. Immuno-capture is another simple and efficient method of sample preparation (Wetzel (1992) , which is hereby incorporated by reference) . First, crude ELISA extracts can be used directly for RT-PCR. Second, it provides not only a definitive answer, but may also be an indication to a virus serotype. Third, with an immuno-capture step, virus particles are trapped by an antibody, and inhibitory substances may be washed away. Nested PCR with samples prepared by the immuno- capture method is 10 3 times more sensitive than with samples prepared by proteinase K-treated crude extract. However, this approach requires a virus specific antibody. For some newly discovered or hard to purify viruses, a virus specific antibody might not be available. There are at least six serologically distinctive closteroviruses associated with grapevine leafroll disease (Boscia (1995) ) . Example 13 - Nucleotide Sequence and Open Reading Frames A lambda ZAPII library was prepared from cDNA that was synthesized with random primed, reverse transcription of GLRaV-3 specific dsRNA. Initially, white/blue color selection in IPTG/X-gal containing plates was used to estimate the ratio of recombination. There were 15.7% white plaques, or an estimated 7 X 10 4 GLRaV-3 specific recombinants in this cDNA library. The library was screened with probes prepared from UNI-AMP™ PCR-amplified GLRaV-3 cDNA. More than 300 clones with inserts of up to 3 kb were selected after screening the „, « « * „™ PCT/US96/20747 WO 97/22700 45 cDNA library with probe prepared from UNI-AMP™ PCR-amplified GLRaV-3 cDNA. In Northern blot hybridization, a probe prepared from the cloned insert of pC4, reacted strongly to the 16 kb dsRNA as well as to several other smaller Mr dsRNAs. No hybridization with nucleic acids from healthy grape or to dsRNA of CTV was observed (Figure 1) . Clone pB3-l was selected and sequenced after screening the library with HSP70 degenerate primer (5'GGIGGIGGIACITTYGAYGTITCI (SEQ ID NO:25)) . Other clones that were chosen for nucleotide sequencing were selected by the clone walking strategy. The nucleotide sequencing strategy employed was based on terminal sequencing of random selected clones assisted with GCG fragment assembly program to assemble and extend the sequence. The step-by-step primer extension method was used to sequence the internal region of a selected clone. A total of 54 clones were selected for sequencing. Among them, 16 clones were completely sequenced on both DNA strands (Figure 9) . A total of 15,227 nucleotides were sequenced; nine open reading frames (ORFs) were identified designated as ORFs la, lb, and 2 to 8. The sequenced region was estimated to cover about 80% of the complete GLRaV-3 genome. Major genetic components, such as helicase (ORF la) , RdRp (ORF lb) , HSP70 homologue (ORF 4) , HSP90 homologue (ORF 5) and coat protein (ORF 6) were identified. ORF la was an incomplete ORF from which the 5 ' terminal portion has yet to be cloned and sequenced. The sequenced region presented in Figure 10 and Table 4 represents approximately two-thirds of the expected ORF la , as compared to the ORF la from BYV, CTV, and LIYV. The partial ORF la was terminated by the UGA stop codon at positions 4165-4167; the respective product consisted of 1388 amino acid residues and had a deduced Mr of 148,603. Database searching indicated that the C-terminal portion of this protein shared significant similarity with the Superfamily 1 helicase of positive-strand RNA viruses. Comparison of the conserved domain region (291 amino acids) showed a 38.4% identity with an additional 19.7% 46 similarity between GLRaV-3 and BYV and a 32.4% identity with an additional 21.1% similarity between GLRaV-3 and LIYV (Table 6) . Six helicase conserved motifs of Superfamily 1 helicase of positive-strand RNA viruses (Hodgman, Nature 333:22-23 (Erratum 578) (1988) ; Koonin et al. , Crit. Rev. Biochem. o ec. Biol .. 28:375-430 (1993)) were also retained in GLRaV- 3. Analysis of the predicted phylogenetic relationship in helicase domains between GLRaV-3 and the other positive-strand RNA viruses placed GLRaV-3 along with the other closteroviruses, including BYV, CTV, and LIYV, into the "tobamo" branch of the alphavirus-like supergroup (Figure 11, Table 5) . Table 5 compares the amino acid sequence alignment of the helicase of GLRaV-3 with respect to BYV, CTV, and LIYV. Consensus amino acid residues are shown. Uppercase letters indicate identical amino acids, lowercase letters indicate at least three identical or functionally similar amino acids. Six conserved motifs (I to VI) that are conserved among the Superfamily 1 helicase (Koonin et al. , Crit, Rev, in Biochem. Molec. Biol.. 28:375-430 (1993)) of the positive-strand RNA viruses are overlined. ORF lb overlapped the last 113 nucleotides of ORF la and terminated at the UAG codon at positions 5780 to 5782. This ORF encodes a protein of 536 amino acid residues with a calculated Mr of 61,050 (Figures 10, Table 4) . Database screening of this protein revealed significant similarity to the Supergroup 3 RdRp of the positive-strand RNA viruses. Sequence comparison of GLRaV-3 with BYV, LIYV, and CTV over a 313-amino acid sequence fragment revealed a striking amino acid sequence similarity among eight conserved motifs (Table 8) . Consensus amino acid residues are shown. Uppercase letters indicate identical amino acids, and lowercase letters indicate at least three identical or functionally similar amino acids. The motifs (I to VIII) that are conserved among the Supergroup 3 RNA polymerase of positive-strand RNA viruses are overlined. The best alignment was with BYV, while the least alignment was with LIYV (Table 6) . Analysis of predicted phylogenetic relationships of the RdRp domains of the alphavirus-like supergroup viruses again placed GLRaV-3 into the tobamo branch along with other closteroviruses, BYV, CTV, BYSV, and LIYV (Figure 12) . Publications on BYV, CTV, and LIYV have proposed that ORF lb is expressed via a +1 ribosomal frameshift (Agranovsky (1994) ; Dolja et al. , Ann. Rev. Phytopathol .. 32:261-285 (1994) ; Karasev (1995) , and Klaassen (1995)) . Direct nucleotide sequence comparison was performed within the ORFla/lb overlap of GLRaV-3 with respect to BYV, CTV, or LIYV. An apparently significant similarity was observed only to LIYV (Table 9) , and not to BYV or CTV. The so-called "slippery" GGGUUU sequence and the stem-and-loop structure that were proposed to be involved in the BYV frameshift was absent from the GLRaV-3 ORFla/lb overlap. The predicted frameshift within the GLRaV-3 ORF la/lb overlap was selected based on an inspection of the C-terminal portion of the helicase alignment and the N-terminal portion of the RdRp alignment between GLRaV-3 and LIYV. Table 9 compares the aligned GLRaV-3 and LIYV nucleotide sequences (presented as DNA) in the vicinity of the proposed frameshift, nt 4099-4165 in GLRaV-3 and nt 5649-5715 in LIYV. Identical nucleotides are uppercase. LIYV predicted +1 frameshift region (aAAG) and the corresponding GLRaV-3 (cACA) are bold and italic. The encoded C-terminus of HEL and N- terminus of RdRp are presented above (GLRaV-3) and below (LIYV) the nucleotide alignment. Repeat sequences are underlined. The GLRaV-3 ORF la/lb frameshift was predicted to occur in the homologous region of the LIYV genome, and was also preceded by a repeat sequence (GCTT) (Figure 24) . Unlike LIYV, this repeat sequence was not a tandem repeat and was separated by one nucleotide (T) in GLRaV-3. The frameshift was predicted to occur at CACA (from His to Thr) in GLRaV-3 rather than slippery sequence AAAG in LIYV. However, additional experiments on in vi tro expression of GLRaV-3 genomic RNA are needed in order to determine whether or not a large fusion protein is actually produced. ORF 2 is predicted to encode a small peptide of 51 amino acids and a calculated Mr of 5,927. Database searching did not reveal any obvious protein matches within the existing Genbank (Release 84.0) . Intergenic regions of 220 bp between ORF lb and ORF 2 and 1065 bp between ORF 2 and ORF 3 were identified. There is no counterpart in the BYV or LIYV genomes; instead, an ORF of 33K in CTV (Karasev et al. , J. Gen. Virol.. 75:1415-1422 (1994)) or 32K in LIYV (Klaassen (1995) ) is observed over this similar region. ORF 3 encodes a small peptide of 45 amino acids and a calculated Mr of 5,090 (p5K) . Database searching revealed that it was most closely related to the small hydrophobic, transmembrane proteins of BYV (6.4K) , CTV (6K) , and LIYV (5K) Individual comparison (Table 3) showed that LIYV was its closest relative (45.8%) at the nucleotide level and BYV was the most homologous (30.4%) at the amino acid level. Table 10 compares the aligned amino acid sequences the small hydrophobic transmembrane protein of GLRaV-3 p5K with those of BYV (p6K) , CTV (p6K) , and LIYV (p5K) . Consensus amino acid residues are shown. Lowercase letters indicate at least three identical or functionally similar amino acids . The transmembrane domain that has been identified in several other closteroviruses, BYV, CTV, and LIYV (Karasev et al . , Virology. 208:511-520 (1995)) , is overlined. ORF 4 encodes a protein of 549 amino acids and a calculated Mr of 59,113 (p59) (Figure 10, Table 4) . Database screening revealed significant similarity to the HSP70 family, the p65 protein of BYV, the p65 protein of CTV, and the p62 protein of LIYV. A multiple amino acid sequence alignment of GLRaV-3 p59 with HSP70 analogs of other closteroviruses showed striking sequence similarity among eight conserved motifs (A- H) . Functionally important motifs (A-C) that are characteristic of all proteins containing the ATPase domain of the HSP70 type (Bork et al. , Pτ-oc. Natl. Acad. Sci. USA. 89:7290-7294 (1992)) were also preserved in GLRaV-3 p59, which suggested that this HSP70 chaperonin-like protein may also possess ATPase activity on its N-terminal domain and protein- protein interaction on its C-terminal domain (Dolja (1994) . Table 11 presents the amino acid sequence alignment of the HSP70-related protein of GLRaV-3 (p59K) with those of BYV (p65K) , CTV (p65K) , and LIYV (p62K) . The eight conserved motifs (A to H) of cellular HSP70 are overlined. Consensus amino acid residues are shown. Uppercase letters indicate identical amino acids, and lowercase letters indicate at least three identical or functionally similar amino acids. Analysis of the predicted phylogenetic relationship of p59 of GLRaV-3 with HSP70-related proteins of other closteroviruses (BYV, CTV, and BYSV) and cellular HSP70s again placed the four closteroviruses together and the rest of the cellular HSP70s on the other branches (Figure 13) . Although several closterovirus HSP70-related proteins are closely related to each other and distant from other cellular members of this family, inspection of the phylogenetic tree indicates that GLRaV-3 may be an ancestral closterovirus relatively early in evolution as predicted by Dolja (1994) , because GLRaV-3 was placed in between closteroviruses and the other cellular HSP70 members. ORF 5 encodes a protein of 483 amino acids with a calculated Mr of 54,852 (p55) (Figure 10, Table 4) . Table 12 compares the alignment of the amino acid sequence deduced from the PCR fragment of GLRaV-3 with respective regions of HSP90 homologues of beet yellow virus (BYV) (p64) , citrus tristeza virus (CTV) (p61) , and lettuce infectious yellow virus (LIYV) (p59) . Consensus amino acid residues are shown. Uppercase letters indicate identical amino acids, lowercase letters indicate at least three identical or functionally similar amino acids. No significant sequence homology with other proteins was observed in the current database (GenBank, release 84.0) . Direct comparison with other counterparts (p61 of CTV, p64 of BYV, and p59 of LIYV) of closteroviruses revealed some degree of amino acid sequence similarity, with 21.7% to BYV, 17.5% to CTV, and 16.7% to LIYV, respectively (Tables 6, 11, 12) . Two conserved regions of HSP90 previously described in BYV and CTV (Pappu (1994)) were identified in the p55 of GLRaV-3 (Table 13) . ORF 6 encodes a protein of 313 amino acids with a calculated Mr of 34,866 (p35) (Figure 10 and Table 4) . The fact that this ORF was encoded by three overlapping GLRaV-3 immunpositive clones indicates that it contains the coat protein gene of GLRaV-3. Alignment of the product of ORF 6 (p35) with the coat protein sequences of BYV, CTV, and LIYV, is presented in Table 3. The typical consensus amino acid residues (S, R, and D) of the coat protein of the filamentous plant viruses (Dolja (1991) ) , which may be involved in salt bridge formation and the proper folding of the most conserved core region (Boyko (1992) ) , were also retained in the p35 (Table 3) . Individual sequence comparison showed the highest similarity to CTV (20.5%) and BYV (20.3%), and the lowest similarity to LIYV (17.8%) . Analysis of predicted phylogenetic relationships with other filamentous plant viruses tentatively placed GLRaV-3 into a separate, but a closely related branch of closteroviruses (Figure 5) . ORF 7 encodes a protein of 477 amino acids with a calculated Mr of 53,104 (p53) (Figure 10 and Table 4) . Based on the presence of conserved seuqences, this protein is designated as grapevine leafroll virus coat protein repeat (p53) . ORF 8 encodes an undefined polypeptide of a calculated Mr of 21,248 (p21) . ORF 9 encodes an undefined protein of calculated Mr of 19,588 (p20) . ORF 10 encodes an undefined polypeptide with a calculated Mr of 19,653 (p20) . ORF 11 encodes an undefined protein of calculated Mr of 6963 (p7) . In the present study, many GLRaV-3 dsRNA specific cDNA clones were identified using a probe generated from UNI-AMP™ PCR-amplified cDNA. Using UNI-AMP™ adapters and primers (Clontech) in PCR has several advantages. First, it is not necessary to know the nucleotide sequence of an amplified fragment. Second, cDNA can be amplified in sufficient amounts for specific probe preparation. In general, cDNA amplified by PCR using UNI-AMP™ primers and adapters could be used for cloning as well as a probe for screening of cDNA libraries. However, low abundance of the starting material and many cycles of PCR amplification often incorporate errors into the nucleotide sequence (Keohavong et al., Proc. Natl. Acad. Sci . IZSA, 86:9253-9257 (1989) ; Saiki et al . , Science, 239:487-491 (1988)) . In the present study, only UNI-AMP™ PCR amplified cDNA was used as a probe for screening. The cDNA library was generated by direct cloning of the cDNA that was synthesized by AMV reverse transcriptase. Therefore, the cDNA cloned inserts are believed to more accurately reflect the actual sequence of the dsRNA and the genomic RNA of GLRaV-3. A total of 15,227 nucleotides or about 80% of the estimated 16 kb GLRaV-3 dsRNA was cloned and sequenced. Identification of this sequence fragment as the GLRaV-3 genome was based on its sequence alignment with the coat protein gene of GLRaV-3. This is the first direct evidence showing that high molecular weight dsRNA (-16 kb) isolated from GLRaV-3 infected vines is derived from GLRaV-3 genomic RNA. Based upon the nine ORFs identified, the genome organization of GLRaV-3 bears significant similarity to the other closteroviruses sequenced (BYV, CTV, and LIYV) (Figure 10) . Dolja (1994) tentatively divided the closterovirus genome into four modules. For GLRaV-3, the 5' accessory module including protease and vector transmission factor is yet to be identified. The core module, including key domains in RNA replication machinery (MET-HEL-RdRp) that is conserved throughout the alphavirus supergroup, has been revealed in parts of the HEL and RdRp domains. The MET domain has not yet been identified for GLRaV-3. The chaperon module, including three ORFs coding for the small transmembrane protein, the HSP70 homologue, and the distantly related HSP90 homologue, has been fully sequenced. The last module includes coat protein and its possible diverged copy and is also preserved in GLRaV-3. Overall similarity of the genome organization of GLRaV-3 with other closteroviruses further support the inclusion of GLRaV-3 as a member of closteroviruses (Hu (1990) and Martelli (1991) , which are hereby incorporated by reference) . However, observation of a predicted ambisense gene on its 3' terminal region may separate GLRaV-3 from other closteroviruses. Further comparative sequence analysis (Table 3) as well as phylogenetic observation of GLRaV-3 with respect to other closteroviruses over the entire genome sequence region suggested that GLRaV-3 is most closely related to BYV, followed by CTV, and LIYV. As suggested by others (Agranovsky (1994) , Dolja (1994) , Karasev (1995) , and Klaassen (1995)) , expression of ORF lb in closteroviruses may be via a +1 ribosomal frameshift mechanism. In GLRaV-3, a potential translation frameshift of ORF lb could make a fusion HEL-RdRp protein of over 1,926 amino acid residues with a capacity to encode a protein of more than 210K Comparative study of GLRaV-3 with respect to other closteroviruses over the ORF la/lb overlap revealed a significant sequence similarity to LIYV, but not to BYV or to CTV. The so-called slippery sequence (GGGUUU) and stem-loop and pseudoknot structures identified in BYV (Agranovsky (1994) , which is hereby incorporated by reference) is not present in GLRaV-3. Thus, a frameshift mechanism that is similar to LIYV may be employed for GLRaV-3. However, protein analysis is necessary in order to determine the protein encoding capacities of these ORFs. Differing from BYV, both CTV and LIYV have an extra ORF (ORF 2) in between RdRp (ORF lb) and the small membrane protein (ORF 3) and potentially encoding a protein of 33K or 32K, respectively. However, in GLRaV-3, there is a much smaller ORF 2 (7K) followed by a long intergenic region of 1065 bp. So far, among all plant viruses described, the HSP70 related gene is present only in the closteroviruses (Dolja (1994)) . Identification of the GLRaV-3 HSP70 gene was based on an assumption that this gene should also be present in the closterovirus associated with grapevine leafroll disease, specifically GLRaV-3. Thus, cDNA clones that reacted with HSP70-degenerated primers were identified for sequence analysis. The identification of subsequent clones for sequencing was based on the gene-walking methodology. However, identification of immunopositive clones enabled identification of the coat protein gene of GLRaV-3 and proved that the HSP70-containing sequence fragment is present in the GLRaV-3 RNA genome. The 16 kb dsRNA used for cDNA synthesis was assumed to be a virus replicative form (Hu (1990) . Selected clones have been shown by Northern hybridization to hybridize to the 16 kb dsRNA and several smaller RNAs (presumably subgenomic RNAs) (Figure 1) . Second, three GLRaV-3 antibody-reacting clones were identified after immuno-screening of the protein expression library with both GLRaV-3 polyclonal (Zee (1987) ) and monoclonal (Hu (1990)) antibodies. After nucleotide sequencing, these three antibody-reacting clones were shown to overlap one another and contain a common ORF which potentially encodes a protein with calculated Mr of 35K. This is consistent with the Mr estimated on SDS-PAGE (41K) . Third, analysis of the partial genome sequence of GLRaV-3 suggested a close similarity in genome organization and gene sequences to the other closteroviruses (Dolja (1994)) . Information regarding the genome of GLRaV-3 provides a better understanding of this and related viruses and adds to the fundamental knowledge of closteroviruses. Present work on the nucleotide sequence and genome organization (about 80% of the estimated genome sequence) has provided direct evidence for a close relationship between GLRaV-3 and other closteroviruses. It has also enabled, for the first time, the evaluation of phylogenetic relationships of GLRaV-3 based on a wide range of genes and gene products (helicase, polymerase, HSP70 homologue, HSP90 homologue, and coat protein) . Based upon major differences in genome format and organization between BYV, CTV, and LIYV, along with phylogenetic analysis, Dolja (1994)) proposed the establishment of the new family Closteroviridae with three new genera of Closterovirus (BYV) , Ci trivirus (CTV) , and Biclovirus (LIYV) . This work on genome organization and phylogenetic analysis, along with evidence that this virus is transmitted by mealybugs (see hereinabove) indicates that a new genus under Closteroviridae family should be established. Thus, GLRaV-3 (the NY1 isolate) is proposed as the type representative of the new genus, Graclovirus (gra¬ pevine cl o-sterovirus) . Further sequencing of other grapevine leafroll associated closteroviruses may add more members to this genus. Another cDNA library of GLRaV-3 has been established recently from dsRNA of an Italian isolate of GLRaV-3 (Saldarelli et al . , Plant Pathology ( Oxford) . 43:91-96 (1994) , which is hereby incorporated by rsference) . Selected clones react specifically to GLRaV-3 dsRNA on a Northern blot; however, no direct evidence was provided to suggest that those clones were indeed from GLRaV-3 genomic RNA. Meanwhile, a small piece of sequence information from one of those cDNA clones was used to synthesize primers for the development of a PCR detection method (Minafra (1994) , which is hereby incorporated by reference) . Direct sequence comparison of these primer sequences to GLRaV-3 genome sequence obtained in the present study, showed that one of the primers (H229, 5 ΆTAAGCATTCGGGATGGACC (SEQ ID NO:27)) is located at nucleotides 5562-5581 and the other (C547, 5'ATTAACtTgACGGATGGCACGC (SEQ ID NO:28)) is in reverse direction and is the complement of nucleotides 5880-5901. Mismatching nucleotides between the primers and GLRaV-3 sequence are shown in lowercase letters. Sequence comparison over these short primer regions to GLRaV-3 (isolate NY1) genome sequence showed a 90-95% identity, which suggested that these two isolates belong to the same virus (GLRaV-3) . Moreover, the primers prepared by Minafra (1994) , which is hereby incorporated by reference, from the Italian isolate of GLRaV-3 produced an expected size of PCR product with templates prepared from the NY1 isolate of GLRaV-3. The remainder of the GLRaV-3 genome can be readily sequenced using the methods described herein and/or techniques well known to the art. Example U - Identification and Characterization of the A3 ORF The complete nucleotide sequence of the GLRaV-3 HSP90- related gene is given in Table 4. Initial sequencing work indicated that an open reading frame (ORF) encoding for a protein with a calculated Mr of 43K (Table 14) was downstream of the HSP70-related gene. This gene was selected for engineering because the size of its encoded product is similar to the GLRaV-3 coat protein gene. However, after sequence analysis, this incomplete ORF was located in the 3' terminal region of the HSP90-related gene. It is referred to herein as the incomplete GLRaV-3 HSP90 gene or as the 43K ORF. Example I - Cnstom-PCR Engineering the Incomplete GT,RaV-3 HSP90 Gene for Expression in Plant Tissues Two custom synthesized oligonucleotide primers, 5' primer (93-224, tacttatctagaaccATGGAAGCGAGTCGACGACTA (SEQ ID NO:29)) and 3' complementary primer (93-225, tcttgaggatccatggAGAAACATCGTCGCATACTA (SEQ ID NO:30)) that flank the 43K ORF were designed to amplify the incomplete HSP90 gene fragment by polymerase chain reaction. Addition of a restriction enzyme Ncol site in the primer facilitates cloning and protein expression (Table 15) (Slightom, Gene, 100:251-255 (1991)) . Using these primers, a product of the proper size (1.2 kb) was amplified by RT-PCR using GLRaV-3 double-stranded RNA (dsRNA) as template. Table 14 shows the nucleotide sequence fragment containing the 43 kDa open reading frame that used to engineer the plant expression cassette, pBI525GLRaV-3hsp90. This fragment (nucleotides 9404 to 10,503 of the partial GLRaV-3 genome sequence, Table 4) is located in the 3' portion of GLRaV-3 HSP90-related gene. Nucleotides shown in lower case facilitate cloning by adding Ncol restriction sites. The PCR amplified product was treated with Ncol, isola t ed from a low-melting temperature agarose gel, and cloned into the same restriction enzyme treated binary vector pBI525 (obtained from William Crosby, Plant Biotechnology Institute, Saskatoon, Sask., Canada) , resulting in a clone pBI525GLRaV- 3hsp90 (Figure 31) . A plant expression cassette, the EcoRI and HindiII fragment of clone pBI525GLRaV-3hsp90, which contains properly engineered CaMV 35S promoters and a Nos 3 ' untranslated region, was excised and cloned into a similar restriction enzyme digested plant transformation vector, pBinl9 (Figure 14) (Clontech Laboratories, Inc.) . Two clones, pBinl9GLRaV-3hsp90-12-3 and pBinl9GLRaV-3hsp90-12-4 that were shown by PCR to contain the proper size of the incomplete HSP90 gene were used to transform the avirulent A . tumefaciens , strain LBA4404 via electroporation (Bio-Rad) . The potentially transformed Agrobacterium was plated on selective media with 75 μg/ml of kanamycin. Agrobacterium lines which contain the HSP90 gene sequence were used to transform tobacco (Nicotiana tobacum cv.Havana 423) using standard procedures (Horsch et al. , Science. 227:1229-1231 (1985)) . Kanamycin resistant tobacco plants were analyzed by PCR for the presence of the transgene. Transgenic tobacco plants with the transgene were self pollinated and seed was harvested. Example 16 - Custom-PCR Engineering of the 43K ORF The complete sequence of the GLRaV-3 hsp90 gene was reported in Table 4. However, in the present study, using two custom synthesized oligo primers (93-224, tacttatctagaaccATGGAAGCGAGTCGACGACTA (SEQ ID N0:29) and 93- 225, tcttgaggatccatggAGAAACATCGTCGCATACTA (SEQ ID NO:30)) and GLRaV-3 dsRNA as template, the incomplete HSP90 related gene sequence was amplified by RT-PCR which added an Ncol restriction enzyme recognition sequence (CCATGG) around the potential translation initiation codon (ATG) and another Ncol site, 29 nt downstream from the translation termination codon (TAA) (Table 14) . The PCR amplified fragment was digested with Ncol, and cloned into the same restriction enzyme treated plant expression vector, pBI525. Under ampicillin selective conditions, hundreds of antibiotic resistant transfor ants of E. coli strain DH5a were generated. Clones derived from five colonies were selected for further analysis. Restriction enzyme mapping (Ncol or BamHI and EcoRV) showed that three out of five clones contained the proper size of the incomplete GLRaV-3 HSP90 sequence. Among them, two clones were engineered in the correct 5' -3' orientation with respect to the CaMV-AMV gene regulatory elements in the plant expression vector, pBI525. A graphical structure in the region of the plant expression cassette of clone pBI525GLRaV-3hsp90-12 is presented in Figure 14. The GLRaV-3 HSP90 expression cassette was removed from clone pBI525GLRaV-3hsp90-12 by a complete digestion with HindiII and EcoRI and cloned into the similar restriction enzyme treated plant transformation vector pBinl9. A clone designated as pBinl9GLRaV-3hsp90-12 was then obtained (Figure 14) and was subsequently mobilized into the avirulent Agrobacterium strain LBA4404 using a standard electroporation protocol (Bio-Rad) . Potentially transformed Agrobacterium cells were then plated on a selective medium (75 μg/ml kanamycin) , and antibiotic resistant colonies were analyzed further by PCR with specific synthesized primers (93-224 and 93-225) to see whether or not the incomplete HSP90 gene was still present. After analysis, clone LBA4404/pBinl9GLRaV- 3hsp90-12 was selected and used to transform tobacco tissues. Example 17 - Transformati n and Characterization of Transgenic Plants The genetically engineered A. tumefaciens strain, LBA4404/pBinl9GLRaV-3hsp90-12, was co-cultivated with tobacco leaf discs as described (Horsch (1985) ) , Potentially transformed tobacco tissues were selected on MS regeneration medium (Murashige et al., Physiologia Plantaru r 15:473-497 (1962) ) containing 300 μg/ml of kanamycin. Numerous shoots developed from kanamycin resistant calli in about 6 weeks. Rooted tobacco plants were obtained following growth of developed shoots on a rooting medium (MS without hormones) containing 300 μg/ml of kanamycin. Eighteen independent, regenerated kanamycin resistant plants were transplanted in a greenhouse and tested for the presence of the HSP90-related gene by PCR. Fourteen out of eighteen selected kanamycin resistant putative transgenic lines were shown to contain a PCR product with the expected size of 1.2 kb. The genetically engineered Agrobacterium tumefaciens strain LBA4404/pBinl9GLRaV-3hsp90-12 was also used to transfrom the grapevine rootstock C. 3309 (Vitis riparia x Vi tis rupestris) . Embryogenic calli of C. 3309 were obtained by culturing anthers on MSE medium (Murashige and Skoog salts plus 0.2% sucrose, 1.1 mg/L 2,-4-D, and 0.2 mg/L BA. The medium was adjust to pH 6.5 and 0.8% Noble agar was added. After autoclaving 100 ml M-0654, 100 ml M-0529 and 1 ml vitamin M-3900 were added to the medium. Ater 60 days primary calli were indcued and transferred to hormone-free HMG medium (1/2 Murashige salts with 10 g/L sucrose, 4.6 g/L glycerol and 0.8% Noble agar) for embryogenesis. Calli with globular or heart-shaped embryos were immersed for 15 min. in A. tumefaciens LBA4404/pBinl9GLRaV-3hsp90-12 suspended in MS liquid medium. The embryos were blotted on filter paper to remove excess liquid and transferred to HMG medium with acetosyringone (100 μM) and kept for 48 hrs. in the dark at 28°C. The calli were then washed 2-3 times in MS liquid medium plus cefotaxime (300 μg/ml) and carbenicillin (200 μg/ml) and transferred to HMG medium with the same antibiotics for 1-2 weeks. Subsequently, the embryogenic calli were transferred to HMG medium containing 20 or 20 μg/ml kanmamycin and 300 μg/ml cefotaxime plus 200 μg/ml carbenicillin to select for transgenic embryos. After being on selective medium for 3-4 months, growing embryos were transferred to HMG, MGC (full-strength MS salts amended with 20 g/L sucrose, 4.6 g/L glycerol, 1 g/L casein hydrolysate and 0.8% Noble agar) , or MSE medium with kanamycin. After 4 months germinated embryos were transferred to baby food jars containing rooting medium (Woody plant medium described by Lloyd and McCown (1981) "Commercially feasible micropropagation of mountain laurel, Kal ia la tifola , by use of shoot tip culture," Proc . Intl . Plant Prop. Soc .3_0_:421-427, supplemented with 0.1 mg/L BA, 3 g/L activated charcoal and 1.5% sucrose. The pH was adjusted to 5.8 and Noble agar was added to 0.7%) . Plantlets with roots were transplatned to pots with artificial soil mix and grown in greenhouses. 88 grapevine plants have cultivated, and several have been shown to contain the 43 kDa protein gene (by PCR) . Using the methods described above, engineering of the incomplete HSP90 gene of GLRaV-3 into plant expression and transformation vectors has been effected. The targeted gene sequence was shown to be integrated into the plant genome by PCR analysis of the putative transgenic tobacco plants. The engineered A . tumefaciens strain LBA4404/pBinl9GLRaV-3hsp90-12 has been used to transform grapes and tobacco. Furthermore, this plant transformation vector can serve as a model for construction of other GLRaV-3 vectors, such as coat protein, RdRp, and HSP70, for which nucleotide sequences are disclosed herein. Since the first demonstration of transgenic tobacco plants expressing the coat protein gene of TMV resulted in resistance against TMV infection (Powell-Abel et al . , Science, 232:738-743 (1986), which is hereby incorporated by reference) , the phenomenon of the coat protein-mediated protection has been observed for over 20 viruses in at least 10 different taxonomic groups in a wide variety of dicotyledonous plant species (Beachy et al., Ann . Rev. Phytopatho .. 28:451-74 (1990); Wilson, Proc. Natl. Acad. Sci.. USA. 90:3134-3141 (1993)) . If gene silencing (or co- suppression) (Finnegan et al., Pin/Technolo g y. 12:883-888 (1994) ; Flavell, Proc. Natl . Acad. Sci. USA. 91:3490-3496 (1994)) is one of the resistance mechanisms (Lindbo et al., The Plant Cell. 5:1749-1759 (1993); Pang et al., Bio/Technology. 11:819-824 (1993); Smith et al. , The Plant Cell r 6:1441-1453 (1994)) , then one would expect to generate transgenic plants expressing any part of a viral genome sequence to protect plants from that virus infection. Thus, in the present study, transgenic plants expressing the 43K ORF (or the incomplete hsp90 gene) are protected from GLRaV-3 infection. Since tobacco (Nicotiana tobaccum cv . Havana 423) is not the host of GLRaV-3, direct evaluation of virus resistance was not possible in tobacco. However, after mechanical inoculation of N. benthamiana with grapevine leafroll infected tissue, Boscia (1995) have recovered a long closterovirus from N. benthamiana which is probably GLRaV-2. Thus, it is believed that other types of grapevine leafroll associated closteroviruses can also be mechanically transmitted to N. benthamiana . With transfer of an engineered 43K ORF from GLRaV-3 to JV. benthamiana and to the grapevine rootstock Couderc 3309, it is possible to evaluate the resistance of those plants against GLRaV-2 infection. Example Iff - Coat Protein-mediated Protection and Other Forms of Pathoge -derived Resistance The successful engineering technique used in the above work can be utilized to engineer other gene sequences of GLRaV-3 which have since been identified. Among these, the coat protein gene of GLRaV-3 is the primary candidate since coat protein-mediated protection (Beachy (1990) ; Hull et al. , Crit. Rev. Plant Sci.. 11:17-33 (1992) ; Wilson (1993)) has been the most successful example in the application of the concept of pathogen-derived resistance (Sanford et al . , J. Theor. Biol .. 113:395-405 (1985)) . Construction of plant expression vector (pEPT8/cpGLRaV-3) and Agrobacterium binary vector (pGA 82pEPT8/cpGLRaV-3) was done following a strategy similar to the above. The GLRaV-3 coat protein gene was PCR amplified with primers (KSL95-5, actatttctagaaccATGGCATTTGAACTGAAATT (SEQ ID N0.-31) , and KSL95- 6, ttctgaggatccatggTATAAGCTCCCATGAATTAT (SEQ ID NO:32)) and cloned into pEPT8 after Ncol treatment . The expression cassette from pEPT8/cpGLRaV-3 (including double CaMV 35S enhancers, 35S promotor, alfalfa mosaic virus leader sequence, GLRaV-3 coat protein gene, and 35S terminator) was digested with Hindi11 and cloned into pGA482G (Figure 15) . The resulting Agrobacterium binary vector (pGA482GpEPT8/cpGLRaV-3) was mobilized into A. tumefaciens strain C58Z707 and used for transformation of grapevines. Other gene sequences (e.g., ORF lb, the RNA dependent RNA polymerase) can also be used, as replicase-mediated protection has been effectively used to protect plants from virus infection (Carr et al., Seminars in Virolog y . 4:339-347 (1993); Golemboski et al. , Proc. Natl. Acad. Sci. USA. 87:6311-6315 (1990)) . The HSP70 homologue can also be used to generate transgenic plants that are resistant to all types of grapevine leafroll associated closteroviruses because significant sequence similarity is observed over HSP70 conserved domains. Moreover, the phenomenon of RNA-mediated protection has also been observed (de Haan et al. , Bio/Technology. 10:1133-1137 (1992) ; Farinelli et al. , M l . Plant Microbe Interact.. 6:284-292 (1993); Kawchuk et al. , Mol. Plant Microbe Interact. 4:247-253 (1991) ; Lindbo et al. , Virology. 189:725-733 (1992) ; Lindbo et al. , Mol. Plant Microbe Interact. 5:144-153 (1992) ; Lindbo et al., Seminars in Virology. 4:369-379 (1993) ; Pang (1993); Van Der Wilk et al. , Plant Mol. Biol .. 17:431-440 (1991)) . Thus, untranslatable transcript versions of the above mentioned GLRaV-3 genes also produce leafroll resistant transgenic plants. Another form of pathogen-derived resistance effective in the control of plant viral disease is the use of antisense RNA. Transgenic tobacco plants expressing the antisense sequence of the coat protein gene of cucumber mosaic virus (CMV) showed a delay in symptom expression by CMV infection (Cuozzo et al., Bio/Technology. 6:549-554 (1988)) . Transgenic plants expressing either potato virus X (PVX) coat protein or its antisense transcript were protected from infection by PVX. However, plants expressing antisense RNA were protected only at low inoculum concentration. The extent of this protection mediated by antisense transcript is usually lower than transgenic plants expressing the coat protein (Hemenway et al., EMB J.. 7:1273-1280 (1988)) . This type of resistance has also been observed in bean yellow mosaic virus (Hammond et al., Phytopathology. 81:1174 (1991) , tobacco etch virus (Lindbo et al. , Virology, 189:725-733 (1992)) potato, virus Y (Farinelli (1993)) , and zucchini yellow mosaic virus (Fang et al., Mol. Plant Microbe Interact.. 6:358-367 (1993)) . However, high level of resistance mediated by antisense sequence was observed to be similar to potato plants (Russet Burbank) expressing potato leafroll virus coat protein (Kawchuk (1991) ) . Besides using antisense transcript of the virus coat protein gene, other virus genome sequences have also been demonstrated to be effective. These included the 51-nucleotide sequences near the 5' end of TMV RNA (Nelson et al., Gen≤. (Abst) , 127:227-232 (1993)) and noncoding region of turnip yellow mosaic virus genome (Zaccomer et al. , Gene, 87- 94 (1993) ) . GLRaV-3 has been shown to be transmitted by mealybugs and in some cases it has been shown to spread rapidly in vineyards (see hereinabove) . This disease will become more of a problem if mealybugs become resistant to insecticides or if insecticide use is restricted. Thus, the development of leafroll resistant grapevines is environmentally sound and good for the economics of grape growing. Although grapevine is a natural host of Agrobacterium (A. vi tis is the causal agent of the grapevine crown gall disease) , transformation of grapevine has proven difficult (Baribault et al. , . Ex . Bot.. 41:1045-1049 (1990); Baribault et al., Plant Cell Reports, 8:137-140 (1989) ; Colby et al., J. Am. Soc . Hor . Sci.. 116:356-361 (1991); Guellec et al., Plant Cell Tissue Organ Cult.. 20:211-216 (1990) ; Hebert et al., Plant Cell Reports. 12:585-589 (1993) ; Le Gall et al..Plant Science. 102:161-170 (1994) ; Martinelli et al. , Theor. Ap l . Genetics. 88:621-628 (1994) ; Mullins et al. , Bio/Technol gy. 8:1041-1045 (1990)) . Recently, an efficient regeneration system using proliferative somatic embryogenesis and subsequent plant development has been developed from zygotic embryos of stenospermic seedless grapes (Mozsar, J. et al., Vi is. 33:245-246 (1994) ; Emerschad (1995)) . Using this regeneration system, Scorza et al., Plant Cell Rennrfs, 14:589-592 (1995) succeeded in obtaining transgenic grapevines through zygotic-derived somatic embryos after particle- wounding/A. tumefaciens treatment. Using a Biolistic device, tiny embryos were shot with gold particles (1.0 μm in diameter) . The wounded embryos were then co-cultivated with A . tumefaciens containing engineered plasmids carrying the selection marker of kanamycin resistance and β-glucuronidase (GUS) genes. Selection of transgenic grapevines was carried out with 20 μg/ml kanamycin in the initial stage and then 40 μg/ml for later proliferation. Small rooted seedlings were obtained from embryogenic culture within 5 months of bombardment /A. tumefaciens (Scorza (1995) ) . Transgenic grapevines were analyzed by PCR and Southern hybridization, and shown to carry the transgenes. The above-mentioned grapevine transformation approach has been carried out in the current investigation to generate transgenic grapevines expressing GLRaV-3 genes. Evaluation of any potential leafroll resistance on transgenic grapevines is carried out using insect vectors or by grafting. Example 19 - Production of Antibodies Recognizing GT,RaV3 E. coli harboring the clone pCPlO-l, which contains the major portion of the coat protein gene of GLRaV3 (Figure 4) , was used to express the coat protein and the β-galactosidase fusion protein. About 500 ml of LB medium containing 50 μg/ml of ampicillin was inoculated with a single colony and incubated with rigorous shaking for overnight until log-phase growth. Expression of the fusion protein was induced by the addition of 1 mM IPTG. Bacteria were harvested by centrifugation at 5,000 rpm for 10 min. The bacterial envelope was broken by sonication. After low speed centrifugation to remove cell debris, the fusion protein was precipitated by the addition of saturated ammonium sulfate, then resuspended in PBS buffer and electrophoresed in a SDS- polyacrylamide gel (SDS-PAGE) . The fusion protein band was excised after soaking the SDS-PAGE gel in 0.25M KCl to locate the protein band. The protein was eluted with buffer (0.05M Tris-HCl, pH 7.9, 0.1% SDS, 0.1 mM EDT and 0.15 M NaCl) and precipitated by the addition of trichloroacetic acid to a final concentration of 20%. An antiserum was prepared by immunization of a rabbit with 0.5-1 mg of the purified protein emulsified with Freund's completed adjuvant followed by two more weekly injections of 0.5-1 mg protein emulsified with Freund's incomplete adjuvant. After the last injection, antiserum was prepared from blood collected from the rabbit every week for a period of 4 months . On Western blot analysis, the antibody gave a specific reaction to the 41K protein in GLRaV3 infected tissue as well as to the fusion protein itself (50K) and generated a pattern similar to the pattern seen in Figure 3. This antibody was also successfully used as a coating antibody and as an antibody-conjugate in an enzyme linked immunosorbent assay (ELISA) . The above method of producing antibody to GLRaV3 can also be applied to other GLRaV-3 gene sequences of the present invention. The method affords a large amount of highly purified protein from E. coli from which antibodies can be readily obtained. It is particularly useful in the common case where it is rather difficult to obtain sufficient amount of purified virus from GLRaV3 infected grapevine tissues. Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims. SEQUENCE LISTING ( 1) GENERAL INFORMATION : (i) APPLICANT: Cornell Research Foundation, Inc. (ii) TITLE OF INVENTION: Grapevine Leafroll virus Proteins and Their Uses (iii) NUMBER OF SEQUENCES: 32 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Greenlee, Winner and Sullivan, P.C. (B) STREET: 5370 Manhattan Circle, Suite 201 (C) CITY: Boulder (D) STATE: Colorado (E) COUNTRY: US (F) ZIP: 80303 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/009,008 (B) FILING DATE: 20-DEC-1995 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Ferber, Donna M. (B) REGISTRATION NUMBER: 33,878 (C) REFERENCE/DOCKET NUMBER: 99-96 ZA (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (303) 499-8080 (B) TELEFAX: (303) 499-8089 66 ( 2 ) INFORMATION FOR SEQ ID NO : l : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 4173 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GTGTCTACTT ACGCGAAGAG TGTGATGAAC GACAATTTCA ATATCCTTGA GACCCTGGTA 60 ACTTTGCCCA AGTCCTTTAT AGTCAAAGTA CCTGGTTCGG TGCTGGTTAG CATAACCACT 120 TCGGGCATTT CCGACAAACT TGAACTTCGG GGCGCGTTCG ACGTTTCTAA AAAGAATTTC 180 TCCAGGAGGT TACGTTCGAG TCGTTTGCGC GTATTTTCTA GGGCTATTGT GGAGGATACG 240 ATCAAGGTTA TGAAGGGCAT GAAATCAGAG GATGGTAAAC CACTCCCTAT AGCCGAGGAT 300 TCCGTGTACG CGTTCATGAC AGGCAATATG TCAAACGTTC ATTGCACTAG GGCTGGTTTG 360 CTCGGGGGCT CAAAGGCTTG CGCGGCTTCT TTAGCTGTGA AGGGTGCAGC TTCACGCGCT 420 ACTGGAACAA AACTCTTTTC AGGTCTCACA TCCTTTCTTT CCGCCGGTGG TCTGTTTTAC 480 GATGAAGGCT TGACGCCCGG AGAGAGGCTT GATGCACTAA CGCGCCGTGA ACATGCTGTG 540 AATTCACCTG TAGGCCTCTT AGAACCTGGA GCTTCGGTTG CGAAGCGGGT CGTTTCCGGA 600 ACGAAAGCTT TTCTGTCAGA ATTGTCATTG GAGGACTTCA CCACTTTCGT CATAAAAAAT 660 AGGGTGCTTA TTGGTGTTTT TACTCTTTCC ATGGCTCTCA CTCCGGTGGT CTGGAAGTAC 720 AGAAGGAATA TCGCGCGAAC TGGCGTGGAT GTTTTCCACC GTGCTCGTTC GGGTACCGCG 780 GCCATCGGTT TACAATGTCT TAGTGGAGGA AGGTCGTTAG CTGGTGACGC TGCTCGTGGC 840 GCGTTAACAG TGACTCGAGG AGGGCTATCT TCGGCGGTTG CGGTGACCAG AAATACAGTG 900 GCTAGGCGTC AGGTACCATT GGCGTTGCTT TCGTTTTCCA CGTCTTACGC AGTCAGTGGT 960 TGCACTTTGT TAGGTATTTG GGCTCATGCT CTCCCTAGGC ATTTGATGTT CTTCTTTGGC 1020 CTAGGGACGC TCTTCGGGGT GAGTGCCAGT ACCAATTCTT GGTCGCTTGG GGGCTATACG 1080 AACAGTCTGT TCACCGTACC GGAATTAACT TGGGAAGGGA GGAGTTACAG ATCTTTATTG 1140 CCCCAAGCAG CTTTAGGTAT TTCTCTCGTT GTGCGCGGGT TGTTAAGTGA AACTGTGCCA 1200 CAACTAACGT ACGTACCGCC GATTGAAGGT CGGAATGTTT ATGATCAGGC ACTAAATTTT 1260 TATCGCGACT TTGACTATGA CGATGGTGCA GGCCCATCCG GGACGGCTGG TCAAAGCGAT 1320 CCTGGAACCA ATACTTCGGA TACTTCTTCG GTTTTCTCTG ACGATGGTTT GCCCGCTAGT 1380 GGCGGTGGCT TCGACGCGCG CGTTGAGGCA GGTCCCAGCC ATGCTGTTGA TGAATCACCA 1440 AGGGGTAGTG TTGAGTTCGT CTACAGAGAA CGTGTAGATG AACATCCGGC GTGTGGTGAA 1500 GCTGAAGTTG AAAAGGATCT AATAACACCA CTTGGTACAG CTGTCTTAGA GTCGCCCCCC 1560 GTAGGTCCTG AAGCTGGGAG CGCGCCCAAC GTCGAGGACG GTTGTCCGGA GGTTGAAGCT 1620 GAGAAATGTT CGGAGGTCAT CGTTGACGTT CCTAGTTCAG AACCGCCGGT ACAAGAAGTC 1680 CTTGAATCAA CCAATGGTGT CCAAGCTGCA AGAACTGAAG AGGTTGTGCA GGGCGACACA 1740 TGTGGAGCTG GGGTAGCTAA ATCAGAAGTG AGTCAACGTG TGTTTCCTGC GCAAGTACCC 1800 GCACATGAAG CTGGTCTTGA GGCATCTAGT GGCGCGGTCG TGGAGCCATT GCAAGTTTCT 1860 GTGCCAGTAG CCGTAGAGAA AACTGTTTTA TCTGTCGAGA AGGCGCGTGA GCTAAAGGCG 1920 GTAGATAAGG GCAAGGCGGT CGTGCACGCA AAGGAAGTCA AGAATGTACC GGTTAAGACG 1980 TTACCACGAG GGGCTCTAAA AATTAGTGAG GATACCGTTC GTAAGGAATT GTGCATGTTT 2040 AGAACGTGTT CCTGCGGCGT GCAGTTGGAC GTGTACAATG AAGCGACCAT CGCCACTAGG 2100 TTCTCAAATG CGTTTACCTT TGTCGAT GC TTGAAAGGGA GGAGTGCGGT CTTTTTCTCA 2160 AAGCTGGGTG AGGGGTATAC CTATAATGGT GGTAGCCATG TTTCATCAGG GTGGCCTCGT 222D GCCCTAGAGG ATATCTTAAC GGCAATTAAG TACCCAAGCG TCTTCGACCA CTGTTTAGTG 2280 CAGAAGTACA AGATGGGTGG AGGCGTACCA TTCCACGCTG ATGACGAGGA GTGCTATCCA 2340 TCAGATAACC CTATCTTGAC GGTCAATCTC GTGGGGAAGG CAAACTTCTC GACTAAGTGC 2400 AGGAAGGGTG GTAAGGTCAT GGTCATAAAC GTAGCTTCGG GTGACTATTT TCTTATGCCT 2460 TGCGGTTTTC AAAGGACGCA CTTGCATTCA GTAAACTCCA TCGACGAAGG GCGCATCAGT 2520 TTGACGTTCA GGGCAACTCG GCGCGTCTTT GGTGTAGGCA GGATGTTGCA GTTAGCCGGC 2580 GGCGTGTCGG ATGAGAAGTC ACCAGGTGTT CCAAACCAGC AACCACAGAG CCAAGGTGCT 2640 ACCAGAACAA TCACACCAAA ATCGGGGGGC AAGGCTCTAT CTGAGGGAAG TGGTAGGGAA 2700 GTCAAGGGGA GGTCGACATA CTCGATATGG TGCGAACAAG ATTACGTTAG GAAGTGTGAG 2760 TGGCTCAGGG CTGATAATCC AGTGATGGCT CTTAAACCTG GCTACACCCC AATGACATTT 2820 GAAGTGGTTA AAGCCGGGAC CTCTGAAGAT GCCGTCGTGG AGTACTTGAA GTATCTGGCT 2880 ATAGGCATTG GGAGGACATA CAGGGCGTTG CTTATGGCTA GAAATATTGC CGTCACTACC 2940 GCCGAAGGTG TTCTGAAAGT ACCTAATCAA GTTTATGAAT CACTACCGGG CTTTCACGTT 3000 TACAAGTCGG GCACAGATCT CATTTTTCAT TCAACACAAG ACGGCTTGCG TGTGAGAGAC 3060 CTACCGTACG TATTCATAGC TGAGAAAGGT ATTTTTATCA AGGGCAAAGA TGTCGACGCG 3120 GTAGTAGCTT TGGGCGACAA TCTGTCCGTA TGTGATGATA TATTGGTTTT CCATGATGCT 3180 ATTAATTTGA TGGGTGCACT GAAAGTTGCT CGATGTGGTA TGGTGGGTGA ATCATTTAAG 3240 TCGTTCGAAT ACAAATGCTA TAATGCTCCC CCAGGTGGCG GTAAGACGAC GATGCTAGTG 3300 GACGAATTTG TCAAGTCACC CAATAGCACG GCCACCATTA CGGCTAACGT GGGAAGTTCT 3360 GAGGACATAA ATATGGCGGT GAAGAAGAGA GATCCGAATT TGGAAGGTCT CAACAGTGCT 3420 ACCACAGTTA ACTCCAGGGT GGTTAACTTT ATTGTCAGGG GAATGTATAA AAGGGTTTTG 3480 GTGGATGAGG TGTACATGAT GCATCAAGGC TTACTACAAC TAGGCGTCTT CGCAACCGGC 3540 GCGTCGGAAG GCCTCTTTTT TGGAGACATA AATCAGATAC CATTCATAAA CCGGGAGAAG 3600 GTGTTTAGGA TGGATTGTGC TGTATTTGTT CCAAAGAAGG AAAGCGTTGT ATACACTTCT 3660 AAATCATACA GGTGTCCGTT AGATGTTTGC TACTTGTTGT CCTCAATGAC CGTAAGGGGA 3720 ACGGAAAAGT GTTACCCTGA AAAGGTCGTT AGCGGTAAGG ACAAACCAGT AGTAAGATCG 3780 CTGTCCAAAA GGCCAATTGG AACCACTGAT GACGTAGCTG AAATAAACGC TGACGTGTAC 3840 TTGTGCATGA CCCAGTTGGA GAAGTCGGAT ATGAAGAGGT CGTTGAAGGG AAAAGGAAAA 3900 GAAACACCAG TGATGACAGT GCATGAAGCA CAGGGAAAAA CATTCAGTGA TGTGGTATTG 3960 TTTAGGACGA AGAAAGCCGA TGACTCCCTA TTCACTAAAC AACCGCATAT ACTTGTTGGT 4020 TTGTCGAGAC ACACACGCTC ACTGGTTTAT GCCGCTCTGA GCTCAGAGTT GGACGATAAG 4080 GTCGGCACAT ATATTAGCGA CGCGTCGCCT CAATCAGTAT CCGACGCTTT GCTTCACACG 4140 TTCGCCCCGG CTGGTTGCTT TCGAGGTATA TGA 4173 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1390 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Val Ser Thr Tyr Ala Lys Ser Val Met Asn Asp Asn Phe Asn lie Leu 1 5 10 15 Glu Thr Leu Val Thr Leu Pro Lys Ser Phe lie Val Lys Val Pro Gly 20 25 30 Ser Val Leu Val Ser lie Thr Thr Ser Gly lie Ser Asp Lys Leu Glu 35 40 45 Leu Arg Gly Ala Phe Asp Val Ser Lys Lys Asn Phe Ser Arg Arg Leu 50 55 60 Arg Ser Ser Arg Leu Arg Val Phe Ser Arg Ala lie Val Glu Asp Thr 65 70 75 80 He Lys Val Met Lys Gly Met Lys Ser Glu Asp Gly Lys Pro Leu Pro 85 90 95 He Ala Glu Asp Ser Val Tyr Ala Phe Met Thr Gly Asn Met Ser Asn 100 105 110 Val His Cys Thr Arg Ala Gly Leu Leu Gly Gly Ser Lys Ala Cys Ala 115 120 125 Ala Ser Leu Ala Val Lys Gly Ala Ala Ser Arg Ala Thr Gly Thr Lys 130 135 140 Leu Phe Ser Gly Leu Thr Ser Phe Leu Ser Ala Gly Gly Leu Phe Tyr 145 150 155 160 Asp Glu Gly Leu Thr Pro Gly Glu Arg Leu Asp Ala Leu Thr Arg Arg 165 170 175 Glu His Ala Val Asn Ser Pro Val Gly Leu Leu Glu Pro Gly Ala Ser 180 185 190 Val Ala Lys Arg Val Val Ser Gly Thr Lys Ala Phe Leu Ser Glu Leu 195 200 205 Ser Leu Glu Asp Phe Thr Thr Phe Val He Lys Asn Arg Val Leu He 210 215 220 Gly Val Phe Thr Leu Ser Met Ala Leu Thr Pro Val Val Trp Lys Tyr 225 230 235 240 Arg Arg Asn He Ala Arg Thr Gly Val Asp Val Phe His Arg Ala Arg 245 250 255 Ser Gly Thr Ala Ala He Gly Leu Gin Cys Leu Ser Gly Gly Arg Ser 260 265 270 Ala Ala Arg Gly Ala Leu Thr Val Thr Arg Gly Gly Leu Ala Gly Asp 275 280 285 Leu Ser Ser Ala Val Ala Val Thr Arg Asn Thr Val Ala Arg Arg Gin 290 295 300 Val Pro Leu Ala Leu Leu Ser Phe Ser Thr Ser Tyr Ala Val Ser Gly 315 320 305 310 Cys Thr Leu Leu Gly He Trp Ala His Ala Leu Pro Arg His Leu Met 325 330 335 Phe Phe Phe Gly Leu Gly Thr Leu Phe Gly Val Ser Ala Ser Thr Asn 340 Ser Trp Ser Leu Gly Gly Tyr Thr Asn Ser Leu Phe Thr Val Pro Glu 355 360 365 Leu Thr Trp Glu Gly Arg Ser Tyr Arg Ser Leu Leu Pro Gin Ala Ala 370 375 380 Leu Gly He Ser Leu Val Val Arg Gly Leu Leu Ser Glu Thr Val Pro 385 390 395 400 Gin Leu Thr Tyr Val Pro Pro He Glu Gly Arg Asn Val Tyr Asp Gin 4 05 410 415 Ala Leu Asn Phe Tyr Arg Asp Phe Asp Tyr Asp Asp Gly Ala Gly Pro 420 425 430 Ser Gly Thr Ala Gly Gin Ser Asp Pro Gly Thr Asn Thr Ser Asp Thr 435 440 445 Ser Ser Val Phe Ser Asp Asp Gly Leu Pro Ala Ser Gly Gly Gly Phe i 460 450 45b Asp Ala Arg Val Glu Ala Gly Pro Ser His Ala Val Asp Glu Ser Pro 475 480 465 470 A r α Gly S er V al Glu Phe Val Tyr Arg Glu Arg V al Asp Glu His Pro 4 85 490 Ala Cys Glv Glu Ala Glu Val Glu Lys Asp Leu He Thr Pro Leu Gly 500 505 510 Thr Ala Val Leu Glu Ser Pro Pro Val Gly Pro Glu Ala Gly Ser Ala 515 520 525 Pro Asn Val Glu Asp Gly Cys Pro Glu Val Glu Ala Glu Lys Cys Ser 530 535 540 Glu Val He Val Asp Val Pro Ser Ser Glu Pro Pro Val Gin Glu Val 545 550 555 560 Leu Glu Ser Thr Asn Gly Val Gin Ala Ala Arg Thr Glu Glu Val Val 565 570 575 Gin Gly Asp Thr Cys Gly Ala Gly Val Ala Lys Ser Glu Val Ser Gin 580 585 590 Arg Val Phe Pro Ala Gin Val Pro Ala His Glu Ala Gly Leu Glu Ala 595 600 605 Ser Ser Gly Ala Val Val Glu Pro Leu Gin Val Ser Val Pro Val Ala 610 615 620 Val Glu Lys Thr Val Leu Ser Val Glu Lys Ala Arg Glu Leu Lys Ala 625 630 635 640 Val Asp Lys Gly Lys Ala Val Val His Ala Lys Glu Val Lys Asn Val 645 650 655 Pro Val Lys Thr Leu Pro Arg Gly Ala Leu Lys He Ser Glu Asp Thr 660 665 670 Val Arg Lys Glu Leu Cys Met Phe Arg Thr Cys Ser Cys Gly Val Gin 675 680 685 Leu Asp Val Tyr Asn Glu Ala Thr He Ala Thr Arg Phe Ser Asn Ala 690 695 700 Phe Thr Phe Val Asp Ser Leu Lys Gly Arg Ser Ala Val Phe Phe Ser 705 710 715 720 Lys Leu Gly Glu Gly Tyr Thr Tyr Asn Gly Gly Ser His Val Ser Ser 725 730 735 Gly Trp Pro Arg Ala Leu Glu Asp He Leu Thr Ala He Lys Tyr Pro 740 745 750 Ser Val Phe Asp His Cys Leu Val Gin Lys Tyr Lys Met Gly Gly Gly 755 760 765 Val Pro Phe His Ala Asp Asp Glu Glu Cys Tyr Pro Ser Asp Asn Pro 770 775 780 He Leu Thr Val Asn Leu Val Gly Lys Ala Asn Phe Ser Thr Lys Cys 785 790 795 800 Arg Lys Gly Gly Lys Val Met Val He Asn Val Ala Ser Gly Asp Tyr 805 810 815 Phe Leu Met Pro Cys Gly Phe Gin Arg Thr His Leu His Ser Val Asn 820 825 830 Ser He Asp Glu Gly Arg He Ser Leu Thr Phe Arg Ala Thr Arg Arg 835 840 845 Val Phe Gly Val Gly Arg Met Leu Gin Leu Ala Gly Gly Val Ser Asp 850 855 860 Glu Lys Ser Pro Gly Val Pro Asn Gin Gin Pro Gin Ser Gin Gly Ala 865 870 875 880 Thr Arg Thr He Thr Pro Lys Ser Gly Gly Lys Ala Leu Ser Glu Gly 885 890 895 Ser Gly Arg Glu Val Lys Gly Arg Ser Thr Tyr Ser He Trp Cys Glu 900 905 910 Gin Asp Tyr Val Arg Lys Cys Glu Trp Leu Arg Ala Asp Asn Pro Val 915 920 925 Met Ala Leu Lys Pro Gly Tyr Thr Pro Met Thr Phe Glu Val Val Lys 930 935 940 Ala Gly Thr Ser Glu Asp Ala Val Val Glu Tyr Leu Lys Tyr Leu Ala 945 950 955 960 He Gly He Gly Arg Thr Tyr Arg Ala Leu Leu Met Ala Arg Asn He 965 970 975 Ala Val Thr Thr Ala Glu Gly Val Leu Lys Val Pro Asn Gin Val Tyr 980 985 990 Glu Ser Leu Pro Gly Phe His Val Tyr Lys Ser Gly Thr Asp Leu He 995 1000 1005 Phe His Ser Thr Gin Asp Gly Leu Arg Val Arg Asp Leu Pro Tyr Val 1010 1015 1020 Phe He Ala Glu Lys Gly He Phe He Lys Gly Lys Asp Val Asp Ala 1025 1030 1035 1040 Val Val Ala Leu Gly Asp Asn Leu Ser Val Cys Asp Asp He Leu Val 1045 1050 1055 Phe His Asp Ala He Asn Leu Met Gly Ala Leu Lys Val Ala Arg Cys 1060 1065 1070 Gly Met Val Gly Glu Ser Phe Lys Ser Phe Glu Tyr Lys Cys Tyr Asn 1075 1080 1085 Ala Pro Pro Gly Gly Gly Lys Thr Thr Met Leu Val Asp Glu Phe Val 1090 1095 1100 Lys Ser Pro Asn Ser Thr Ala Thr He Thr Ala Asn Val Gly Ser Ser 1105 1110 1115 1120 Glu Asp He Asn Met Ala Val Lys Lys Arg Asp Pro Asn Leu Glu Gly 1125 1130 1135 Leu Asn Ser Ala Thr Thr Val Asn Ser Arg Val Val Asn Phe He Val 1140 1145 1150 Arg Gly Met Tyr Lys Arg Val Leu Val Asp Glu Val Tyr Met Met His 1155 1160 1165 Gin Gly Leu Leu Gin Leu Gly Val Phe Ala Thr Gly Ala Ser Glu Gly 1170 1175 1180 Leu Phe Phe Gly Asp He Asn Gin He Pro Phe He Asn Arg Glu Lys 1185 1190 1195 1200 Val Phe Arg Met Asp Cys Ala Val Phe Val Pro Lys Lys Glu Ser Val 1205 1210 1215 Val Tyr Thr Ser Lys Ser Tyr Arg Cys Pro Leu Asp Val Cys Tyr Leu 1220 1225 1230 Leu Ser Ser Met Thr Val Arg Gly Thr Glu Lys Cys Tyr Pro Glu Lys 1235 1240 1245 Val Val Ser Gly Lys Asp Lys Pro Val Val Arg Ser Leu Ser Lys Arg 1250 1255 1260 Pro He Gly Thr Thr Asp Asp Val Ala Glu He Asn Ala Asp Val Tyr 1265 1270 1275 1280 Leu Cys Met Thr Gin Leu Glu Lys Ser Asp Met Lys Arg Ser Leu Lys 1285 1290 1295 Gly Lys Gly Lys Glu Thr Pro Val Met Thr Val His Glu Ala Gin Gly 1300 1305 1310 Lys Thr Phe Ser Asp Val Val Leu Phe Arg Thr Lys Lys Ala Asp Asp 1315 1320 1325 Ser Leu Phe Thr Lys Gin Pro His He Leu Val Gly Leu Ser Arg His 1330 1335 1340 Thr Arg Ser Leu Val Tyr Ala Ala Leu Ser Ser Glu Leu Asp Asp Lys 1345 1350 1355 1360 Val Gly Thr Tyr He Ser Asp Ala Ser Pro Gin Ser Val Ser Asp Ala 1365 1370 1375 Leu Leu His Thr Phe Ala Pro Ala Gly Cys Phe Arg Gly He 1380 1385 1390 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1602 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATGAATTTTG GACCGACCTT CGAAGGGGAG TTGGTACGGA AGATACCAAC AAGTCATTTT 60 GTAGCCGTGA ATGGGTTTCT CGAGGACTTA CTCGACGGTT GTCCGGCTTT CGACTATGAC 120 TTCTTTGAGG ATGATTTCGA AACTTCAGAT CAGTCTTTCC TCATAGAAGA TGTGCGCATT 180 TCTGAATCTT TTTCTCATTT TGCGTCGAAA ATAGAGGATA GGTTTTACAG TTTTATTAGG 240 TCTAGCGTAG GTTTACCAAA GCGCAACACC TTGAAGTGTA ACCTCGTCAC GTTTGAAAAT 300 AGGAATTCCA ACGCCGATCG CGGTTGTAAC GTGGGTTGTG ACGACTCTGT GGCGCATGAA 360 CTGAAGGAGA TTTTCTTCGA GGAGGTCGTT AACAAAGCTC GTTTAGCAGA GGTGACGGAA 420 AGCCATTTGT CCAGCAACAC GATGTTGTTA TCAGATTGGT TGGACAAAAG GGCACCTAAC 480 GCTTACAAGT CTCTCAAGCG GGCTTTAGGT TCGGTTGTCT TTCATCCGTC TATGTTGACG 540 TCTTATACGC TCATGGTGAA AGCAGACGTA AAACCCAAGT TGGACAATAC GCCATTGTCG 600 AAGTACGTAA CGGGGCAGAA TATAGTCTAC CACGATAGGT GCGTAACTGC GCTTTTTTCT 660 TGCATTTTTA CTGCGTGCGT AGAGCGCTTA AAATACGTAG TGGACGAAAG GTGGCTCTTC 720 TACCACGGGA TGGACACTGC GGAGTTGGCG GCTGCATTGA GGAACAATTT GGGGGACATC 780 CGGCAATACT ACACCTATGA ACTGGATATC AGTAAGTACG ACAAATCTCA GAGTGCTCTC 840 ATGAAGCAGG TGGAGGAGTT GATACTCTTG ACACTTGGTG TTGATAGAGA AGTTTTGTCT 900 ACTTTCTTTT GTGGTGAGTA TGATAGCGTC GTGAGAACGA TGACGAAGGA ATTGGTGTTG 960 TCTGTCGGCT CTCAGAGGCG CAGTGGTGGT GCTAACACGT GGTTGGGAAA TAGTTTAGTC 1020 TTGTGCACCT TGTTGTCCGT AGTACTTAGG GGATTAGATT ATAGTTATAT TGTAGTTAGC 1080 GGTGATGATA GCCTTATATT TAGTCGGCAG CCGTTGGATA TTGATACGTC GGTTCTGAGC 1140 GATAATTTTG GTTTTGACGT AAAGATTTTT AACCAAGCTG CTCCATATTT TTGTTCTAAG 1200 TTTTTAGTTC AAGTCGAGGA TAGTCTCTTT TTTGTTCCCG ATCCACTTAA ACTCTTCGTT 1260 AAGTTTGGAG CTTCCAAAAC TTCAGATATC GACCTTTTAC ATGAGATTTT TCAATCTTTC 1320 GTCGATCTTT CGAAGGGTTT CAATAGAGAG GACGTCATCC AGGAATTAGC TAAGCTGGTG 1380 ACGCGGAAAT ATAAGCATTC GGGATGGACC TACTCGGCTT TGTGTGTCTT GCACGTTTTA 1440 AGTGCAAATT TTTCGCAGTT CTGTAGGTTA TATTACCACA ATAGCGTGAA TCTCGATGTG 1500 CGCCCTATTC AGAGGACCGA GTCGCTTTCC TTGCTGGCCT TGAAGGCAAG AATTTTAAGG 1560 TGGAAAGCTT CTCGTTTTGC CTTTTCGATA AAGAGGGGTT AA 1602 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 533 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Asn Phe Gly Pro Thr Phe Glu Gly Glu Leu Val Arg Lys He Pro 1 5 10 15 Thr Ser His Phe Val Ala Val Asn Gly Phe Leu Glu Asp Leu Leu Asp 20 25 30 Gly Cys Pro Ala Phe Asp Tyr Asp Phe Phe Glu Asp Asp Phe Glu Thr 35 40 45 Ser Asp Gin Ser Phe Leu He Glu Asp Val Arg He Ser Glu Ser Phe 50 55 60 Ser His Phe Ala Ser Lys He Glu Asp Arg Phe Tyr Ser Phe He Arg 65 70 75 80 Ser Ser Val Gly Leu Pro Lys Arg Asn Thr Leu Lys Cys Asn Leu Val 85 90 95 Thr Phe Glu Asn Arg Asn Ser Asn Ala Asp Arg Gly Cys Asn Val Gly 100 105 110 Cys Asp Asp Ser Val Ala His Glu Leu Lys Glu He Phe Phe Glu Glu 115 120 125 Val Val Asn Lys Ala Arg Leu Ala Glu Val Thr Glu Ser His Leu Ser 130 135 140 Ser Asn Thr Met Leu Leu Ser Asp Trp Leu Asp Lys Arg Ala Pro Asn 145 150 155 160 Ala Tyr Lys Ser Leu Lys Arg Ala Leu Gly Ser Val Val Phe His Pro 165 170 175 Ser Met Leu Thr Ser Tyr Thr Leu Met Val Lys Ala Asp Val Lys Pro 180 185 190 Lys Leu Asp Asn Thr Pro Leu Ser Lys Tyr Val Thr Gly Gin Asn He 195 200 205 Val Tyr His Asp Arg Cys Val Thr Ala Leu Phe Ser Cys He Phe Thr 210 215 220 Ala Cys Val Glu Arg Leu Lys Tyr Val Val Asp Glu Arg Trp Leu Phe 225 230 235 240 Tyr His Gly Met Asp Thr Ala Glu Leu Ala Ala Ala Leu Arg Asn Asn 245 250 255 Leu Gly Asp He Arg Gin Tyr Tyr Thr Tyr Glu Leu Asp He Ser Lys 260 265 270 Tyr Asp Lys Ser Gin Ser Ala Leu Met Lys Gin Val Glu Glu Leu He 275 280 285 Leu Leu Thr Leu Gly Val Asp Arg Glu Val Leu Ser Thr Phe Phe Cys 290 295 300 Gly Glu Tyr Asp Ser Val Val Arg Thr Met Thr Lys Glu Leu Val Leu 305 310 315 320 Ser Val Gly Ser Gin Arg Arg Ser Gly Gly Ala Asn Thr Trp Leu Gly 325 330 335 Asn Ser Leu Val Leu Cys Thr Leu Leu Ser Val Val Leu Arg Gly Leu 340 345 350 Asp Tyr Ser Tyr He Val Val Ser Gly Asp Asp Ser Leu He Phe Ser 355 360 365 Arg Gin Pro Leu Asp He Asp Thr Ser Val Leu Ser Asp Asn Phe Gly 370 375 380 Phe Asp Val Lys He Phe Asn Gin Ala Ala Pro Tyr Phe Cys Ser Lys 385 390 395 400 Phe Leu Val Gin Val Glu Asp Ser Leu Phe Phe Val Pro Asp Pro Leu 405 410 415 Lys Leu Phe Val Lys Phe Gly Ala Ser Lys Thr Ser Asp He Asp Leu 420 425 430 Leu His Glu He Phe Gin Ser Phe Val Asp Leu Ser Lys Gly Phe Asn 435 440 445 Arg Glu Asp Val He Gin Glu Leu Ala Lys Leu Val Thr Arg Lys Tyr 450 455 460 Lys His Ser Gly Trp Thr Tyr Ser Ala Leu Cys Val Leu His Val Leu 465 470 475 480 Ser Ala Asn Phe Ser Gin Phe Cys Arg Leu Tyr Tyr His Asn Ser Val 485 490 495 Asn Leu Asp Val Arg Pro He Gin Arg Thr Glu Ser Leu Ser Leu Leu 500 505 510 Ala Leu Lys Ala Arg He Leu Arg Trp Lys Ala Ser Arg Phe Ala Phe 515 520 525 Ser He Lys Arg Gly 530 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1650 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY : not relevant ( i i ) MOLECULE TYPE : cDNA ( iii ) HYPOTHETICAL : NO ( iv) ANT I - SENSE : NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATGGAAGTAG GTATAGATTT TGGAACCACT TTCAGCACAA TCTGCTTTTC CCCATCTGGG 60 GTCAGCGGTT GTACTCCTGT GGCCGGTAGT GTTTACGTTG AAACCCAAAT TTTTATACCT 120 GAAGGTAGCA GTACTTACTT AATTGGTAAA GCTGCGGGGA AAGCTTATCG TGACGGTGTA 180 GAGGGAAGGT TGTATGTTAA CCCGAAAAGG TGGGCAGGTG TGACGAGGGA TAACGTCGAA 240 CGCTACGTCG AGAAATTAAA ACCTACATAC ACCGTGAAGA TAGACAGCGG AGGCGCCTTA 300 TTAATTGGAG GTTTAGGTTC CGGACCAGAC ACCTTATTGA GGGTCGTTGA CGTAATATGT 360 TTATTCTTGA GAGCCTTGAT ACTGGAGTGC GAAAGGTATA CGTCTACGAC GGTTACAGCA 420 GCTGTTGTAA CGGTACCGGC TGACTATAAC TCCTTTAAAC GAAGCTTCGT TGTTGAGGCG 480 CTAAAAGGTC TTGGTATACC GGTTAGAGGT GTTGTTAACG AACCGACGGC CGCAGCCCTC 540 TATTCCTTAG CTAAGTCGCG AGTAGAAGAC CTATTATTAG CGGTTTTTGA TTTTGGGGGA 600 GGGACTTTCG ACGTCTCATT CGTTAAGAAG AAGGGAAATA TACTATGCGT CATCTTTTCA 660 GTGGGTGATA ATTTCTTGGG TGGTAGAGAT ATTGATAGAG CTATCGTGGA AGTTATCAAA 720 CAAAAGATCA AAGGAAAGGC GTCTGATGCC AAGTTAGGGA TATTCGTATC CTCGATGAAG 780 GAAGACTTGT CTAACAATAA CGCTATAACG CAACACCTTA TCCCCGTAGA AGGGGGTGTG 840 GAGGTTGTGG ATTTGACTAG CGACGAACTG GACGCAATCG TTGCACCATT CAGCGCTAGG 900 GCTGTGGAAG TATTCAAAAC TGGTCTTGAC AACTTTTACC CAGACCCGGT TATTGCCGTT 960 ATGACTGGGG GGTCAAGTGC TCTAGTTAAG GTCAGGAGTG ATGTGGCTAA TTTGCCGCAG 1020 ATATCTAAAG TCGTGTTCGA CAGTACCGAT TTTAGATGTT CGGTGGCTTG TGGGGCTAAG 1080 GTTTACTGCG ATACTTTGGC AGGTAATAGC GGACTGAGAC TGGTGGACAC TTTAACGAAT 1140 ACGCTAACGG ACGAGGTAGT GGGTCTTCAG CCGGTGGTAA TTTTCCCGAA AGGTAGTCCA 1200 ATACCCTGTT CATATACTCA TAGATACACA GTGGGTGGTG GAGATGTGGT ATACGGTATA 1260 TTTGAAGGGG AGAATAACAG AGCTTTTCTA AATGAGCCGA CGTTCCGGGG CGTATCGAAA 1320 CGTAGGGGAG ACCCAGTAGA GACCGACGTG GCGCAGTTTA ATCTCTCCAC GGACGGAACG 1380 GTGTCTGTTA TCGTTAATGG TGAGGAAGTA AAGAATGAAT ATCTGGTACC CGGGACAACA 1440 AACGTACTGG ATTCATTGGT CTATAAATCT GGGAGAGAAG ATTTAGAGGC TAAGGCAATA 1500 CCAGAGTACT TGACCACACT GAATATTTTG CACGATAAGG CTTTCACGAG GAGAAACCTG 1560 GGTAACAAAG ATAAGGGGTT CTCGGATTTA AGGATAGAAG AAAATTTTTT AAAATCCGCC 1620 GTAGATACAG ACACGATTTT GAATGGATAA 1650 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 549 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 : Met Glu Val Gly He Asp Phe Gly Thr Thr Phe Ser Thr He Cys Phe 1 5 10 15 Ser Pro Ser Gly Val Ser Gly Cys Thr Pro Val Ala Gly Ser Val Tyr 20 25 30 Val Glu Thr Gin He Phe He Pro Glu Gly Ser Ser Thr Tyr Leu He 35 40 45 Gly Lys Ala Ala Gly Lys Ala Tyr Arg Asp Gly Val Glu Gly Arg Leu 50 55 60 Tyr Val Asn Pro Lys Arg Trp Ala Gly Val Thr Arg Asp Asn Val Glu 65 70 75 80 Arg Tyr Val Glu Lys Leu Lys Pro Thr Tyr Thr Val Lys He Asp Ser 85 90 95 Gly Gly Ala Leu Leu He Gly Gly Leu Gly Ser Gly Pro Asp Thr Leu 100 105 110 Leu Arg Val Val Asp Val He Cys Leu Phe Leu Arg Ala Leu He Leu 115 120 125 Glu Cys Glu Arg Tyr Thr Ser Thr Thr Val Thr Ala Ala Val Val Thr 130 135 140 Val Pro Ala Asp Tyr Asn Ser Phe Lys Arg Ser Phe Val Val Glu Ala 145 150 155 160 Leu Lys Gly Leu Gly He Pro Val Arg Gly Val Val Asn Glu Pro Thr 165 170 175 Ala Ala Ala Leu Tyr Ser Leu Ala Lys Ser Arg Val Glu Asp Leu Leu 180 185 190 Leu Ala Val Phe Asp Phe Gly Gly Gly Thr Phe Asp Val Ser Phe Val 195 200 205 Lys Lys Lys Gly Asn He Leu Cys Val He Phe Ser Val Gly Asp Asn 210 215 220 Phe Leu Gly Gly Arg Asp He Asp Arg Ala He Val Glu Val He Lys 225 230 235 240 Gin Lys He Lys Gly Lys Ala Ser Asp Ala Lys Leu Gly He Phe Val 245 250 255 Ser Ser Met Lys Glu Asp Leu Ser Asn Asn Asn Ala He Thr Gin His 260 265 270 Leu He Pro Val Glu Gly Gly Val Glu Val Val Asp Leu Thr Ser Asp 275 280 285 Glu Leu Asp Ala He Val Ala Pro Phe Ser Ala Arg Ala Val Glu Val 290 295 300 Phe Lys Thr Gly Leu Asp Asn Phe Tyr Pro Asp Pro Val He Ala Val 305 310 315 320 Met Thr Gly Gly Ser Ser Ala Leu Val Lys Val Arg Ser Asp Val Ala 325 330 335 Asn Leu Pro Gin He Ser Lys Val Val Phe Asp Ser Thr Asp Phe Arg 340 345 350 Cys Ser Val Ala Cys Gly Ala Lys Val Tyr Cys Asp Thr Leu Ala Gly 355 360 365 Asn Ser Gly Leu Arg Leu Val Asp Thr Leu Thr Asn Thr Leu Thr Asp 370 375 380 Glu Val Val Gly Leu Gin Pro Val Val He Phe Pro Lys Gly Ser Pro 385 390 395 400 He Pro Cys Ser Tyr Thr His Arg Tyr Thr Val Gly Gly Gly Asp Val 405 410 415 Val Tyr Gly He Phe Glu Gly Glu Asn Asn Arg Ala Phe Leu Asn Glu 420 425 430 Pro Thr Phe Arg Gly Val Ser Lys Arg Arg Gly Asp Pro Val Glu Thr 435 440 445 Asp Val Ala Gin Phe Asn Leu Ser Thr Asp Gly Thr Val Ser Val He 450 455 460 Val Asn Gly Glu Glu Val Lys Asn Glu Tyr Leu Val Pro Gly Thr Thr 465 470 475 480 Asn Val Leu Asp Ser Leu Val Tyr Lys Ser Gly Arg Glu Asp Leu Glu 485 490 495 Ala Lys Ala He Pro Glu Tyr Leu Thr Thr Leu Asn He Leu His Asp 500 505 510 Lys Ala Phe Thr Arg Arg Asn Leu Gly Asn Lys Asp Lys Gly Phe Ser 515 520 525 Asp Leu Arg He Glu Glu Asn Phe Leu Lys Ser Ala Val Asp Thr Asp 530 535 540 Thr He Leu Asn Gly 545 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1452 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: ATGGATAAAT ATATTTATGT AACGGGGATA TTAAACCCTA ACGAGGCTAG AGACGAGGTA 60 TTCTCGGTAG TGAATAAGGG ATATATTGGA CCGGGAGGGC GCTCCTTTTC GAATCGTGGT 120 AGTAAGTACA CCGTCGTCTG GGAAAACTCT GCTGCGAGGA TTAGTGGATT TACGTCGACT 180 TCGCAATCTA CGATAGATGC TTTCGCGTAT TTCTTGTTGA AAGGCGGATT GACTACCACG 240 CTCTCTAACC CAATAAACTG TGAGAATTGG GTCAGGTCAT CTAAGGATTT AAGCGCGTTT 300 TTCAGGACCC TAATTAAAGG TAAGATTTAT GCATCGCGTT CTGTGGACAG CAATCTTCCA 360 AAGAAAGACA GGGATGACAT CATGGAAGCG AGTCGACGAC TATCGCCATC GGACGCCGCC 420 TTTTGCAGAG CAGTGTCGGT TCAGGTAGGG AAGTATGTGG ACGTAACGCA GAATTTAGAA 480 AGTACGATCG TGCCGTTAAG AGTTATGGAA ATAAAGAAAA GACGAGGATC AGCACATGTT 540 AGTTTACCGA AGGTGGTATC CGCTTACGTA GATTTTTATA CGAACTTGCA GGAATTGCTG 600 TCGGATGAAG TAACTAGGGC CAGAACCGAT ACAGTTTCGG CATACGCTAC CGACTCTATG 660 GCTTTCTTAG TTAAGATGTT ACCCCTGACT GCTCGTGAGC AGTGGTTAAA AGACGTGCTA 720 GGATATCTGC TGGTACGGAG ACGACCAGCA AATTTTTCCT ACGACGTAAG AGTAGCTTGG 780 GTATATGACG TGATCGCTAC GCTCAAGCTG GTCATAAGAT TGTTTTTCAA CAAGGACACA 840 CCCGGGGGTA TTAAAGACTT AAAACCGTGT GTGCCTATAG AGTCATTCGA CCCCTTTCAC 900 GAGCTTTCGT CCTATTTCTC TAGGTTAAGT TACGAGATGA CGACAGGTAA AGGGGGAAAG 960 ATATGCCCGG AGATCGCCGA GAAGTTGGTG CGCCGTCTAA TGGAGGAAAA CTATAAGTTA 1020 AGATTGACCC CAGTGATGGC CTTAATAATT ATACTGGTAT ACTACTCCAT TTACGGCACA 1080 AACGCTACCA GGATTAAAAG ACGCCCGGAT TTCCTCAATG TGAGGATAAA GGGAAGAGTC 1140 GAGAAGGTTT CGTTACGGGG GGTAGAAGAT CGTGCCTTTA GAATATCAGA AAAGCGCGGG 1200 ATAAACGCTC AACGTGTATT ATGTAGGTAC TATAGCGATC TCACATGTCT GGCTAGGCGA 1260 CATTACGGCA TTCGCAGGAA CAATTGGAAG ACGCTGAGTT ATGTAGACGG GACGTTAGCG 1320 TATGACACGG CTGATTGTAT AACTTCTAAG GTGAGAAATA CGATCAACAC CGCAGATCAC 1380 GCTAGCATTA TACACTATAT CAAGACGAAC GAAAACCAGG TTACCGGAAC TACTCTACCA 1440 CACCAGCTTT AA 1452 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 483 ammo acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein ( iii ) HYPOTHETICAL : YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 : Met Asp Lys Tyr He Tyr Val Thr Gly He Leu Asn Pro Asn Glu Ala 1 5 10 15 Arg Asp Glu Val Phe Ser Val Val Asn Lys Gly Tyr He Gly Pro Gly 20 25 30 Gly Arg Ser Phe Ser Asn Arg Gly Ser Lys Tyr Thr Val Val Trp Glu 35 40 45 Asn Ser Ala Ala Arg He Ser Gly Phe Thr Ser Thr Ser Gin Ser Thr 50 55 60 He Asp Ala Phe Ala Tyr Phe Leu Leu Lys Gly Gly Leu Thr Thr Thr 65 70 75 80 Leu Ser Asn Pro He Asn Cys Glu Asn Trp Val Arg Ser Ser Lys Asp 85 90 95 Leu Ser Ala Phe Phe Arg Thr Leu He Lys Gly Lys He Tyr Ala Ser 100 105 110 Arg Ser Val Asp Ser Asn Leu Pro Lys Lys Asp Arg Asp Asp He Met 115 120 125 Glu Ala Ser Arg Arg Leu Ser Pro Ser Asp Ala Ala Phe Cys Arg Ala 130 135 140 Val Ser Val Gin Val Gly Lys Tyr Val Asp Val Thr Gin Asn Leu Glu 145 150 155 160 Ser Thr He Val Pro Leu Arg Val Met Glu He Lys Lys Arg Arg Gly 165 170 175 Ser Ala His Val Ser Leu Pro Lys Val Val Ser Ala Tyr Val Asp Phe 180 185 190 Tyr Thr Asn Leu Gin Glu Leu Leu Ser Asp Glu Val Thr Arg Ala Arg 195 200 205 Thr Asp Thr Val Ser Ala Tyr Ala Thr Asp Ser Met Ala Phe Leu Val 210 215 220 Lys Met Leu Pro Leu Thr Ala Arg Glu Gin Trp Leu Lys Asp Val Leu 225 230 235 240 Gly Tyr Leu Leu Val Arg Arg Arg Pro Ala Asn Phe Ser Tyr Asp Val 245 250 255 Arg Val Ala Trp Val Tyr Asp Val He Ala Thr Leu Lys Leu Val He 260 265 270 Arg Leu Phe Phe Asn Lys Asp Thr Pro Gly Gly He Lys Asp Leu Lys 275 280 285 Pro Cys Val Pro He Glu Ser Phe Asp Pro Phe His Glu Leu Ser Ser 290 295 300 Tyr Phe Ser Arg Leu Ser Tyr Glu Met Thr Thr Gly Lys Gly Gly Lys 305 310 315 320 He Cys Pro Glu He Ala Glu Lys Leu Val Arg Arg Leu Met Glu Glu 325 330 335 Asn Tyr Lys Leu Arg Leu Thr Pro Val Met Ala Leu He He He Leu 340 345 350 Val Tyr Tyr Ser He Tyr Gly Thr Asn Ala Thr Arg He Lys Arg Arg 355 360 365 Pro Asp Phe Leu Asn Val Arg He Lys Gly Arg Val Glu Lys Val Ser 370 375 380 Leu Arg Gly Val Glu Asp Arg Ala Phe Arg He Ser Glu Lys Arg Gly 385 390 395 400 He Asn Ala Gin Arg Val Leu Cys Arg Tyr Tyr Ser Asp Leu Thr Cys 405 410 415 Leu Ala Arg Arg His Tyr Gly He Arg Arg Asn Asn Trp Lys Thr Leu 420 425 430 Ser Tyr Val Asp Gly Thr Leu Ala Tyr Asp Thr Ala Asp Cys He Thr 43 5 440 445 Ser Lys Val Arg Asn Thr He Asn Thr Ala Asp His Ala Ser He He 450 455 460 His Tyr He Lys Thr Asn Glu Asn Gin Val Thr Gly Thr Thr Leu Pro 465 470 475 480 His Gin Leu (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 942 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: ATGGCATTTG AACTGAAATT AGGGCAGATA TATGAAGTCG TCCCCGAAAA TAATTTGAGA 60 GTTAGAGTGG GGGATGCGGC ACAAGGAAAA TTTAGTAAGG CGAGTTTCTT AAAGTACGTT 120 AAGGACGGGA CACAGGCGGA ATTAACGGGA ATCGCCGTAG TGCCCGAAAA ATACGTATTC 180 GCCACAGCAG CTTTGGCTAC AGCGGCGCAG GAGCCACCTA GGCAGCCACC AGCGCAAGTG 240 GCGGAACCAC AGGAAACCGA TATAGGGGTA GTGCCGGAAT CTGAGACTCT CACACCAAAT 300 AAGTTGGTTT TCGAGAAAGA TCCAGACAAG TTCTTGAAGA CTATGGGCAA GGGAATAGCT 360 TTGGACTTGG CGGGAGTTAC CCACAAACCG AAAGTTATTA ACGAGCCAGG GAAAGTATCA 420 GTAGAGGTGG CAATGAAGAT TAATGCCGCA TTGATGGAGC TGTGTAAGAA GGTTATGGGC 480 GCCGATGACG CAGCAACTAA GACAGAATTC TTCTTGTACG TGATGCAGAT TGCTTGCACG 540 TTCTTTACAT CGTCTTCGAC GGAGTTCAAA GAGTTTGACT ACATAGAAAC CGATGATGGA 600 AAGAAGATAT ATGCGGTGTG GGTATATGAT TGCATTAAAC AAGCTGCTGC TTCGACGGGT 660 TATGAAAACC CGGTAAGGCA GTATCTAGCG TACTTCACAC CAACCTTCAT CACGGCGACC 720 CTGAATGGTA AACTAGTGAT GAACGAGAAG GTTATGGCAC AGCATGGAGT ACCACCGAAA 780 TTCTTTCCGT ACACGATAGA CTGCGTTCGT CCGACGTACG ATCTGTTCAA CAACGACGCA 840 ATATTAGCAT GGAATTTAGC TAGACAGCAG GCGTTTAGAA ACAAGACGGT AACGGCCGAT 900 AACACCTTAC ACAACGTCTT CCAACTATTG CAAAAGAAGT AG 942 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 313 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES ( i) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Ala Phe Glu Leu Lys Leu Gly Gin He Tyr Glu Val Val Pro Glu 1 5 10 15 Asn Asn Leu Arg Val Arg Val Gly Asp Ala Ala Gin Gly Lys Phe Ser 20 25 30 Lys Ala Ser Phe Leu Lys Tyr Val Lys Asp Gly Thr Gin Ala Glu Leu 35 40 45 Thr Gly He Ala Val Val Pro Glu Lys Tyr Val Phe Ala Thr Ala Ala 50 55 60 Leu Ala Thr Ala Ala Gin Glu Pro Pro Arg Gin Pro Pro Ala Gin Val 65 70 75 80 Ala Glu Pro Gin Glu Thr Asp He Gly Val Val Pro Glu Ser Glu Thr 85 90 95 Leu Thr Pro Asn Lys Leu Val Phe Glu Lys Asp Pro Asp Lys Phe Leu 100 105 110 Lys Thr Met Gly Lys Gly He Ala Leu Asp Leu Ala Gly Val Thr His 115 120 125 Lys Pro Lys Val He Asn Glu Pro Gly Lys Val Ser Val Glu Val Ala 130 135 140 Met Lys He Asn Ala Ala Leu Met Glu Leu Cys Lys Lys Val Met Gly 145 150 155 160 Ala Asp Asp Ala Ala Thr Lys Thr Glu Phe Phe Leu Tyr Val Met Gin 165 170 175 He Ala Cys Thr Phe Phe Thr Ser Ser Ser Thr Glu Phe Lys Glu Phe 180 185 190 Asp Tyr He Glu Thr Asp Asp Gly Lys Lys He Tyr Ala Val Trp Val 195 200 205 Tyr Asp Cys He Lys Gin Ala Ala Ala Ser Thr Gly Tyr Glu Asn Pro 210 215 220 Val Arg Gin Tyr Leu Ala Tyr Phe Thr Pro Thr Phe He Thr Ala Thr 225 230 235 240 Leu Asn Gly Lys Leu Val Met Asn Glu Lys Val Met Ala Gin His Gly 245 250 255 Val Pro Pro Lys Phe Phe Pro Tyr Thr He Asp Cys Val Arg Pro Thr 260 265 270 Tyr Asp Leu Phe Asn Asn Asp Ala He Leu Ala Trp Asn Leu Ala Arg 275 280 285 Gin Gin Ala Phe Arg Asn Lys Thr Val Thr Ala Asp Asn Thr Leu His 290 295 300 Asn Val Phe Gin Leu Leu Gin Lys Lys 305 310 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 156 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: ATGTACAGTA GAGGGTCTTT CTTTAAGTCT CGGGTTACCC TTCCTACTCT TGTCGGAGCA 60 TACATGTGGG AGTTTGAACT CCCGTATCTT ACGGACAAGA GACACATCAG CTATAGCGCG 120 CCAAGTGTCG CGACTTTTAG CCTTGTGTCG AGGTAG 156 (2) INFORMATION FOR SEQ ID NO:12: ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 51 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Met Tyr Ser Arg Gly Ser Phe Phe Lys Ser Arg Val Thr Leu Pro Thr 1 10 15 Leu Val Gly Ala Tyr Met Trp Glu Phe Glu Leu Pro Tyr Leu Thr Asp 20 25 30 Lys Arg His He Ser Tyr Ser Ala Pro Ser Val Ala Thr Phe Ser Leu 35 40 45 Val Ser Arg 50 (2) INFORMATION FOR SEQ ID NO:13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 138 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant Ui) MOLECULE TYPE: cDNA (m) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: ATGGATGATT TTAAACAGGC AATACTGTTG CTAGTAGTCG ATTTTGTCTT CGTGATAATT 60 CTGCTGCTGG TTCTTACGTT CGTCGTCCCG AGGTTACAGC AAAGCTCCAC CATTAATACA 120 GGTCTTAGGA CAGTGTGA 138 (2) INFORMATION FOR SEQ ID NO: 14: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 ammo acids (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (n) MOLECULE TYPE: protein (ill) HYPOTHETICAL: YES (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Met Asp Asp Phe Lys Gin Ala He Leu Leu Leu Val Val Asp Phe Val 1 5 10 15 Phe Val He He Leu Leu Leu Val Leu Thr Phe Val Val Pro Arg Leu 20 25 30 Gin Gin Ser Ser Thr He Asn Thr Gly Leu Arg Thr Val 35 40 45 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1434 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: ATGGGAGCTT ATACACATGT AGACTTTCAT GAGTCGCGGT TGCTGAAAGA CAAACAAGAC 60 TATCTTTCTT TCAAGTCAGC GGATGAAGCT CCTCCTGATC CTCCCGGATA CGTTCGCCCA 120 GATAGTTATG TGAGGGCTTA TTTGATACAA AGAGCAGACT TTCCCAATAC TCAAAGCTTA 180 TCAGTTACGT TATCGATAGC CAGTAATAAG TTAGCTTCAG GTCTTATGGG AAGCGACGCA 240 GTATCATCGT CGTTTATGCT GATGAACGAC GTGGGAGATT ACTTCGAGTG CGGCGTGTGT 300 CACAACAAAC CCTACTTAGG ACGGGAAGTT ATCTTCTGTA GGAAATACAT AGGTGGGAGA 360 GGAGTGGAGA TCACCACTGG TAAGAACTAC ACGTCGAACA ATTGGAACGA GGCGTCGTAC 420 GTAATACAAG TGAACGTAGT CGATGGGTTA GCACAGACCA CTGTTAATTC TACTTATACG 480 CAAACGGACG TTAGTGGTCT ACCCAAAAAT TGGACGCGTA TCTACAAAAT AACAAAGATA 540 GTGTCCGTAG ATCAGAACCT CTACCCTGGT TGTTTCTCAG ACTCGAAACT GGGTGTAATG 600 CGTATAAGGT CACTGTTAGT TTCCCCAGTG CGCATCTTCT TTAGGGATAT CTTATTGAAA 660 CCTTTGAAGA AATCGTTCAA CGCAAGAATC GAGGATGTGC TGAATATTGA CGACACGTCG 720 TTGTTAGTAC CGAGTCCTGT CGTACCAGAG TCTACGGGAG GTGTAGGTCC ATCAGAGCAG 780 CTGGATGTAG TGGCTTTAAC GTCCGACGTA ACGGAATTGA TCAACACTAG GGGGCAAGGT 840 AAGATATGTT TTCCAGACTC AGTGTTATCG ATCAATGAAG CGGATATCTA CGATGAGCGG 900 TATTTGCCGA TAACGGAAGC TCTACAGATA AACGCAAGAC TACGCAGACT CGTTCTTTCG 960 AAAGGCGGGA GTCAAACACC ACGAGATATG GGGAATATGA TAGTGGCCAT GATACAACTT 1020 TTCGTACTCT ACTCTACTGT AAAGAATATA AGCGTCAAAG ACGGGTATAG GGTGGAGACC 1080 GAATTAGGTC AAAAGAGAGT CTACTTAAGT TATTCGGAAG TAAGGGAAGC TATATTAGGA 1140 GGGAAATACG GTGCGTCTCC AACCAACACT GTGCGATCCT TCATGAGGTA TTTTGCTCAC 1200 ACCACTATTA CTCTACTTAT AGAGAAGAAA ATTCAGCCAG CGTGTACTGC CCTAGCTAAG 1260 CACGGCGTCC CGAAGAGGTT CACTCCGTAC TGCTTCGACT TCGCACTACT GGATAACAGA 1320 TATTACCCGG CGGACGTGTT GAAGGCTAAC GCAATGGCTT GCGCTATAGC GATTAAATCA 1380 GCTAATTTAA GGCGTAAAGG TTCGGAGACG TATAACATCT TAGAAAGCAT TTGA 1434 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS : (A) LENGTH: 477 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Met Gly Ala Tyr Thr His Val Asp Phe His Glu Ser Arg Leu Leu Lys 1 5 10 15 Asp Lys Gin Asp Tyr Leu Ser Phe Lys Ser Ala Asp Glu Ala Pro Pro 20 25 30 Asp Pro Pro Gly Tyr Val Arg Pro Asp Ser Tyr Val Arg Ala Tyr Leu 35 40 45 He Gin Arg Ala Asp Phe Pro Asn Thr Gin Ser Leu Ser Val Thr Leu 50 55 60 Ser He Ala Ser Asn Lys Leu Ala Ser Gly Leu Met Gly Ser Asp Ala 65 70 75 80 Val Ser Ser Ser Phe Met Leu Met Asn Asp Val Gly Asp Tyr Phe Glu 85 90 95 Cys Gly Val Cys His Asn Lys Pro Tyr Leu Gly Arg Glu Val He Phe 100 105 110 Cys Arg Lys Tyr He Gly Gly Arg Gly Val Glu He Thr Thr Gly Lys 115 120 125 Asn Tyr Thr Ser Asn Asn Trp Asn Glu Ala Ser Tyr Val He Gin Val 130 135 140 Asn Val Val Asp Gly Leu Ala Gin Thr Thr Val Asn Ser Thr Tyr Thr 145 150 155 160 Gin Thr Asp Val Ser Gly Leu Pro Lys Asn Trp Thr Arg He Tyr Lys 165 170 175 He Thr Lys He Val Ser Val Asp Gin Asn Leu Tyr Pro Gly Cys Phe 180 185 190 Ser Asp Ser Lys Leu Gly Val Met Arg He Arg Ser Leu Leu Val Ser 195 200 205 Pro Val Arg He Phe Phe Arg Asp He Leu Leu Lys Pro Leu Lys Lys 210 215 220 Ser Phe Asn Ala Arg He Glu Asp Val Leu Asn He Asp Asp Thr Ser 225 230 235 240 Leu Leu Val Pro Ser Pro Val Val Pro Glu Ser Thr Gly Gly Val Gly 245 250 255 Pro Ser Glu Gin Leu Asp Val Val Ala Leu Thr Ser Asp Val Thr Glu 260 265 270 Leu He Asn Thr Arg Gly Gin Gly Lys He Cys Phe Pro Asp Ser Val 275 280 285 Leu Ser He Asn Glu Ala Asp He Tyr Asp Glu Arg Tyr Leu Pro He 290 295 300 Thr Glu Ala Leu Gin He Asn Ala Arg Leu Arg Arg Leu Val Leu Ser 305 310 315 320 Lys Gly Gly Ser Gin Thr Pro Arg Asp Met Gly Asn Met He Val Ala 325 330 335 Met He Gin Leu Phe Val Leu Tyr Ser Thr Val Lys Asn He Ser Val 340 345 350 Lys Asp Gly Tyr Arg Val Glu Thr Glu Leu Gly Gin Lys Arg Val Tyr 355 360 365 Leu Ser Tyr Ser Glu Val Arg Glu Ala He Leu Gly Gly Lys Tyr Gly 370 375 380 Ala Ser Pro Thr Asn Thr Val Arg Ser Phe Met Arg Tyr Phe Ala His 385 390 395 400 Thr Thr He Thr Leu Leu He Glu Lys Lys He Gin Pro Ala Cys Thr 405 410 415 Ala Leu Ala Lys His Gly Val Pro Lys Arg Phe Thr Pro Tyr Cys Phe 420 425 430 Asp Phe Ala Leu Leu Asp Asn Arg Tyr Tyr Pro Ala Asp Val Leu Lys 435 440 445 Ala Asn Ala Met Ala Cys Ala He Ala He Lys Ser Ala Asn Leu Arg 450 455 460 Arg Lys Gly Ser Glu Thr Tyr Asn He Leu Glu Ser He 465 470 475 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 558 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: ATGGAATTCA GACCAGTTTT AATTACAGTT CGCCGTGATC CCGGCGTAAA CACTGGTAGT 60 TTGAAAGTGA TAGCTTATGA CTTACACTAC GACAATATAT TCGATAACTG CGCGGTAAAG 120 TCGTTTCGAG ACACCGACAC TGGATTCACT GTTATGAAAG AATACTCGAC GAATTCAGCG 180 TTCATACTAA GTCCTTATAA ACTGTTTTCC GCGGTCTTTA ATAAGGAAGG TGAGATGATA 240 AGTAACGATG TAGGATCGAG TTTCAGGGTT TACAATATCT TTTCGCAAAT GTGTAAAGAT 300 ATCAACGAGA TCAGCGAGAT ACAACGCGCC GGTTACCTAG AAACATATTT AGGAGACGGG 360 CAGGCTGACA CTGATATATT TTTTGATGTC TTAACCAACA ACAAAGCAAA GGTAAGGTGG 420 TTAGTTAATA AAGACCATAG CGCGTGGTGT GGGATATTGA ATGATTTGAA GTGGGAAGAG 480 AGCAACAAGG AGAAATTTAA GGGGAGAGAC ATACTAGATA CTTACGTTTT ATCGTCTGAT 540 TATCCAGGGT TTAAATGA 558 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 185 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Met Glu Phe Arg Pro Val Leu He Thr Val Arg Arg Asp Pro Gly Val 1 5 10 15 Asn Thr Gly Ser Leu Lys Val He Ala Tyr Asp Leu His Tyr Asp Asn 20 25 30 He Phe Asp Asn Cys Ala Val Lys Ser Phe Arg Asp Thr Asp Thr Gly 35 40 45 Phe Thr Val Met Lys Glu Tyr Ser Thr Asn Ser Ala Phe He Leu Ser 50 55 60 Pro Tyr Lys Leu Phe Ser Ala Val Phe Asn Lys Glu Gly Glu Met He 65 70 75 80 Ser Asn Asp Val Gly Ser Ser Phe Arg Val Tyr Asn He Phe Ser Gin 85 90 95 Met Cys Lys Asp He Asn Glu He Ser Glu He Gin Arg Ala Gly Tyr 100 105 110 Leu Glu Thr Tyr Leu Gly Asp Gly Gin Ala Asp Thr Asp He Phe Phe 115 120 125 Asp Val Leu Thr Asn Asn Lys Ala Lys Val Arg Trp Leu Val Asn Lys 130 135 140 Asp His Ser Ala Trp Cys Gly He Leu Asn Asp Leu Lys Trp Glu Glu 145 150 155 160 Ser Asn Lys Glu Lys Phe Lys Gly Arg Asp He Leu Asp Thr Tyr Val 165 170 175 Leu Ser Ser Asp Tyr Pro Gly Phe Lys 180 185 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 534 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: ATGAAGTTGC TTTCGCTCCG CTATCTTATC TTAAGGTTGT CAAAGTCGCT TAGAACGAAC 60 GATCACTTGG TTTTAATACT TATAAAGGAG GCGCTTATAA ACTATTACAA CGCCTCTTTC 120 ACCGATGAGG GTGCCGTATT AAGAGACTCT CGCGAAAGTA TAGAGAATTT TCTCGTAGCC 180 AGGTGCGGTT CGCAAAATTC CTGCCGAGTC ATGAAGGCTT TGATCACTAA CACAGTCTGT 240 AAGATGTCGA TAGAAACAGC CAGAAGTTTT ATCGGAGACT TAATACTCGT CGCCGACTCC 300 TCTGTTTCAG CGTTGGAAGA AGCGAAATCA ATTAAAGATA ATTTCCGCTT AAGAAAAAGG 360 AGAGGCAAGT ATTATTATAG TGGTGATTGT GGATCCGACG TTGCGAAAGT TAAGTATATT 420 TTGTCTGGGG AGAATCGAGG ATTGGGGTGC GTAGATTCCT TGAAGCTAGT TTGCGTAGGT 480 AGACAAGGAG GTGGAAACGT ACTACAGCAC CTACTAATCT CATCTCTGGG TTAA 534 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 177 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Met Lys Leu Leu Ser Leu Arg Tyr Leu He Leu Arg Leu Ser Lys Ser 1 5 10 15 Leu Arg Thr Asn Asp His Leu Val Leu He Leu He Lys Glu Ala Leu 20 25 30 He Asn Tyr Tyr Asn Ala Ser Phe Thr Asp Glu Gly Ala Val Leu Arg 35 40 45 Asp Ser Arg Glu Ser He Glu Asn Phe Leu Val Ala Arg Cys Gly Ser 50 55 60 Gin Asn Ser Cys Arg Val Met Lys Ala Leu He Thr Asn Thr Val Cys 65 70 75 80 Lys Met Ser He Glu Thr Ala Arg Ser Phe He Gly Asp Leu He Leu 85 90 95 Val Ala Asp Ser Ser Val Ser Ala Leu Glu Glu Ala Lys Ser He Lys 100 105 110 Asp Asn Phe Arg Leu Arg Lys Arg Arg Gly Lys Tyr Tyr Tyr Ser Gly 115 120 125 Asp Cys Gly Ser Asp Val Ala Lys Val Lys Tyr He Leu Ser Gly Glu 130 135 140 Asn Arg Gly Leu Gly Cys Val Asp Ser Leu Lys Leu Val Cys Val Gly 145 150 155 160 Arg Gin Gly Gly Gly Asn Val Leu Gin His Leu Leu He Ser Ser Leu 165 170 175 Gly (2 ) INFORMATION FOR SEQ ID NO : 21 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 540 base pairs (B ) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : not relevant ( ii ) MOLECULE TYPE : cDNA ( iii ) HYPOTHETICAL : NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: ATGGACCTAT CGTTTATTAT TGTGCAGATC CTTTCCGCCT CGTACAATAA TGACGTGACA 60 GCACTTTACA CTTTGATTAA CGCGTATAAT AGCGTTGATG ATACGACGCG CTGGGCAGCG 120 ATAAACGATC CGCAAGCTGA GGTTAACGTC GTGAAGGCTT ACGTAGCTAC TACAGCGACG 180 ACTGAGCTGC ATAGAACAAT TCTCATTGAC AGTATAGACT CCGCCTTCGC TTATGACCAA 240 GTGGGGTGTT TGGTGGGCAT AGCTAGAGGT TTGCTTAGAC ATTCGGAAGA TGTTCTGGAG 300 GTCATCAAGT CGATGGAGTT ATTCGAAGTG TGTCGTGGAA AGAGGGGAAG CAAAAGATAT 360 CTTGGATACT TAAGTGATCA ATGCACTAAC AAATACATGA TGCTAACTCA GGCCGGACTG 420 GCCGCAGTTG AAGGAGCAGA CATACTACGA ACGAATCATC TAGTCAGTGG TAATAAGTTC 480 TCTCCAAATT TCGGGATCGC TAGGATGTTG CTCTTGACGC TTTGTTGCGG AGCACTATAA 540 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 179 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Met Asp Leu Ser Phe He He Val Gin He Leu Ser Ala Ser Tyr Asn 1 5 10 15 Asn Asp Val Thr Ala Leu Tyr Thr Leu He Asn Ala Tyr Asn Ser Val 20 25 30 Asp Asp Thr Thr Arg Trp Ala Ala He Asn Asp Pro Gin Ala Glu Val 35 40 45 Asn Val Val Lys Ala Tyr Val Ala Thr Thr Ala Thr Thr Glu Leu His 50 55 60 Arg Thr He Leu He Asp Ser He Asp Ser Ala Phe Ala Tyr Asp Gin 65 70 75 80 Val Gly Cys Leu Val Gly He Ala Arg Gly Leu Leu Arg His Ser Glu 85 90 95 Asp Val Leu Glu Val He Lys Ser Met Glu Leu Phe Glu Val Cys Arg 100 105 110 Gly Lys Arg Gly Ser Lys Arg Tyr Leu Gly Tyr Leu Ser Asp Gin Cys 115 120 125 Thr Asn Lys Tyr Met Met Leu Thr Gin Ala Gly Leu Ala Ala Val Glu 130 135 140 Gly Ala Asp He Leu Arg Thr Asn His Leu Val Ser Gly Asn Lys Phe 145 150 155 160 Ser Pro Asn Phe Gly He Ala Arg Met Leu Leu Leu Thr Leu Cys Cys 165 170 175 Gly Ala Leu (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 183 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO ( iv) ANTI - SENSE : NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: ATGAGGCACT TAGAAAAACC CATCAGAGTA GCGGTACACT ATTGCGTCGT GCGAAGTGAC 60 GTTTGTGACG GGTGGGATGT ATTTATAGGC GTAACGTTAA TCGGTATGTT TATTAGTTAC 120 TATTTATATG CTCTAATTAG CATATGTAGA AAAGGAGAAG GTTTAACAAC CAGTAATGGG 180 TAA 183 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24 : Met Arg His Leu Glu Lys Pro He Arg Val Ala Val His Tyr Cys Val 1 5 10 15 Val Arg Ser Asp Val Cys Asp Gly Trp Asp Val Phe He Gly Val Thr 20 25 30 Leu He Gly Met Phe He Ser Tyr Tyr Leu Tyr Ala Leu He Ser He 35 40 45 Cys Arg Lys Gly Glu Gly Leu Thr Thr Ser Asn Gly 50 55 60 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide" (iii) HYPOTHETICAL: NO (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..24 (D) OTHER INFORMATION: /product= "Oligonucleotide" /note= "N is inosine at sites in this sequence." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GGNGGNGGNA CNTTYGAYGT NTCN 24 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide." (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: UGAGUGAACG CGAUG 15 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide." (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: ATAAGCATTC GGGATGGACC 20 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide." (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: ATTAACTTGA CGGATGGCAC GC 22 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTE ISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide." (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: TACTTATCTA GAACCATGGA AGCGAGTCGA CGACTA 36 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (n) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide." (ill) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: TCTTGAGGAT CCATGGAGAA ACATCGTCGC ATACTA 36 (2) INFORMATION FOR SEQ ID NO:31: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide." (ui) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: ACTATTTCTA GAACCATGGC ATTTGAACTG AAATT 35 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide." (ill) HYPOTHETICAL: NO (Xl) SEQUENCE DESCRIPTION: SEQ ID NO:32: TTCTGAGGAT CCATGGTATA AGCTCCCATG AATTAT 3 6 TABLE 1 Particle Coat protein Mr Reference length, (X10 J ) (nm) TABLE 2 Nucleotide and Eeduced Amino Acid Sequences for GLRaV-3 Coat Protein. ATCGCATT GAAC GAAATTACGGCAGATATATGAAGTCSTCCCCGAAAATAAT TGAGA 1 ., « . . 6a M A F E K G Q I E V V P E N M L R GrrAGAG AGGGGATGCGCCACAAGGAAAATTTAGTAAGGCGAG i 1 i '.TAΛAGTACGTT 61 - + + + ,. 120 V R V G D A A Q G K F S K A S F L K Y V AAX»CG^ACACΛGGCGGAATTAACGG-AA XX^CGTAGTX- CCGAAAAATACGTATTC 121 - * 1 * + + lao K D G T Q A E T G I A V V P E K Y V F GCC^aUSCAGCTTTGG TACAGCGGCGCAGGAGCCACC AGGCAGCCACCAGCGCAAGTG 181 ■ * 1- — ( ■ + -*• + 2 0 A T A A L A T A A Q E P P R Q P P A Q V GTGGAACCACAGGAAACCGATATAGGGG AGTGCCGGAATCTGAGACTCTCACACCAAAT 241 -> * • + ■ * » 300 V E P Q E T D I G V V P E S E T T P N AAGrrCGTTTTCGAGA-*^GATCCAGACAAG TCrTGAAGACTATGGGCAAGGGAATAGCT 301 * * ♦ * * + 360 K V F E K D P D K F L K T M ' G K G I A TTGGACT GACGGGACrrTACCC-ACAAACCGAAAGTTATTAACGAGCCAGGGAAAGTATCA 361 • * • * + + * 420 D T C V T H K P K V I N E P G K V S GTAGAGGTCKICAATGAAGAT AATGCCGCATTGATGGAGCTGTGTAAGAAGGTTATGGGC 421 - * * ■ *- * 4 80 V E V A M K I N A A L M E L C K K V M G GCCGATGACC AC^lAACTAAGACAAAATTIJl -'r^TACGTGATGCAGATTG ri'GCACG 481 ' H + * * 540 A D D A A T T K F F Y V M Q I A C T T -TTITACATCG CTTCGACCGAGTTCAAAGAG TTGACTACATAGAAACCGATGATGGA 541 + * * 600 F F T S S S T E F K E F D Y I E T D D C AAGAAGATATATGCGO'HSTC^yjrATATGATTGCATrAAAC'AAGC'^ 601 * * -ι 1 -f ,. 660 K I Y A V W V Y D C I K Q A A A S T G TATGAAAACCCGGTAAG<-CAGTATCTAGCGTACT CACACCAAC^7r^^ 661 * +- 1 — + ♦ 720 Y E N P V R Q λ Y F T P- T F I T A T CTGAATGCTAAAC AC GATGAACGAGAAϋ riATGK-A-ΛGCAτGGAGTACCACCGAAA 721 * 1 * * ♦ 780 L N C K L V M N E K V M A Q H G V P P K r' llCCGTAC-ACGATAGALTUCg.'TCGTCCGACSTAm F F P Y T I D C V R P T Y D F N N D A' ATATTAGCATTX;AA -- * TAGCRRAGA<-AGCAGCCGTTTACAAA C -AAGACGGTAACGGCCGAT 841 * * — * - ' 900 I L A W N L A R Q Q A F R N K T V T A D AACACC ACACAACG C CCAAC ArrGCAAAACAAC-TAC 901 942 N T L H N V F Q L Q K * TABLE 3 Comparison of Coat Protein Sequences of GLRaV-3 with BTV CTV and LIYV. i 50 3YV_C? - CTV_C? LIYV_C? GLRaV3_CP MAFELKLGQI YEWPENNLR VRVGDAAQGK FSKASFLKYV KDGTQAELTG CONSENSUS 51 100 BYV_CP CTV_CP HDDETKXLKN LIYV_CP MDTDGD NDVFGSG DT RNNDDKKKEE MKQNISDNSQ GLRaV3_CP IA PΞXYVF ATAALATAAQ ΞPPRQPPAQV VEPQETDMGV VFESETLTPN CONSENSUS 101 150 BYV_C? MGΞAE PISAIA..TF ENVSL.AD.Q TCLHGEDCDK RK N CTV_C? KNKETKEGDD WAAES..SF GSVNLHID.P TLITMNDVRQ LΞTQQNAAJL IYV_CP II TRDHEAD IIGSISKEDL SKIWRVDRH DALSANDVQS FR...EAMIN GLRaV3_CP KLVFEKDPDK FLKTMGKGIA LDLTGVTHKP KVI ..NEPGK VSVEVAMKIN CONSENSUS -nd- -N 151 - 200 BYV_C? FEECLKLKG. ...VPEDNLG IALGLCLYΞC AT.IGTSNKV NVQPTΞ.TFI CTV_C? RDLFLALKG YPNLPDKDKD FHIAMMLYRL AV.KSSSLQS DODTTGITYT LIYV_CP ...FMRDKDP NRNQPSDKLI IAMEVGVYQH VI LGTSAKL G.NANNLEFT GLRaV3_C? .AALMELCKK VMGADDAATX TKFFLYVMQI ACTFFTS..S STEFKEFDYI CONSENSUS -lJe- - d- -es- 201 250 BYV_C? KASFGGGKEL YLTHGELNSF LGSQKLLECK PNKLRCFCRT FQKDYISLRK CTV_CP R....EGVEV DLSDKLWTDI VYNSKGIGNR TNALRVWGRT NDALYLAFC LrrV_CP rAYDQETRTY KVAD..FVNY MQSR..MRNS PNWRQYARA MEKTrN ZRS GLRaV3_CP ET..DDGXKr Y. -AVWVYDC IKQAAASTGY ENPVRQYLAY FTPTFITATL CONSENSUS -eg- - —R-y-r- 251 300 BYV_CP EYRCXLPPIA RANRHGLPAE DHYLAADF.I STSTELTDLQ QSRLLLAREN CTV_CP QNR.NLSYGG RPLDAGIPAG YHYLCADF.L .TCAGLTDLE CAVYΪQAKEQ LΓYV_C? AGIIN.SNGV LAAKHGVLAS YRNSYS FAV GFGNDTTDAQ LTSLM ARKQ GLR-lV3_CP NGKLVMNE V MA.QHGVPPK FFPYTIDCVR PTYDLFNNDA ILA NLARQQ CONSENSUS -hGvpa- y Df — -C ltd — LAr-q 301 328 BYV_C? ATH.TEFSSE SPVTSLKQLG RCLGTGR- CTV_CP LLX.KRGADΞ VVVTrnRQLG K.FNTR*. LIYV_C? ALC.KGEGGS ΞH-Λ1TMQLA NUCHPC * . GLRaV3_C? AFRNKTVTAD NT-.HNVFQL-. QKK * .... CONSENSUS al- -QL- TABLE 4 Partial GLRaV-3 Nucleotide Sequence and Encoded Proteins. ORFla (ESLICASE) GTGTCTACTTACGCGAAGAGTGTGATGAACGACAATTTCAATATCCTTGAGACCCTGGTA 1 + + • * ■ + ■ *- SO CACAGATGAATGCGCTTCTCACACTACTTGCTGTTAAAGTTATAGGAACTCTGGGACCAT V S T Y A Ξ V M N D N F N I L E T V ACTTTGCCCAAGTCCTTTATAGTCAAAGTACCTGGTTCGGTGCTGGTTAGCATAACCACT 61 -t* + + + + + 120 TGAAACGGGTTCAGGAAATATCAGTTTCATGGACCAAGCCACGACCAATCGTATTGGTGA T P K S F I V K V P G S V L V S I T T TCGGGCATTTCCGACAAACTTGAACTTCGGGGCGCGTTCGACGTTTCTAAAAAGAATTTC 21 + + + + * + !80 AGCCCGTAAAGGCTGTTTGAACTTGAAGCCCCGCGCAAGCTGCAAAGATTTTTCTTAAAG S G I S D K E L R G A F D V S K K N F TCCAGGAGGTTACGTTCGAGTCGTTTGCGCGTATTTTCTAGGGCTATTGTGGAGGATACG 1 + + + + + + 240 AGGTCCTCCAATGCAAGCTCAGCAAACGCGCATAAAAGATCCCGATAACACCTCCTATGC S R R R S S R L R V F S R A I V Ξ D T ATCAAGGTTATGAAGGGCATGAAATCAGAGGATGGTAAACCACTCCCTATAGCCGAGGAT 1 + + + + + + 300 TAGTTCCAATACTTCCCGTACTTTAGTCTCCTACCATTTGGTGAGGGATATCGGCTCCTA I K V M K G M K S E D G K P P I A E D TCCGTGTACGCGTTCATGACAGGCAATATGTCAAACGTTCATTGCACTAGGGCTGGTTTG 1 + H + + + + 360 AGGCACATGCGCAAGTACTGTCCGTTATACAGTTTGCAAGTAACGTGATCCCGACCAAAC S V Y A F M T G N M S N V H C T R A G CTCGGGGGCTCAAAGGCTTGCGCGGCTTCTTTAGCTGTGAAGGGTGCAGCTTCACGCGCT 1 + + + + + + 420 GAGCCCCCGAGTTTCCGAACGCGCCGAAGAAATCGACACTTCCCACGTCGAAGTGCGCGA L G G S K A C A A S L A V K G A A S R A ACTGGAACAAAACTCTTTTCAGGTCTCACATCCTTTCTTTCCGCCGGTGGTCTGTTTTAC 1 + + + + + + 480 TGACCTTGTTTTGAGAAAAGTCCAGAGTGTAGGAAAGAAAGGCGGCCACCAGACAAAATG T G T K F S G T S F L S A G G F Y GATGAAGGC TGACGCCCGGAGAGAGGCTTGATGCACTAACGCGCCGTGAACATGCTGTG 1 + + + + + + 54o CTACT CCGAACTGCGGGCCTCTCTCCGAACTACGTGA TGCGCGGCACT GTACGACAC D E G L T P G E R L D A T R R E H A V AATTCACC GTAGGCCTCT AGAACCTX^GCT CGGTTGCGAAGCGGGTCGTT CCGGA + + + H -•- + 600 T AAGTGGACATCCGGAGAATCTTGGACCTCGW\.GCCAACG:TTCGCCCAG AAAGGCCT N S P V G L E P G A S V A K R V V S G ACGAAAGCTT CTGTCAGAATTGTCA TGOAGGACTTCACCAC TTCGTCATAAAAAAT + -i- + + + + 660 TGCTTTCGAAAAGACAGTCTTAACAGTAACCTCCTGAAGTGGTGAAAGCAGTATTTTTTA T K A F L S E S E D F T T F V I K N GGGTGCTTATTGGTGTTTTTACTCTTTCCATGGCTC CACTC GGTGGTCTGGAAGTAC 661 + H + + + 720 TCCCACGAATAACCACAAAAATGAGAAAGGTACCGAGAGTGAGGCCACCAGACCTTCATG R V L I G V F T S M A T P V V W K Y AGAAGGAATATCGCGCGAACTGGCGTGGATGTTTTCCACCGTGCTCGT CGGGTACCGCG 721 + + + J + - r 780 TCTTCCTTATAGCGCGCTTGACCGCACCTACAAAAG-GTGGCACGAGCAAGCCCATGGCGC R R N I A R T G V D V F H R A R S G T A GCCATCGGTTTACAATGTCTTAGTGGAGGAAGGTCGTTAGCTGGTGACGCTGCTCGTGGC 781 + -H + + T + 840 CGGTAGCCAAATGTTACAGAATCACCTCCTTCCAGCAATCGACCACTGCGACGAGCACCG A I G L Q C S G G R S A G D A A R G GCGTTAACAGTGACTCGAGGAGGGCTATCTTCGGCGGTTGCGGTGACCAGAAATACAGTG 841 + + -r -i- + + 900 CGCAATTGTCACTGAGCTCCTCCCGATAGAAGCCGCCAACGCCACTGGTCTTTATGTCAC A T V T R G G L S S A V A V T R N T V GCTAGGCGTCAGGTACCATTGGCGTTGCTTTCGTTTTCCACGTCTTACGCAGTCAGTGGT 901 + + -t- + + + 960 CGATCCGCAGTCCATGGTAACCGCAACGAAAGCAAAAGGTGCAGAATGCGTCAGTCACCA A R R Q V P A L S F S T S Y A V S G TGCACTTTGTTAGGTATTTGGGCTCATGCTCTCCCTAGGCATTTGATGTTCTTCTTTGGC 961 + + + + + + 1020 ACGTGAAACAATCCATAAACCCGAGTACGAGAGGGATCCGTAAACTACAAGAAGAAACCG C T L L G I W A H A P R H F F F G CTAG^GACGCTCTTCGGGGTGAGTGCCAGTACCAATTCTTGGTCGCTTGGGGGCTATACG 1021 + + + + + + 1080 GATCCCTGCGAGAAGCCCCACTCACGGTCATGGTTAAGAACCAGCGAACCCCCGATATGC G T F G V Ξ A S T N S W Ξ L G G Y T AACAGTCTGTTCACCGTACCGGAATTAACTTGGGAAGGGAGGAGTTACAGATCTTTATTG 1081 + + + + + T 1140 TTGTCAGACAAGTGGCATGGCCTTAATTGAACCCTTCCCTCCTCAATGTCTAGAAATAAC ' N S II F T V P E L T W E G R S Y R S L CCCCAAGCAGCTTTAGGTATTTCTCτCGTTGTGCGCGGGTTGTTAAGTGAAACTGTGCCA 1141 -r + + + + + 1200 GG<-KΞTTCGTCGAAATCCATAAAGAGAGIAAC-ACGCGCCCAAC-AATTCACT GACACGGT P Q A A Ii G I S V V R G Ii S E T V P CAACTAACGTACGTACCGCCGATTGAAGGTCGGAATGT ATGATCAGGCACTAAAT T 1201 -i- + + + + + 1260 GT GATTGCATGCATGGCGC-CTAACTTCCAGCCTTACAAATACTAGTCCGTGATTTAAAA Q L T Y V P P I E G R N V Y D Q A L N F TATCGCGACT TGACTATGACGATGGTGCAGGCCCATCCGGGACGGCTGGTCAAAGCGAT 1261 + -t- + + + + 1320 ATAGCGCTGAAACTGATACTGCTACCACGTCCGGGTAGGCCCTGCCGACCAGTT CGCTA Y R D F D Y D D G A G P S G T A G Q S D CCTG AA CAATACTTCGGATACTTCT'rCGGTTTTCTCTGACGATGGTTTGCCCGCTAGT 1321 + + -r + + 1380 GGACCTTG^TTATGAAGCCTATGAAGAAGCCAAAAGAGACTGCTACCAAACGGGCGATCA F G T N T S D T 3 S V F S D D G P A S GGCGGTGGCTTCGACGCGCGCGTTGAGGCAGGTCCCAGCCATGCTGTTGATGAATCACCA 1381 -r + + H + -t- 1440 CCGCCACCGAAGCTGCGCGCGCAACTCCGTCCAGGGTCGGTACGACAACTACTTAGTGGT G G G F D A R V E A G P S H A V D E S P AGGGGTAGTGTTGAGTTCGTCTACAGAGAACGTGTAGATGAACATCCGGCGTGTGGTGAA 1441 + -t- + + + + 1500 TCCCCATCACAACTCAAGCAGATGTCTCTTGCACATCTACTTGTAGGCCGCACACCACTT R G S V E F V Y R E R V D E H P A C G E GCTGAAGTTGAAAAGGATCTAATAACACCACTTGGTACAGCTGTCTTAGAGTCGCCCCCC 1501 + + + + + + 1560 CGACTTCAACTTTTCCTAGATTATTGTGGTGAACCATGTCGACAGAATCTCAGCGGGGGG A E V E K D L I T P L G T A V E S P P GTAGGTCCTGAAGCTGGGAGCGCGCCCAACGTCGAGGACGGTTGTCCGGAGGTTGAAGCT 1561 + + + + + + 1620 CATCCAGGACTTCGACCCTCGCGCGGGTTGCAGCTCCTGCCAACAGGCCTCCAACTTCGA V G P E A G S A P N V E D G C P E V E A GAGAAATGTTCGGAGGTCATCGTTGACGTTCCTAGTTCAGAACCGCCG-GTACAAGAAGTC 1621 + + + + + + 1680 CTCTTTACAAGCCTCCAGTAGCAACTGCAAGGATCAAGTCTTGGCGGCCATGTTCTTCAG E K C S E V I V D V P S S E P P V Q E V CTTGAATCAACCAATGGTGTCCAAGCTGCAAGAACTGAAGAGGTTGTGCAGGGCGACACA 1681 + + + -t* + * 1740 GAACTTAGTTGGTTACCACAGGTTCGACGTTCTTGACTTCTCCAACACGTCCCGCTGTGT L E S T N G V Q A A R T Ξ E V V Q G D T TGTGGAGCTGGGGTAGCTAAATCAGAAGTGAGTCAACGTGTGTTTCCTGCGCAAGTACCC 1741 + + + + + + 1800 ACACCTCGACCCCATCGATTTAGTCTTCACTCAGTTGCACACAAAGGACGCGTTCATGGG C G A G V A K S E V S Q R V F P A Q V P GCACATGAAGCTGGTCTTGAGGCATCTAGTGGCGCGGTCGTGGAGCCATTGCAAGTTTCT 1801 + ■+■ + + + + 1860 CGTGTACTTCGACCAGAACTCCGTAGATCACCGCGCCAGCACCTCGGTAACGTTCAAAGA A H E A G E A S S G A V V E P L Q V S GTGCCAGTAGCCGTAGAGAAAACTG T TATCTGTCGAGAAGGCGCGTGAGCTAAAGGCG 1861 + + + + + + 1920 CACGGTCATCGGCATCTC T TGACAAAATAGACAGCTCTTCCGCGCACTCGATTTCCGC V P V A V E K T V S V E K A R E L K A GTAGATAAGGG-CAAGGCG-GTCGTGCACGCAAAGGAAGTCAAGAATGTACCGGTTAAGACG 1921 + + + + + + 1980 CATCTATTCCCGTTCCGCCAGCACG HGCGT TCCT CAGTTCTTACATGGCCAATTCTGC V D K G K A V V H A K E V K N V P V K T TTACCACGAGGGGCTCTA-AAAATTAGTGAGGATACCGTTCGTAAGGAATTGTGCATGTTT 1931 + + r 2Q40 AATGGTGCTCCCCGAGATTTTTAATCACTCCTATGGCAAGCATTCCTTAACACGTACAAA L P R G A K I S E D T V R K E L C M F AGAACGTGTTCCTGCGGCGTGCAGTTGGACGTGTACAATGAAGCGACCATCGCCACTAGG 2041 + -r + + + ,. 2100 TCTTGCACAAGGACGCCGCACGTCAACCTGCACATGTTACTTCGCTGGTAGCGGTGATCC R T C S C G V Q D V Y N E A T I A T R TTCTCAAATGCGTTTACCTTTGTCGATAGCTTGAAAGGGAGGAGTGCGGTCTTTTTCTCA 2101 + + + + + -_ 2160 AAGAGTTTACGCAAATGGAAACAGCTATCGAACTTTCCCTCCTCACGCCAGAAAAAGAGT F S N A F T F V D Ξ L K G R S A V F F S AAGCTGGGTGAGGGGTATACCTATAATGGTGGTAGCCATGTTTCATCAGGGTGGCCTCGT 2161 + ■+■ + + + .. 2220 TTCGACCCACTCCCCATATGGATATTACCACCATCGGTACAAAGTAGTCCCACCGGAGCA K L G E G Y T Y N G G S H V S S G W P R GCCCTAGAGGATATCTTAACGGCAATTAAGTACCCAAGCGTCTTCGACCACTGTTTAGTG 2221 + + + + + + 2280 CGGGATCTCCTATAGAATTGCCGTTAATTCATGGGTTCGCAGAAGCTGGTGACAAATCAC A E D I L T A I K Y P S V F D H C V CAGAAGTACAAGATGGGTGGAGGCGTACCATTCCACGCTGATGACGAGGAGTGCTATCCA 2281 + + + + + + 2340 GTCTTCATGTTCTACCCACCTCCGCATGGTAAGGTGCGACTACTGCTCCTCACGATAGGT Q K Y K M G G G V P F H A D D E E C Y P TCAGATAACCCTATCTTGACGGTCAATCTCGTGGGGAAGGCAAACTTCTCGACTAAGTGC 2341 + + + + + + 2400 AGTCTATTGGGATAGAACTGCCAGTTAGAGCACCCCTTCCGTTTGAAGAGCTGATTCACG AGGAAGGGTGGTAAGGTCATGGTCATAAACGTAGCTTCGGGTGACTATTTTCTTATGCCT 2401 + + + + + + 2460 TCCTTCCCACCATTCCAGTACCAGTATTTGCATCGAAGCCCACTGATAAAAGAATACGGA R K G G K V V I N V A S G D Y F L M P TGCGGTTTTCAAAGGACGCACTTGCATTCAGTAAACTCCATCGACGAAGGGCGCATCAGT 2461 + + + + + + 2520 ACGCCAAAAGT TCCTGCGTGAACGTAAGTCATTTGAGGTAGCTGCTTCCCGCGTAGTCA C G F Q R T H H S V N S I D E G R I S T GACGTTt^GGGCAACTCO-K:GCGTCTTrGGTGTAGGCAGGATGTTGCAGTTAGCCGGC 2521 + + + + + + 2580 AACTGCAAGTCCCGTTGAGCCGCGCAGAAACCACATCCGTCCTACAACGTCAATCGGCCG T F R A T R R V F G V G R M L Q L A G GGCGTGTCGGATGAGAAGTCACCAGGTGTTCCAAACCAGCAACCACAGAGCCAAG-GTGCT 2581 + + + + + + 2640 CCGCACAGCCTACTCTTC^GTGGTCCACAAGGTTTGGTCGTTGGTGTCTCGGTTCCACGA G V S D E S P G V P N Q Q P Q S Q G A ACCAGA\CA^.TCACACCA^AATCGGGGG.CAAGGCTCTATCTGAGGGAAGTGGTAGGGAA 2641 -t- T -r -r + + 2700 TGGTCTTGTTAGTGTGGTTTTAGCCCCCCGTTCCGAGATAGACTCCCTTCACCATCCCTT T R T I T P K S G G K A L S E G S G R E GTCAAGGGGAGGTCGACATACTCGATATG TGCGAACAAGATTACGTTAGGAAGTGTGAG 2701 -t- + -• ■ + + 2760 CAGTTCCCCTCCAGCTGTATGAGCTATACCACGCTTGTTCTAATGCAATCCTTCACACTC V G R S T Y S I C E Q D Y V R K C E TGGCTCAGGGCTGATAATCCAGTGATGGCTCTTRAACCTGGCTACACCCCAATGACATTT 2761 + + + + + + 2820 ACCGAGTCCCGACTATTAGGTCACTACCGAGAAYTTGGACCGATGTGGGGTTACTGTAAA R A D N P V M A L. 7 P G Y T P M T F GAAGTGGTTAAAGCCGGGACCTCTGAAGATGCCGTCGTGGAGTACTTGAAGTATCTGGCT 2821 + + -i- + + + 2880 CTTCACCAATTTCGGCCCTGGAGACTTCTACGGCAGCACCTCATGAACTTCATAGACCGA E V V K A G T S E D A V V E Y K Y L A ATAGGCATTGGGAGGACATACAGGGCGTTGCTTATGGCTAGAAATATTGCCGTCACTACC 2881 + + + + + + 2940 TATCCGTAACCCTCCTGTATGTCCCGCAACGAATACCGATCTTTATAACGGCAGTGATGG I G I G R T Y R A A R N I A V T T GCCGAAGGTGTTCTGAAAGTACCTAATCAAGTTTATGAATCACTACCGGG-CTTTCACGTT 2941 + + + + + + 3000 CGGCTTCCACAAGACTTTCATGGATTAGTTCAAATACTTAGTGATGGCCCGAAAGTGCAA A E G V K V P N Q V Y E S L P G F H V TACAAGTCGGGCACAGATCTCATTTTTCATTCAACACAAGACGGCTTGCGTGTGAGAGAC 3001 + + + -i- -t* + 3060 ATGTTCAGCCCGTGTCTAGAGTAAAAAGTAAGTTGTGTTCTGCCGAACGCACACTCTCTG Y K S G T D L I F H S T Q D G R V R D CTACCGTACGTATTCATAGCTGAGAAAGGTATTTTTATCAAGGGCAAAGATGTCGACGCG 3061 + + + + + + 3120 GATGGCATGCATAAGTATCGACTCTTTCCATAAAAATAGTTCCCGTTTCTACAGCTGCGC Ii P Y V F X A E K G I F I K G K D V D A GTAGTAGCTTTGGGCGACAATCTGTCCGTATGTGATGATATATTGGTTTTCCATGATGCT 3121 + + + + + + 3180 CATCATCGAAACCCGCTGT AGACAGGCATACACTACTATATAACCAAAAGGTACTACGA ATTAAT TGATGGCTGCACTGAAAGTTGCTCGATGTGGTATGGTGGGTGAATCATTTAAG 3181 + -t- + *♦* + + 3240 TAATTAAACTACCCACGTGACTTTCAACGAGCTACACCATACCACCCACTTAGTAAATTC I N M G A L K V A R C G M V G E S F K TCGTTCGAATACAAATGCTATAATGCTCCCCCAGGTGGCGGTAAGACGACGA GCTAGTG 3241 + + + + + + 3300 AGCAAGCTTA GT TACGATATTACGAGGGGGTCCACCGCCATTCTGCTGCTACGATCAC S F E Y K C Y N A P P G G G T T M V GACGAATTTGTCAAGTCACCCAATAGCACGGCCACCAT ACGGCTAACGTGGGAAGTTCT 3301 1* --- -r 3360 CTGC TAAACAGTTCAGTGGGTTATCGTGCCGGTGGTAATGCCGATTGCACCCTTCAAGA D Ξ F V X S P N S T A T I T A N V G Ξ S GAGGACATAAATATGGCGGTGAAGAAGAGAGATCCGAATTTGGAAGGTCTCAACAGTGCT 3361 + + ■ > + J- -r 3420 CTCCTGTATTTATACCGCCACTTCTTCTCTCTAGGCTTAAACCTTCCAGAGTTGTCACGA E D I N M A V K K R D P N E G L N S A ACCACAGTTAACTCCAGGGTGGTTAACTTTATTGTCAGGGGAATGTATAAAAGGGTTTTG 3421 + -+■ + + + + 3480 TGGTGTCAATTGAGGTCCCACCAATTGAAATAACAGTCCCCTTACATATTTTCCCAAAAC T T V N S R V V N F I V R G M Y K R V L GTGGATGAGGTGTACATGATGCATCAAGGCTTACTACAACTAGGCGTCTTCGCAACCGGC 3481 + ■*• + + + + 3540 CACCTACTCCACATGTACTACGTAGTTCCGAATGATGTTGATCCGCAGAAGCGTTGGCCσ V D E V Y M M H Q G L L Q L G V F A T G GCGTCGGAAGGCCTCTTTTTTGGAGACATAAATCAGATACCATTCATAAACMGGGAGAAG 3541 + + + + + -i- 3600 CGCAGCCTTCCGGAGAAAAAACCTCTGTATTTAGTCTATGGTAAGTATTTGKCCCTCTTC A S E G F F G D I N Q I P F I N R E K GTGTTTAGGATGGATTGTGCTGTATTTGTTCCAAAGAAGGAAAGCGTTGTATACACTTCT 3601 + + + + + + 3660 CACAAATCCTACCTAACACGACATAAACAAGGTTTCTTCCTTTCGCAACATATGTGAAGA V F R M D C A V F V P K E S V V Y T S AAATCATACAGGTGTCCGTTAGATGTTTGCTACTTGTTGTCCTCAATGACCGTAAGGGGA 3661 + + + + + + 3720 TTTAGTATGTCCACAGGCAATCTACAAACGATGAACAACAGGAGTTACTGGCATTCCCCT ACGGAAAAGTGTTACCCTGAAAAGGTCGTTAGCGGTAAGGACAAACCAGTAGTAAGATCG 3721 + -t- + + + -<- 3780 TGCCTTTTCACAATGGGACTTTTCCAGCAATCGCCATTCCTGTTTGGTCATCATTCTAGC T E K C Y P E K V V S G K D K P V V R S CTGTCCAAAAGGCCAA TGGAACCACTGATGACGTAGCTGAAATAAACGCTGACGTGTAC 3781 + + + + + -•• 3840 GACAGGTTTTCCGGTTAACCTTGGTGACTACTGCATCGACTTTATTTGCGACTGCACATG L S K R P I G T T D D V A E I N A D V Y TTGTG ATGACCCAGT GGAGAAGTCGGATATGAAGAGGTCGTTGAAGGGAAAAGGAAAA 3841 + + + + + + 3900 AACACGTACTGGGTCAACC C CAGCCTATACTTCTCCAGC-AACTTCCC TTTCC T T L C M T Q E K S D M R Ξ K G K G GAAACACCAGTGATGACAGTGCATGAAGCACAGGGAAAAACATTCAGTGATGTGGTATTG 3901 + + + + + + 3960 CT TGTGGTCACTACTGTCACGTACT CGTGTCCCTTTTTGTAAGTCACTACACCATAAC E T P V M T V H E A Q G T F S D V V L TTTAGGACGAAGAAAGC GATGAC CCCT.-.TTCACrAAACAACCGCATATACTTGTTCGT 3961 + + + + + ^ 4020 AAATCCTGCTTCTTTCGGCTACTGAGGGATAAGTGATTTGTTGGCGTATATGAACAACCA a F R T K K A D D S F T Q P H I L. V G TTGTCGAGACACACACGCTCAC GGTTTAXGCCGCTCTGAGCTCAGAGTTGGACGATAAG 4021 -r + -r -* ■ -r + 40S0 AACAGCTCTGTGTGTGCGAGTGACCAAATACGGCGAGACTCGAGTCTCAACCTGCTATTC a L S R K T R S V Y A A L S S E L D D ' A Q S W T I R - ( FRAMESHIFT) GTCGGCACATATATTAGCGACGCGTCGCCTCAATCAGTATCCGACGCTTTGCTTCACACG 4081 + + + + + + 4140 CAGCCGTGTATATAATCGCTGCGCAGCGGAGTTAGTCATAGGCTGCGAAACGAAGTGTGC a V G T Y I S D A S P Q S V S D A L f T S A H I L A T R H L N Q Y P T L C F 'V R - ORF11 * (RdRp) TTCGCCCCGGCTGGTTGCTTTCGAGGTATATGAGCGTATGAATTTTGGACCGACCTTCGA 4141 1- + + + + ■>■ 4200 AAGCGGGGCCGACCAACGAAAGCTCCATATACTCGCATACTTAAAACCTGGCTGGAAGCT a F A P A G C F R G I * b S P R V A F E V Y E R M N F G P T F E - AGGGGAGTTGGTACGGAAGATACCAACAAGTCATTTTGTAGCCGTGAATGGGT TCTCGA 4201 + + + + + + 4260 TCCCCTCAACCATGCCTTCTATGGTTGTTCAGTAAAACATCGGCACTTACCCAAAGAGCT b G E V R K I P T S H F V A V N G F E - GGACTTACTCGACGGTTGTCCGGCTTTCGACTATGACTTCTTTGAGGATGATTTCGAAAC 4261 + + + + + + 4320 CCTGAATGAGCTGCCAACAGGCCGAAAGCTGATACTGAAGAAACTCCTACTAAAGCTTTG b D L D G C P A F D Y D F F E D D F E T - TTCAGATCAGTCTTTCCTCATAGAAGATGTGCGCATTTCTGAATCTTTTTCTCATTTTGC 4321 + + + + + + 4380 AAGTCTAGTCAGAAAGGAGTATCTTCTACACGCGTAAAGACTTAGAAAAAGAGTAAAACG b S D Q S F L I E D V R I S E S F S H F A - GTCGAAAATAGAGGATAGGT TTACAGTTTTATTAGGTCTAGCGTAGGTTTACCAAAGCG 4381 + + -i + + + 4440 CAGCT ATCTCCTATCCAAAATGTCAAAATAATCCAGATCGCATCCAAATGGTTTCGC b S K I E D R F Y S F I R S S V G P K R - CAACACCTTGAAGTGTAACCTCGTCACGTTTGAAAATAGGAA TCCAACGCCGATCGCGG 4441 + + -t- -i -i + 4500 GTTGTGGAAC TCACATTGGAGCAGTGCAAACTTTTATCCTTAAGGTTGCGGCTAGCGCC B N T L K C N L V T F E N R N S N A D R G - T GTAACGTGGGTTGTGACGACTCTGTGK:GCATGAACTGAAGGAG^T TTCTTCGAGGA 4501 + + + + + + 4560 AACAT GCACCCAAC-AC GCTGAGACACCσCGTACTTGACTTCCTCTAAAAGAAGCτCCT 0 C N V G C D D S V A H E L K E I F F E E - GGTCC-TTAACAAAGCTCGT TAGCAGAGGTGACGGAAAGCCATTrGTCCAGCAACACGAT 4561 T Λ. -, + + .- 4620 CCAGCAATTGTTTCGAGCAAATCGTCTCCACTGCCTTTCGGTAAACAGGTCGTTGTGCTA V V N K A R L A E V T E S H L S S N T - GTTGTTATCAGATTGGTTGGACAAAAGGGCACCTAACGCTTACAAGTCTCTCAAGCGGGC 4621 + + + 4680 CAACAATAGTCTAACCAACCTGTTTTCCCGTGGATTGCGAATGTTCAGAGAGTTCGCCCG S D W D K R A P N A Y K S L K R A - TTTAGGTTCGGTTGTCTTTCATCCGTCTATGTTGACGTCTTATACGCTCATGGTGAAAGC 4681 + H + + + + 47 0 AAATCCAAGCCAACAGAAAGTAGGCAGATACAACTGCAGAATATGCGAGTACCACTTTCG G S V V F H P S M L T S Y T L M V K A - AGACGTAAAACCCAAGTTGGACAATACGCCATTGTCGAAGTACGTAACGGGGCAGAATAT 4741 + +• + + + + 4800 TCTGCATTTTGGGTTCAACCTGTTATCCGGTAACAGCTTCATGCATTGCCCCGTCTTA'IA D V K P L D N T P Ξ Y V T G Q N I - AGTCTACCACGATAGGTGCGTAACTGCGCTTTTTTCTTGCATTTTTACTGCGTGCGTAGA 4801 + + + + + + 4860 TCAGATGGTGCTATCCACGCATTGACGCGAAAAAAGAACGTAAAAATGACGCACGCATCT V Y H D R C V T A L F S C I F T A C V E - GCGCTTAAAATACGTAGTGGACGAAAGGTGGCTCTTCTACCACGGGATGGACACTGCGGA 4861 + + + -t- + + 4920 CGCGAATTTTATGCATCACCTGCTTTCCACCGAGAAGATGGTGCCCTACCTGTGACGCCT R L K Y V V D E R Ii F Y H G D T A E - GTTGGCGGCTGCATTGAGGAACAATTTGGGGGACATCCGGCAATACTACACCTATGAACT 4921 + + + + + + 4980 CAACCGCCGACGTAACTCCTTGTTAAACCCCCTGTAGGCCGTTATGATGTGGATACTTGA Ii A A A L R N N L G D I R Q Y Y T Y E L - GGATATCAGTAAGTACGACAAATCTCAGAGTGCTCTCATGAAGCAGGTGGAGGAGTTGAT 4981 + -t- + + + -r 5040 CCTATAGTCATTCATGCTGTTTAGAGTCTCACGAGAGTACTTCGTCCACCTCCTCAACTA D I S K Y D K S Q S A Ii M Q V E E Ii l - ACTCTTGACACTTGGTGTTGATAGAGAAGTTTTGTCTACTTTCTTTTGTGGTGAGTATGA 5041 + + + + + + 5100 TGAGAACTGTGAACCACAACTATCTCTTCAAAACAGATGAAAGAAAACACCACTCATACT L T G V D R E V S T F F C G E Y D - AGCGTCGTGAGAACGATGACGAAGGAATTGGTGTTGTCTGTCGGCTCTCAGAGGCGCAG 5101 4- 4- 4- 4- 4- 4- 5160 ATCGCAGCACTCTTGCTACTGCTTCCTTAACCACAACAGACAGCCGAGAGTCTCCGCGTC S V V R T T K E V L S V G S Q R R S - TGGTGGTGCTAACACGTGGTTGGGAAATAGTTTAGTCTTGTG ACCTTGTTGTCCGTAGT 5161 4- - + + 4- + 5220 ACCACCACGATTG GCACCAACCCT TATCAAATCAGAACACGTGGAACAACAGGCATCA G G A N T W Ii G N S V L C T Ii S V V - ACTTAGGGGATTAGATTATAGTTATATTGTAGTTAGCGGTGATGATAGCCTTATATTTAG 5221 -t- - f -*■ + 5280 TGAATCCCCTAATCTAATATCAATATAACATCAATCGCCACTACTATCGGAATATAAATC R G D Y S Y I V V S G D D S I F S - TCGGCAGCCGTTGGATATTGATACGTCGGTTCTGAGCGATAATTTTGGTTTTGACGTAAA 5281 4- + ■>- H 4- + 5340 AGCCGTCGGCAACCTATAACTATGCAGCCAAGACTCGCTATTAAAACCAAAACTGCATTT R Q P D I D T S V L S D N F G F D V K - GATTTTTAACCAAGCTGCTCCATATTTTTGTTCTAAGTTTTTAGTTCAAGTCGAGGATAG 5341 - + 4- 4- 4- + 5400 CTAAAAATTGGTTCGACGAGGTATAAAAACAAGATTCAAAAATCAAGTTCAGCTCCTATC I F N Q A A P Y F C S K F L V Q V E D S - TCTCTTTTTTGTTCCCGATCCACTTAAACTCTTCGTTAAGTTTGGAGCTTCCAAAACTTC 5401 4- + 4* 4- 4- + 5460 AGAGAAAAAACAAGGGCTAGGTGAATTTGAGAAGCAATTCAAACCTCGAAGGTTTTGAAG L F F V P D P K F V K F G A S K T S - AGATATCGACCTTTTACATGAGATTTTTCAATCTTTCGTCGATCTTTCGAAGGGTTTCAA 5461 4. 4- 4- 4- + + 5520 TCTATAGCTGGAAAATGTACTCTAAAAAGTTAGAAAGCAGCTAGAAAGCTTCCCAAAGTT D I D H E I F Q S F V D L S K G F N - TAGAGAGGACGTCATCCAGGAATTAGCTAAGCTGGTGACGCGGAAATATAAGCATTCGGG 5521 + + + 4- 4- + 5580 ATCTCTCCTGCAGTAGGTCCTTAATCGATTCGACCACTGCGCCTTTATATTCGTAAGCCC R Ξ D V I Q E A K V T R K Y K H S G - ATGGACCTACTCGGCTTTGTGTGTCTTGCACGTTTTAAGTGCAAATTTTTCGCAGTTCTG 5581 4- 4- 4- 4- 4- 4- 5640 TACCTGGATGAGCCGAAACACACAGAACGTGCAAAATTCACGTTTAAAAAGCGTCAAGAC W T Y S A C V L H V L S A N F S Q F C - TAGGTTATATTACCACAATAGCGTGAATCTCGATGTGCGCCCTATTCAGAGGACCGAGTC 5641 4- 4- 4- 4- 4- 4- 5700 ATCCAATATAATGGTGTTATCGCACTTAGAGCTACACGCGGGATAAGTCTCCTGGCTCAG R Y Y H N S V N L D V R P I Q R T E S - GCTTTCCTTGCTGGCCTTGAAGGCAAGAATTTTAAGGTGGAAAGCTTCTCGTTTTGCCTT 5701 4- 4- 4- 4- 4- 4- 5760 CGAAAGGAACGACCGGAAC TCCGTTCTTAAAATTCCACCTTTCGAAGAGCAAAACGGAA S L Ii A Li K A R I R W K A S R F A F - TTCGATAAAGAGG-GT AATCGCGTTGGCCACGCTATAGTGTT CTGTGCCTCGGTTCT 5761 4- 4- -t- 4- 4- 4- 5820 AAGCTAT TCTCCCCAAT AGCCSCAACCGGTGCGATATCACAAAGACACGGAGCCAAGAA S I K R G * CGTGAGGTTAATACCGAAGGGTCGTCGTACT ATCTCAGT A A TTTTTCGTCTTCT 5821 4- 4- 4- 4- 4- +. 5880 GCACTCCAA TA GGCT CCCAGCAG^TGAATAGAGTCAATAAATAAAAAAGCAGAAGA CTTAGGCGTGCCATCCGTGAAGTTAATACCGGTGGCAC'rCCTTCTCGAAGTGGGTA'rTAA 5881 + + + 4- -t- + 5940 GAATCCGCACGGTAGGCACTTCAATTATGGCCACCGTGAGGAAGAGCTTCACCCATAATT AGACCAAAATTTTTTATTTGTGTGTACTTTTTGTTTTGTTCACACCGTGAGGACAAGACC 5941 4- + -r + 6000 TCTGGTTT AAAAAATAAACACACATGAAAAACAAAACAAGTGTGGCACTCCTGTTCTGG 0RF2 (7 ) GGTGGAACATGTACAGTAGAGGGTCTTTCTTTAAGTCTCGGGTTACCCTTCCTACTCTTG 5001 4- -r -r -t- + + 6060 CCACCTTGTACATGTCATCTCCCAGAAAGAAATTCAGAGCCCAATGGGAAGGATGAGAAC M Y S R G S F F K S R V T P T L V - TCGGAGCATACATGTGGGAGTTTGAACTCCCGTATCTTACGGACAAGAGACACATCAGCT 6061 4- * 4- 4- + + 6120 AGCCTCGTATGTACACCCTCAAACTTGAGGGCATAGAATGCCTGTTCTCTGTGTAGTCGA G A Y M W E F E L P Y T D K R H I S Y - ATAGCGCGCCAAGTGTCGCGACTTTTAGCCTTGTGTCGAGGTAGGATAGGGGCCAACAGG 6121 4- + 4- 4- + + 6180 TATCGCGCGGTTCACAGCGCTGAAAATCGGAACACAGCTCCATCCTATCCCCGGTTGTCC S A P S V A T F S V S R * TGACCAACAGCCTGCACTTAAGGTGCGCTGGAAGTGTTGGATTTGGTCTCAGTGTGCCAA 6181 4- -t- 4- 4- 4- T 6240 ACTGGTTGTCGGACGTGAATTCCACGCGACCTTCACAACCTAAACCAGAGTCACACGGTT ATATCCTTTTAGGCGATGTACAGGAGTCTAGTTTAGTGTGTCTTTGGGGGATGACGGGAG 6241 4- 4- 4- 4- 4- + 6300 TATAGGAAAATCCGCTACATGTCCTCAGATCAAATCACACAGAAACCCCCTACTGCCCTC CGACTAGGTTTAGGACTGTAGCTGCTATGTAAGTCGTGCATGCGGCATTGTGCGTAAGAC 6301 4- 4- 4- 4- -t- + 6360 GCTGATCCAAATCCTGACATCGACGATACATTCAGCACGTACGCCGTAACACGCATTCTG GTGCATGCATTTGGGCGAGTGCCCTAGGGCAGCGTCGGTCAGGTGACTAGCAGCCGGCTC 6361 4- 4- 4- + + + 6420 CACGTACGTAAACCCGCTCACGGGATCCCGTCGCAGCCAGTCCACTGATCGTCGGCCGAG TACGGAGCGCTGAAAGTGCTAGGTCCTGAAGGTACAGTTGGGCTGAGGCAGGACATGGTT 6421 4- 4- 4- -t- + 4- 6480 ATGCCTCGCGACTTTCACGATCCAGGACTTCCATGTCAACCCGACTCCGTCCTGTACCAA GAACGAGTTGACCGTGGGGACCAGCGGCGGTGACTCGGGCCGTAGCCACGCGCGGGGCGG 6481 4- 4- 4- 4- 4- 4- 6540 CTTGCTCAACTGGCACCCCTGGTCGCCGCCACTGAGCCCGGCATCGGTGCGCGCCCCGCC CAG^-GCGTCTCGTGGTGTATCTGGGCAAGATACGGCTT ATTAGGCACCATAATATGGAG 6541 4- 4- 4- 4- + + 6600 GTCCCGCAGAGCACCACATAGACCCGTTCTATGCCGAAATAATCCGTGGTATTATACCTC CCCAAAGCGTCGGGGTCGGGAAACATCTCCATAGCTTAGTGGCAGCAGCCTAAGATAGGC 6601 4- -r -t- + 4- + 6660 GGGTTTCGCAGCCCCAGCCCT GTAGAGGTATCGAATCACCGTCGTCGGATTCTATCCG TG^-JGAGGCCCGT CCC GTAGTAGTGGTGGGTTAGCATGCCACTAAGCGGTGCGGCGTGA 6661 4- 4- + 4- 4- + 6720 ACCCTCCGGGCAAGGGACATCATCACCACCCAATCGTACGGTGATTCGCCACGCCGCACT TAAGGCGCCACCGTCCGTAGTTAGGCGACCCGTGTT TAATAGGGTCTCTTTAGTTAAGT 6721 + -*■ + -*- 6780 ATTCCGCGGTGGCAGGCATCAATCCGCTGGGCACAAAATTATCCCAGAGAAATCAATTCA TTAGGCATGTCGTACAGTTAGGATTTCTTTTTAGATATTCTTTTATTTTTTATTGTTTGT 6781 -t- 4- ÷ -r 4- + 6840 AATCCGTACAGCATGTCAATCCTAAAGAAAAATCTATAAGAAAATAAAAAATAACAAACA TAGTTTAGATGTACATTATTACGTAGGTTACTTTGGCGCTACGCCAGAGGTTTTTCCTCT 6841 4- 4- 4- 4- + + 6900 ATCAAATCTACATGTAATAATGCATCCAATGAAACCσCGATGCGGTCTCCAAAAAGGAGA TTGTGTGTAGCCTTTAATGTAGGTTTCTTTGTTTTATTTTTGCCTTTCAGGCGGCGCGTT 6901 + 4- 4- + 4- + 6960 AACACACATCGGAAATTACATCCAAAGAAACAAAATAAAAACGGAAAGTCCGCCGCGCAA TCTTTTCTTCTATTTAGGTTTATCTTCTTTCCTTAGTGTTGTCGTATATGACGCTACGTC 6961 4- + 4- + 4- + 7020 AGAAAAGAAGATAAATCCAAATAGAAGAAAGGAATCACAACAGCATATACTGCGATGCAG CAAATTATGAATTTTCCTTCGTGTAGGCGTCGTTGAGTGCGTTCATCGGCGCTAGACGAG 7021 + 4- 4- 4- 4- + 7080 GTTTAATACTTAAAAGGAAGCACATCCGCAGCAACTCACGCAAGTAGCCGCGATCTGCTC GTTTAGTGGCGACATAAATAGGTTTTTGCGCGAGATTGG-GATAGAACGAGTTCGCCTTAA 7081 4- 4- 4- 4- 4- 4- 7140 CAAATCACCGCTGTATTTATCCAAAAACGCGCTCTAACCCTATCTTGCTCAAGCG-GAATT AAGAGAAATCGGGGAAGGCGCCACGCGAATGACCTTCGTGCTGAGCGAAGGTAGTATCGT 7141 4. 4- 4- -t- 4- + 7200 TTCTCTTTAGCCCCTTCCGCGGTGCGCTTACTGGAAGCACGACTCGCTTCCATCATAGCA OR3?3 (5K, Membrane protein) GATTTTATATTGAAGTAGGCGTATTTGTTTATGGATGATTTTAAACAGGCAATACTGTTG 7201 + + 4- -t- 4- -t- 7260 CTAAAATATAACTTCATCCGCATAAACAAATACCTACTAAAATTTGTCCGTTATGACAAC M D D F K Q A I L L CTAGTAGTCGATTTTGTC CGTGATAATTCTGCTGCTGGTTCTTACGTTCGTCGTCCCG 7261 4- + + -t- + 4- 7320 GATCATCAGCTAAAACAGAAGCACTAT AAGACGACGACCAAGAATGCAAGCAGCAGGGC Ii V V D F V F V I I L Ii V Ii T F V V P AGGrrAC-AGCAAAGCTCCACCATTAATACAGGTCTTAGGACAGTGTGAT CCTCCTT AG 7321 4- 4- 4- 4- 4- 4- 7380 TCCAATGTCGTT CGAGGTGGTAATTATGTCCAGAATCCTGTCACACTAAGGAGGAAATC R L Q Q S S T I N T G R T V * ORF4 (HSP70 Homolog) TTAGATATGGAAGTAGGTATAGAT TTGGAACCACTTTCAGCACAATCTGCTTTTCCCCA 7381 + 4- 4- - 4- + 7 40 AATCTATACCTTCATCCATATCTAAAACCTTGGTGAAAGTCGTGTΓAGACGAAAAGGGGT M E V G I D F G T T F S T I C F S P TCrGGGGTCAGCGGTTGTACTCCTGTGGCCGGTAGTGTTTACGTTGAAACCCAAATTT T 7441 + + + + . + 7500 AGACCCCAGTCGCCAACATGAGGACACCGGCCATCACAAATGCAACTTTGGGTTTAAAAA S G V S G C T P V G S Y V E T Q I F ATACCTGAAGGTAGCAGTA.CTTACTTAATTGGTAAAGCrGCGGGGAAAGCTTATCGTGAC 7501 4- 4- + 4- + 7560 TATGGACTTCCATCGTCATGAATGAATTAACCATTTCGACGCCCCTTTCGAATAGCACTG I P E G S S T Y I G K A A G K A Y R D GGTGTAGAGGGAAGGTTGTATGTTAACCCGAAAAGGTGGGCAGGTGTGACGAGGGATAAC 7561 4- 4- 4- 4- + -f. 7620 CCACATCTCCCTTCCAACATACAATTGGGCTTTTCCACCCGTCCACACTGCTCCCTATTG G V E G R L Y V N P K R W A G V T R D N GTCGAACGCTACGTCGAGAAATTAAAACCTACATACACCGTGAAGATAGACAGCGGAGGC 7621 4- 4- 4- 4- 4- + 7680 CAGCTTGCGATGCAGCTCTTTAATTTTGGATGTATGTGGCACTTCTATCTGTCGCCTCCG V E R Y V E K L K P T Y T V K I D S G G GCCTTATTAATTGGAGGTTTAGGTTCCGGACCAGACACCTTATTGAGGGTCGTTGACGTA 7681 4- 4- 4- 4- 4- + 7740 CG AATAATTAACCTCCAAATCCAAGGCCTGGTCTGTGGAATAACTCCCAGCAACTGCAT A L L I G G G S G P D T L R V V D V ATATGTTTATTCTTGAGAGCCTTGATACTGGAGTGCGAAAGGTATACGTCTACGACGGTT 7741 -t- -t- 4- 4- 4- + 7800 TATACAAATAAGAACTCTCGGAACTATGACCTCACGCTTTCCATATGCAGATGCTGCCAA I C L F Ii R A Ii l L E C E R Y T S T T V ACAGCAGCTGTTGTAACGGTACCGGCTGACTATAACTCCTTTAAACGAAGCTTCGTTGTT 7801 4- 4- 4- 4- 4- 4- 7860 TGTCGTCGACAACATTGCCATGGCCGACTGATATTGAGGAAATTTGCTTCGAAGCAACAA T A A V V T V P A D Y N S F K R S F V V GAGGCσCTAAAAGGTCTTGGTATACCGGTTAGAGGTGTTGTTAACGAACCGACGGCCGCA 7861 4- 4- 4- 4- 4- + 7920 CTCCGCGATTTTCCAGAACCATATGGCCAATCTCCACAACAATTGCTTGGCTGCCGGCGT E A L K G L G I P V R G V V N E P T A A GCCCTCTATTCCTTAGCTAAGTCGCGAGTAGAAGACCTAT ATTAGCGGTTTTTGATTTT 7921 + 4- 4- 4- 4- 4- 7980 CGGGAGATAAGGAATCGA TCAGCGCTCATCTTCTGGATAATAATCGCCAAAAACTAAAA GGGGGAGGGACTTTCGACGTCTCA CGTTAAGAAGAAGGGAAATATACTATGCGTCATC 7981 4- 4 4- 4- 4- + 8040 CCCCCTCCCTGAAAGCTGCAGAGTAAGCAATTCT CTTCCCTTTATATGATACGCAGTAG G G G T F D V S F V K K K G N I C V I TTTCAGTGGGTGATAATTTCTTGGGTGGTAGAGATATTGATAGAGCTATCGTGGAAGTT 8041 4- 4- -t- + + + 8100 AAAAGTCACCCACTATTAAAGAACCCACCATCTCTATAACTATCTCGATAGCACCTTCAA F S V G D N F L G G R D I D R A I V E V ATCAAACAAAAGATCAAAGGAAAGGCGTCTGATGCCAAGTTAGGGATATTCGTATCCTCG 8101 4- -«- 4- 8160 TAGTTTGTTTTCTAGTTTCCTTTCCGCAGACTACG TTCAATCCCTATAAGCATAGGAGC I K Q I K G X A S D A K G I F V S S ATGAAGGAAGACTTGTCTAACAATAACGCTATAACσCAACA.CCTTATCCCCGTAGAAGGG 8161 -t- -*- + -r -. + . 8220 TACTTCCTTCTGAACAGATTGTTATTGCGATATTGCGTTGTGGAATAGGGGCATCTTCCC M K E D S N N N A I T Q H I P V E G GGTGTGGAGGTTGTGGATTTGACTAGCGACGAACTGGACGCAATCGTTGCACCATTCAGC 8221 + 4- 4* 4- + + 8280 CCACACCTCCAACACCTAAACTGATCGCTGCTTGACCTGCGTTAGCAACGTGGTAAGTCG G V E V V D T S D E L D A I V A P F S GCTAGGGCTGTGGAAGTATTCAAAACTGGTCTTGACAACTTTTACCCAGACCCGGTTATT 8281 4- 4- 4- 4- + + 8340 CGATCCCGACACCTTCATAAGTTTTGACCAGAACTGTTGAAAATGGGTCTGGGCCAATAA A R A V E V F K T G L D N F Y P D P V ' I GCCGTTATGACTGGGGGGTCAAGTGCTCTAGTTAAGGTCAGGAGTGATGTGGCTAATTTG 8341 + 4- 4- 4- + + 8400 CGGCAATACTGACCCCCCAGTTCACGAGATCAATTCCAGTCCTCACTACACCGATTAAAC A V M T G G S S A L V K V R S D V A N L CCGCAGATATCTAAAGTCGTGTTCGACAGTACCGATTTTAGATGTTCGGTGGCTTGTGGG 8401 4- 4- 4- 4- 4- 4- 8460 GGCGTCTATAGATTTCAGCACAAGCTGTCATGGCTAAAATCTACAAGCCACCGAACACCC P Q I S K V V F D S T D F R C S V A C G GCTAAGGTTTACTGCGATACTTTGGCAGGTAATAGCGGACTGAGACTGGTGGACACTTTA 8461 4- 4- 4- 4- 4- 4- 8520 CGATTCCAAATGACGCTATGAAACCGTCCATTATCGCCTGACTCTGACCACCTGTGAAAT ACGAATACGCTAACGGACGAGGTAGTGGGTCTTCAGCCGGTGGTAATTTTCCCGAAAGGT 8521 4- 4- 4- + + + 8580 TGCTTATGCGATTGCCTGCTCCATCACCCAGAAGTCGGCCACCATTAAAAGGGCTTTCCA T N T L T D E V V G Q P V V I F P K G AGTCCAATACCCTGTTCATATACTCATAGATACACAGTGGGTGGTGGAGATGTGGTATAC 8581 4- -t- + H 4- 4- 8640 TCAGGTTATGGGACAAGTATATGAGTATCTATGTGTCACCCACCACCTCTACACCATATG S P I P C S Y T H R Y T V G G G D V V Y GGTATATT GAAGGGGAGAATAACAGAGC TTTCTAAATGAGCCGACGTTCCGGGGCGTA 8641 4- 4- 4- 4- 4- + 8700 CCATATAAACT CCCCTCTTAT GTCTCGAAAAGATTTACTCGGCTGCAAGGCCCCGCAT G X F E G E N N R A F N E P T F R G V TCGAAACGTAGGGGAGACCCAGTAGAGACCGACGTGGCGCAGTTTAATCTCTCCACGGAC 8701 4- 4- 4- 4- 4- 4- 8760 AGCT TG^^TCCCCTCTGGGTCATCTCTGGCTGCACCGCGTCAAAT AGAGAGGTGCCTG S K R R G D P V E T D V A Q F N L S T D GGAACGGTGTCTGTTATCGTTAATGGTGAGGAAGTAAAGAATGAATATCTGGTACCCGGG 3751 -r -i- + + . 8820 CCTTGCCACAGACAATAGCAATTACCACTCCTTCATTTCTTACTTATAGACCATGGGCCC a G T V Ξ V I V N G E Ξ V K E Y L V P G ACAACAAACGTACTGGATTCATTGGTCTATAAATCTGGGAGAGAAGATTTAGAGGCTAAG 8821 + - + + 8880 TGTTGTTTGCATGACCTAAGTAACCAGATATTTAGACCCTCTCTTCTAAATCTCCGATTC a T T N V D S L V Y K S G R E D L E A K GCAATACCAGAGTACTTGACCACACTGAATATTTTGCACGATAAGGCTTTCACGAGGAGA 8881 4 r- 1 r- 1 - 8940 CGTTATGGTCTCATGAACTGGTGTGACTTATAAAACGTGCTATTCCGAAAGTGCTCCTCT a A I P E Y L T T L N I H D K A F T R R AACCTGGGTAACAAAGATAAGK-GTTCTCGGATTTAAGGATAGAAGAAAATTTTTTAAAA 8941 -t- 4- 4- 4- + + 9000 TTGGACCCATTGTTTCTATTCCCCAAGAGCCTAAATTCCTATCTTCTTTTAAAAAATTTT a N L G N K D K G F S D R I E E N F K ORF5 (HSP90 Homolog) TCCGCCGTAGATACAGACACGATTTTGAATGGATAAATATATTTATGTAACGGGGATATT 9001 4- 4- 4- 4- 4- + 9060 AGGCGGCATCTATGTCTGTGCTAAAACTTACCTATTTATATAAATACATTGCCCCTATAA a S A V D T D T I L N G * b D K Y I Y V T G I - AAACCCTAACGAGGCTAGAGACGAGGTATTCTCGGTAGTGAATAAGGGATATATTGGACC 9061 4- -t- 4- 4- 4- +. 9120 TTTGGGATTGCTCCGATCTCTGCTCCATAAGAGCCATCACTTATTCCCTATATAACCTGG b N P N E A R D E V F S V V N K G Y I G P - GGGAGGGCGCTCCTTTTCGAATCGTGGTAGTAAGTACACCGTCGTCTGGGAAAACTCTGC 9121 + 4- 4- 4- 4- + 9180 CCCTCCCGCGAGGAAAAGCTTAGCACCATCATTCATGTGGCAGCAGACCCTTTTGAGACG b G G R S F S N R G S Y T V V W E N S A - TGCGAGGATTAGTGGATTTACGTCGACTTCGCAATCTACGATAGATGCTTTCGCGTATTT 9181 + + + + . + + 9240 ACGCTCCTAATCACCTAAATGCAGCTGAAGCGTTAGATGCTATCTACGAAAGCGCATAAA b A R I S G F T S T S Q S T I D A F A Y F - CTTGTTGAAAGGCGGATTGACTACCACGCTCTCTAACCCAATAAACTGTGAGAATTGGGT 9241 4- + -t- + + + 9300 GAACAACTTTCCGCCTAACTGATGGTGCGAGAGATTGGGTTATTTGACACTCTTAACCCA b L K G G L T T T L S N P I N C E N W V - CAGGTCATCTAAG<-ATTTAAGCGCGTT TrCAGGACCCTAAT AAAGGTAAGAT TATGC 9301 4- 4- 4- 4- 4- + 9360 GTCC^GTAGATTCCTAAAT CGCσCAAAAAGTCCTGGGATTAATTTCCATTCTAAATACG b R S S K D Ii S A F F R T I- I G K I Y A - ATCGCGTTCTGTGGACAGCAATCT CCAAAGAAAGACAt3G3ATGACATCATG43AAGCGAG 9361 -t- -t- 4- 4- -t- + 9420 TAGCσCAAGACACCTGTCGT AGAAGGTTTCTTTCTGTCCCTACTGTAGTACCTTCGCTC b S R S V D S N P K D R D D I M E A S - TCGACGACTATCGCCATCGGACGCCGCCTTTTGCAGAGCAGTGTCGGTTCAGGTAGGGAA 9421 -t- * + -- -<- 9480 AGCTGCTGATAGCGGTAGCCTGCGGCGGAAAACGTCTCGTCACAGCCAAGTCCATCCCTT R R L S P S D A A F C R A V S V Q V G K - GTATGTGGACGTAACGCAGAATTTAGAAAGTACGATCGTGCCGTTAAGAGTTATGGAAAT 9481 4- + + 4- + -r 9540 CATACACCTGCATTGCGTCTTAAATCTTTCATGCTAGCACGGCAATTCTCAATACCTTTA Y V D V T Q N L E S T I V P L R V M E I - AAAGAAAAGACGAGGATCAGCACATGTTAGTTTACCGAAGGTGGTATCCGCTTACGTAGA 9541 4- 4- 4- 4- -t- + 9600 TTTCTTTTCTGCTCCTAGTCGTGTACAATCAAATGGCTTCCACCATAGGCGAATGCATCT K K R R G S A H V S L P K V V S A Y V D - TTTTTATACGAACTTGCAGGAATTGCTGTCGGATGAAGTAACTAGGGCCAGAACCGATAC 9601 4- -t- 4* 4- -t- + 9660 AAAAATATGCTTGAACGTCCTTAACGACAGCCTACTTCATTGATCCCGGTCTTGGCTATG F Y T N Q E L L S D E V T K A R T D T - AGTTTCGGCATACGCTACCGACTCTATGGCTTTCTTAGTTAAGATGTTACCCCTGACTGC 9661 4- 4- 4- 4- 4- + 9720 TCAAAGCCGTATGCGATGGCTGAGATACCGAAAGAATCAATTCTACAATGGGGACTGACG V S A Y A T D S M A F L V K M L P T A - TCGTGAGCAGTGGTTAAAAGACGTGCTAGGATATCTGCTGGTACGGAGACGACCAGCAAA 9721 + + 4- 4- 4- + 9780 AGCACTCGTCACCAATTTTCTGCACGATCCTATAGACGACCATGCCTCTGCTGGTCGTTT R E Q W L K D V G Y V R R R P A N - TTTTTCCTACGACGTAAGAGTAGCTTGGGTATATGACGTGATCGCTACGCTCAAGCTGGT 9781 + + + + + + 9840 AAAAAGGATGCTGCATTCTCATCGAACCCATATACTGCACTAGCGATGCGAGTTCGACCA F S Y D V R V A V Y D V I A T K V - CATAAGATTGTTTTTCAACAAGGACACACCCGGGGGTATTAAAGACTTAAAACCGTGTGT 9841 4- 4- 4- + 4- + 9900 GTATTCTAACAAAAAGTTGTTCCTGTGTGGGCCCCCATAATTTCTGAATTTTGGCACACA I R L F F N K D T P G G I K D K P C V - GCCTATAGAGTCATTCGACCCCTTTCACGAGCTTTCGTCCTATTTCTCTAGGTTAAGTTA 9901 4- 4- 4- 4- 4- + 9960 CGGATATCTCAGTAAGCTGGGGAAAGTGCTCGAAAGCAGGATAAAGAGATCCAATTCAAT P I E S F D P F H E L S S Y F S R S Y - CGAGATGACGACAGGTAAAGGGGGAAAGATATGCCCGGAGATCGCCGAGAAGTTGGTGCG 9961 + 4- 4- 4- 4- 4- 10020 GCTCTACTGCTGTCCTAT TCCCCCTTTCTATACGGGCCTCTAGCGGCTCTTCAACCACGC E M T T G K G G K I C P E I A E K V R - CCGTCTAATGGAGGAAAACTATAAGTTAAGATTGACCCCAGTGATGGCCTTAATAATTAT 021 4- 4- 4* 4- + + 10080 GGCAGATTACCTCCTTTTCATATTα^TTCTAACTGGGGTCACTACCGGAATTATTAATA R L M Ξ E N Y K R L T P V M A L I I I - ACTGGTATACTACTCCATTTACGGCACAAACGCTACCAGGATTAAAAGACGCCCGGATTT 10081 4- * T 10140 TGACCATATGATGAGGTAAATGCCGTGTTTGCGATGGTC TAATTTTCTGCGGGCCTAAA L V Y Y S I Y G T N A T R I R R P D F - CCT AATGTGAGGATAAAGGG.-^GAGTCGAGAAGC-T TCGTTACGGGGGG AG.--AGATCG 10141 4- -*• . + + -. 10200 GGAGTTACACTCCTATTTCCCTTCTCAGCTCTTCCAAAGCAATGCCCCCCATC TCTAGC N V R I K G R V E K V S L R G V Ξ D R - TGCCTTTAGAATATCAGAAAAGCGCGGGATAAACGCTCAACGTGTATTATGTAGGTACTA 10201 4- 4- 4- 4- + ,. 10260 ACGGAAATCTTATAGTCTTTTCGCGCCCTATTTGCGAGTTGCACATAATACATCCATGAT A F R I S E K R G I N A Q R V L C R Y Y - TAGCGATCTCACATGTCTGGCTAGGCGACATTACGGCATTCGCAGGAACAATTGGAAGAC 10261 -t- 4- 4- 4- + + 10320 ATCGCTAGAGTGTACAGACCGATCCGCTGTAATGCCGTAAGCGTCCTTGTTAACCTTCTG S D T C L A R R H Y G I R R N N W K T - GCTGAGTTATGTAGACGGGACGTTAGCGTATGACACGGCTGATTGTATAACTTCTAAG-GT 10321 4- 4- 4- 4- 4- + 10380 CGACTCAATACATCTGCCCTGCAATCGCATACTGTGCCGACTAACATATTGAAGATTCCA S Y V D G T L A Y D T A D C I T S V - GAGAAATACGATCAACACCGCAGATCACGCTAGCATTATACACTATATCAAGACGAACGA 10381 4- 4- + 4- 4- -t- 10440 CTCTTTATGCTAGTTGTGGCGTCTAGTGCGATCGTAATATGTGATATAGTTCTGCTTGCT R N T I N T A D H A S I I H Y I K T N E - AAACCAGGTTACCGGAACTACTCTACCACACCAGCTTTAAAGCTGCGTGTAGTATGCGAC 10441 4- + + 4- + + 10500 TTTGGTCCAATGGCCTTGATGAGATGGTGTGGTCGAAATTTCGACGCACATCATACGCTG N Q V T G T T P H Q * GATGTTTCTCGTATTAGTTTTATAAAAATTTTTAATTGCTCTGTGTGTGGTTTTTGTTGA 10501 4- 4- 4- + 4- + 10560 CTACAAAGAGCATAATCAAAATATTTTTAAAAATTAACGAGACACACACCAAAAACAACT ORF6 (Coat protein) GTGAACGCGATGGCATTTGAACTGAAATTAGGGCAGATATATGAAGTCGTCCCCGAAAAT 10561 4- 4- 4- 4- + + 10620 CACTTGCGCTACCGTAAACTTGACTTTAATCCCGTCTATATACTTCAGCAGGGGCTTTTA M A F E L K L G Q I Y E V V P E N AATTTGAGAGTTAGAGTGGGGGATGCGGCACAAGGAAAAT TAGTAAGGCGAGTTTCTTA 10621 4- + 4- 4- 4- + 10680 TTAAACTCTCAATCTCACCCCCTACGCCGTGTTCCTT TAAATCATTCCGCTCAAAGAAT N R V R V G D A A Q G K F S K A S F AAGTACGTTAAGGACGGGACACAGGCGGAATTAACGGGAATCGCCGTAGTGCCCGAAAAA 10681 4- + 4- 4- 4- -r 10740 TTCATGCAATTCCTGCCCTGTGTCCGCCTTAATTGCCCTTAGCGGCATCACGGGCTTTTT K Y V K D G T Q A E T G I A V V P E K TACGTATTCGCCACAGCAGCTTTGGCTACAGCGGCGCAGGAGCCACCTAGGCAGCCACCA 10741 4- + T 4- + 10800 ATGCATAAGCGGTGTCGTCGAAACCGATGTCGCCGCGTCCTCGGTGGATCCGTCGGTGGT Y V F A T A A L A T A A Q E P P R Q P P GCGCAAGTGGCGGAACCACAGGAAACCGATATAGGGGTAGTGCCGGAATCTGAGACTCTC 10801 ,- + ->- 4- ,. + 10860 CGCGTTCACCGCCTTG-GTGTCCTTTGGCTATATCCCCATCACGGCCTTAGACTCTGAGAG A Q V A E P Q E T D I G V V P E S E T L ACACCAAATAAGTTGGTTTTCGAGAAAGATCCAGACAAGTTCTTGAAGACTATGGGCAAG 10861 4- 4- 4- 4- 4- + 10920 TGTGGTTTATTCAACCAAAAGCTCTTTCTAGGTCTGTTCAAGAACTTCTGATACCCGTTC T P N K L V F E K D P D K F L K T M G K GGAATAGCTTTGGACTTGGCGGGAGTTACCCACAAACCGAAAGTTATTAACGAGCCAGGG 10921 4- 4- 4- -i- + + 10980 CCTTATCGAAACCTGAACCGCCCTCAATGGGTGTTTGGCTTTCAATAATTGCTCGGTCCC G I A D A G V T H K P K V I N E P G AAAGTATCAGTAGAGGTGGCAATGAAGATTAATGCCGCATTGATGGAGCTGTGTAAGAAG 10981 4- 4- + -t- 4- 4- 11040 TTTCATAGTCATCTCCACCGTTACTTCTAATTACGGCGTAACTACCTCGACACATTCTTC K V S V E V A M K I N A A L M E L C K K GTTATGGGCGCCGATGACGCAGCAACTAAGACAGAATTCTTCTTGTACGTGATGCAGATT 11041 4- 4- + 4- 4- 4- 11100 CAATACCCσCGGCTACTGCGTCGTTGATTCTGTCTTAAGAAGAACATGCACTACGTCTAA V M G A D D A A T K T E F F L Y V M Q I GCTTGCACGTTCTTTACATCGTCTTCGACGGAGTTCAAAGAGTTTGACTACATAGAAACC 11101 4- 4- 4- 4- 4- + 11160 CGAACGTGCAAGAAATGTAGCAGAAGCTGCCTCAAGTTTCTCAAACTGATGTATCTTTGG A C T F F T S S S T E F K E F D Y I E T GATGATGGAAAGAAGATATATGCGGTGTGGGTATATGATTGCATTAAACAAGCTGCTGCT 11161 4- + 4- -t- 4- 4- 11220 CTACTACCTTTCTTCTATATACGCCACACCCATATACTAACGTAATTTGTTCGACGACGA D D G K K I Y A V V Y D C I K Q A A A TCGACGGGTTATGAAAACCCG-GTAAGGCAGTATCTAGCGTACTTCACACCAACCTTCATC 11221 4- + 4- 4- 4- 4- 11280 AGCTGCCCAATACTTTTGGGCCATTCCGTCATAGATCGCATGAAGTGTGGTTGGAAGTAG S T G Y E N P V R Q Y L A Y F T P T F I ACGGCGACCCTGAATGGTAAACTAGTGATGAACGAGAAGGTTATGGCACAGCATGGAGTA 11281 4- 4- 4- 4* 4- 4- 11340 TGCCGCTGGGACTTACCATTTGATCACTACTTGCTCTTCCAATACCGTGTCGTACCTCAT T A T N G K V M N E K V A Q H G V CCACCGAAATTCTTTCCGTACACGATAGACTGCGTTCGTCCGACGTACGATCTGTTCAAC 11341 4- 4- -t- 4- 4- + 11400 GGTGGCTTTAAGAAAGGCATGTGCTATCTGACGCAAGCAG^-CTGCATGCTAGACAAGTTG P P F F P Y T I D C V R P T Y D F N AACGACGCAATATTAGCATGGAATTTAGCTAGACAGCAGGCGTTTAGAAACAAGACGGTA 11401 + + -r + 11460 TTGCTGCGTTATAATCGTACCTTAAATCGATCTGTCGTCCGCAAATCTTTGTTCTGCCAT a N D A I L A W N L A R Q Q A F R N K T V ACGGCCGATAACACCTTACACAACGTCT CCAACTATTGCAAAAGAAGTAGCTACGATCG 11461 4- -<• 4- + + τ H520 TGCCGGCTATTGTGGAATGTGTTGCAGAAGGTTGATAACGTTTTCTTCATCGATGCTAGC a T A D N T H N V F Q L L Q K K * 0R77 (CPr) ATGTCTATAAATTGGTGAAAAATTTAGAAATATTTACCTTTTATTGATAATTCATGGGAG 11521 + 4- 4- 4- + + 11580 TACAGATATTTAACCACTTTTTAAATCTTTATAAATG-GAAAATAACTATTAAGTACCCTC a S I N W * c M G A - CTTATACACATGTAGACTTTCATGAGTCσCGGTTGCTGAAAGACAAACAAGACTATCTTT 11581 4- + 4- -r + + 11640 GAATATGTGTACATCTGAAAGTACTCAGCGCCAACGACTTTCTGTTTGTTCTGATAGAAA c Y T H V D F H E S R K D K Q D Y S - CTTTCAAGTCAGCGGATGAAGCTCCTCCTGATCCTCCCGGATACGTTCGCCCAGATAGTT 11641 4- 4- 4- 4- 4- + 11700 GAAAGTTCAGTCGCCTACTTCGAGGAGGACTAGGAGGGCCTATGCAAGCGGGTCTATCAA C F K S A D Ξ A P P D P P G Y V R P D S Y - ATGTGAGGGCTTATTTGATACAAAGAGCAGACTTTCCCAATACTCAAAGCTTATCAGTTA 11701 -t- 4- 4- 4- -t- + 11760 TACACTCCCGAATAAACTATGTTTCTCGTCTGAAAGGGTTATGAGTTTCGAATAGTCAAT c V R A Y I Q R A D F P N T Q S L S V T - CGTTATCGATAGCCAGTAATAAGTTAGCTTCAGGTCTTATGGGAAGCGACGCAGTATCAT 11761 4- 4- -t- 4- 4- + 11820 GCAATAGCTATCGGTCATTATTCAATCGAAGTCCAGAATACCCTTCGCTGCGTCATAGTA c L S I A S N K Ii A S G M G S D A V S S - CGTCGTTTATGCTGATGAACGACGTGGGAGATTACTTCGAGTGCGGCGTGTGTCACAACA 11821 4- 4- 4- 4- 4- + 11880 GCAGCAAATACGACTACTTGCTGCACCCTCTAATGAAGCTCACGCCGCACACAGTGTTGT = S F N D V G D Y F Ξ C G V C H N K - AACCCTACTTAGGACGGGAAGTTATCTTCTGTAGGAAATACATAGGTGGGAGAGGAGTGG 11881 + 4- 4- 4- + + 11940 TTGGGATGAATCCTGCCCTTCAATACAAGACATCCTTTATGTATCCACCCTCTCCTCACC = P Y G R E V I F C R K Y I G G R G V E - AGATC-ACCACTGGTAAGAACTACACGTCGAACAATTGGAACGAGGCGTCGTACGTAATAC 11941 4- 4- 4- 4- + + 12000 TCTAGTGGTGACCATTCTTGATGTGCAGCrrGTTAACCTTG:TCCC3CAGCATGCA , rTATG I T T G K N Y T S N N W N E A S Y V I - AAGTGAACGTAGTCGATGGGTTAGCACAGACCACTGTTAATTCTACTTATACGCAAACGG 12001 4- 4- 4- 4- 4- + 12060 TTCACTTG(-ATC-AGCTACCCAATCGTGTCTG-GTGACAATTAAGATGAATATGCGTTTGCC : V N V V D G L A Q T T V N S T Y T Q T D - ACGTTAGTGGTCTACCCAAAAATTGGACGCGTATC ACAAAATAACAAAGATAGTGTCCG 12061 4. 4- + -r 12120 TGCAATCACCAGATGGGTTTTTAACCTGCGCATAGATGTTTTATTGTTTCTATC..CAGGC V S G P K N W T R I Y K I T K I V S V - TAGATCAGAACCTCTACCCTGGTTGTTTCTCAGACTCGAAACTGGGTGTAATGCGTATAA 12121 -*■ 4- 4- + τ 12180 ATCTAGTCTTGGAGATGGGACCAACAAAGAGTCTGAGCTTTGACCCACATTACGCATATT D Q N Y P G C F S D S G V M R I R - GGTCACTGTTAGTTTCCCCAGTGCGCATCTTCTTTAGGGATATCTTATTGAAACCTTTGA 12181 4- 4- 4- 4- 4- -i- 12240 CCAGTGACAATCAAAGGGGTCACGCGTAGAAGAAATCCCTATAGAATAACTTTGGAAACT S L V S P V R I F F R D I L K P K - AGAAATCGTTCAACGCAAGAATCGAGGATGTGCTGAATATTGACGACACGTCGTTGTTAG 12241 + + + + -t- + 12300 TCTTTAGCA A GTTGCCTTCTTAGCTCCTACACGACTTATAACTGCTGTGCAGCAACAATC K S F N A R I E D V L N I D D T S V - TACCGAGTCCTGTCGTACCAGAGTCTACGGGAGGTGTAGGTCCATCAGAGCAGCTG-GATG 12301 4- 4- 4. 4- 4- + 12360 ATGGCTCAGGACAGCATGGTCTCAGATGCCCTCCACATCCAGGTAGTCTCGTCGACCTAC P S P V V P E S T G G V G P S E Q L D V - TAGTGGCTTTAACGTCCGACGTAACGGAATTGATCAACACTAGGGGGCAAGGTAAGATAT 12361 T 4- 4- 4- 4- + 12420 ATCACCGAAATTGCAGGCTGCATTGCCTTAACTAGTTGTGATCCCCCGTTCCATTCTATA V A T S D V T E Ii l N T R G Q G K I C - GTTTTCCAGACTCAGTGTTATCGATCAATGAAGCGGATATCTACGATGAGCGGTATTTGC 12421 4- 4- 4- 4- 4- + 12480 CAAAAGGTCTGAGTCACAATAGCTAGTTACTTCGCCTATAGATGCTACTCGCCATAAACG F P D S V S I N E A D I Y D E R Y L P - CGATAACGGAAGCTCTACAGATAAACσCAAGACTACσCAGACTCGTTCTTTCGAAAGGCG 12481 + 4- 4- 4- 4- + 12540 GCTATTGCCTTCGAGATGTCTATTTGCGTTCTGATGCGTCTGAGCAAGAAAGCTTTCCGC I T E A L Q I N A R R R V S K G G - GGAGTCAAACACC^CGAGATATGGGGAATATGATAGTGGCCATGATACAACT TTCGTAC 12541 4- + 4- + + 4- 12600 CCTCAGTTTGTGGTGCTCTATACCCCTTATACTATCACCGGTACTATGTTGAAAAGCATG S Q T P R D M G N M I V A I Q F V L - TCTACTCTACTGTAAAGAATATAAGCGTCAAAGACGGGTATAGGGTGGAGACCGAATTAG 12601 + 4- 4- 4- -t- -c 12660 AGATGAGATGACATTTCTTATAT CGCAGTTTCTGCCCATATCCCACCTCTGGCTTAATC Y S T V K N I S V K D G Y R V E T E L G - GTCAAAAGAGAGTCTACTTAAGTTATTCGGAAGTAAGGGAAGCTATATTAGGAGGGAAAT 12661 4- 4- 4- -t- 4- + 12720 CAGTTTTCTCTC^GATGAATTCAATAAG-CCTTC-ATTCCCTTCGATATAATCCTCCCTTTA Q K R V Y L S Y S E V R E A I L. G G K Y - CGGTGCGTCTCCAACCAACACTGTGCGATCCTTCATGAGGTATTTTGCTCACACCACTA 12721 -r 4- -r .. 12780 GCCACGCAGAGGTTGGTTGTGACACGCTAGGAAGTACTCCATAAAACGAGTGTGGTGAT C G A S P T N V R S F M R Y F A H T T I - TTACTCTACTTATAGAGAAGAAAATTCAGCCAGCGTGTACTGCCCTAGCTAAGCACGGCG 12751 4- -*■ -t- -*- + 12840 AATGAGATGAATATCTCTTCTTTTAAGTCGGTCGCACATGACGGGATCGATTCGTGCCGC C T L I E K K I Q P A C T A A K H G V - TCCCGAAGAGGTTCACTCCGTACTGCTTCGACTTCGCACTACTGGATAACAGATATTACC 12841 + + 4- 4- + + 12900 AGGGCTTCTCCAAGTGAGGCATGACGAAGCTGAAGCGTGATGACCTATTGTCTATAATGG c P K R F T P Y C F D F A D N R Y Y P - CGGCGGACGTGTTGAAGGCTAACGCAATGGCTTGCGCTATAGCGATTAAATCAGCTAATT 12901 + 4- + - + 12960 GCCGCCTGCACA CTTCCGATTGCGTTACCGAACGCGATATCGCTAATTTAGTCGATTAA c A D V K A N A M A C A I A I K S A N L - ORF8 TAAGGCGTAAAGGTTCGGAGACGTATAACATCTTAGAAAGCATTTGATTATCTAAAGATG 12961 4- 4- 4- + . 4- - 13020 ATTCCGCATTTCCAAGCCTCTGCATATTGTAGAATCTTTCGTAAACTAATAGATTTCTAC a M - c R R K G S E T Y N I L E S I * GAATTCAGACCAGTTTTAATTACAGTTCGCCGTGATCCCGGCGTAAACACTGGTAGTTTG 13021 4- 4- 4- 4- 4- + 13080 CTTAAGTCTGOTCAAAATTAATGTCAAGCGGCACTAGGGCCGCATTTGTGACCATCAAAC a E F R P V L I T V R R D P G V N T G S L AAAGTGATAGCTTATGACTTACACTACGACAATATATTCGATAACTGCGCGGTAAAGTCG 13081 + 4- 4. 4- 4- + 13140 TTTCACTATCGAATACTGAATGTGATGCTGTTATATAAGCTATTGACGCGCCATTTCAGC a K V I A Y D L H Y D N I F D N C A V K S TTTCGAGACACCGACACTGGATTCACTGTTATGAAAGAATACTCGACGAATTCAGCGTTC 13141 4- + 4- 4- + + 13200 AAAGCTCTGTGGCTGTGACCTAAGTGACAATACTTTCTTATGAGCTGCTTAAGTCGCAAG a F R D T D T G F T V K E Y S T N S A F ATACTAAGTCCTTATAAACTGT TTCCGCGGTCTTTAATAAGGAAGGTGAGATGATAAGT 13201 4* 4- + + 4- 4- 13260 TATGATTCAGGAATArrTGACAAAAGGCGCCAGAAATTATTCCTrCCACTCTACTATTCA a I L S P Y K L F S A V F N K E G E M I S AACGATGTAGGATCGAGTTTCAGGGTTrrACAATATCTTTTCGCAAATGTGTAAAGATATC 13261 4- 4- + 4- 4- + 13320 TTGCTACATCCTAGCTCAAAGTCCCAAATGTTATAGAAAAGCGTTTACACATTTCTATAG a N D V G S S F R V Y N I F S Q M C K D I AACGAGATCAGCGAGATACAACGCGCCGGTTACCTAGAAACATATTTAGGAGACGGGCAG 13321 + + 4- 4- -f - 13380 TTGCTCTAGTCGCTCTATGTTGCGCGGCCAATGGATCTTTGTATAAATCCTCTGCCCGTC a N E I S E I Q R A G Y E T Y L G D G Q GC GACACTGATATATTTTTTGATGTCTTAACCAACAACAAAGC.iAAGGTAAGGTGGTTA 13381 + 4- + 134 0 CGACTGTGACTATATAAAAAACTACAGAATTGGTTGTTGTTTCGTTTCCATTCCACCAAT a A D T D I F F D V L T N N K A K V R W GTTAATAAAGACCATAGCGCGTGGTGTGGGATATTGAATGATTTGAAGTGGGAAGAGAGC 13441 + 4- 4- 4- 4- 13500 CAATTATTTCTGGTATCGCGCACCACACCCTATAACTTACTAAACTTCACCCTTCTCTCG a V N K D H S A C G I N D L W E E S AACAAGGAGAAATTTAAGGGGAGAGACATACTAGATACTTACGTTTTATCGTCTGATTAT 13501 4- + -t- 4- 4- 4- 13560 TTGTTCCTCTTTAAATTCCCCTCTCTGTATGATCTATGAATGCAAAATAGCAGACTAATA a N K E K F K G R D I L D T Y V L S S D Y ORF9 CCAGGGTTTAAATGAAGTTGCTTTCGCTCCGCTATCTTATCTTAAGGTTGTCAAAGTCGC 13561 4- 4- 4- 4- + 4- 13620 GGTCCCAAATTTACTTCAACGAAAGCGAGGCGATAGAATAGAATTCCAACAGTTTCAGCG a P G F K * c M K L L S R Y I L R L S K S L - TTAGAACGAACGATCACTTGGTTTTAATACTTATAAAGGAGGCGCTTATAAACTATTACA 13621 - 4. + 4- + 4- 13680 AATCTTGCTTGCTAGTGAACCAAAATTATGAATATTTCCTCCGCGAATATTTGATAATGT c ' R T N D H Ii V Ii l I K E A L I N Y Y N - ACGCCTCTTTCACCGATGAGGGTGCCGTATTAAGAGACTCTCGCGAAAGTATAGAGAATT 13681 4- + 4- 4- + 4- 13740 TGCGGAGAAAGTGGCTACTCCCACGGCATAATTCTCTGAGAGCGCTTTCATATCTCTTAA c A S F T D E G A V R D S R E S I E N F - TTCTCGTAGCCAGGTGCGGTTCGCAAAATTCCTGCCGAGTCATGAAGGCTTTGATCACTA 13741 + 4- 4- 4- 4- 4- 13800 AAGAGCATCGGTCCACGCCAAGCGTTTTAAGGACGGCTCAGTACTTCCGAAACTAGTGAT c V A R C G S Q N Ξ C R V K A I T N - ACACAGTCTGTAAGATGTCGATAGAAACAGCCAGAAGTTTTATCGGAGACTTAATACTCG 13801 4- 4- + 4- 4- 4- 13860 TGTGTCAGACATTCTACAGCTATCTTTGTCGGTCTTCAAAATAGCCTCTGAATTATGAGC C T V C K M S I E T A R S F I G D I L V - TCGCCGACTCCTCTGTTTCAGCGTTGGAAGAAGCGAAATCAATTAAAGATAATTTCCGCT 13861 -t- + + 4- 4* 4- 13920 AGCGGCTGAGGAGACAAAGTCGCAACCTTCT CGCTTTAGTTAATTTCTATTAAAGGCGA = A D S S V S A L E E A K S I D N F R - TAAGAAAAAGGAGAGGCAAGTATTATTATAGTGGTGATTGTGGATCCGACGTTGCGAAAG 13921 4* + 4- 4- 4- 4- 13980 ATTCTT ^TCCTCTCCGTTCATAATAATATCACCACTAAC^CCTAGGCTGCAACGCTTTC : R K R R G K Y Y Y S G D C G S D V A K V - TTAAGTATATTTTGTCTGGGGAGAATCGAGGATTGGGGTGCGTAGAT CCTTGAAGCTAG 13981 4- 4- + 4- 4- 4- 14040 AATTCATATAAAACAGACCCCTCTTAGCTCCTAACCCCACGCATCTAAGGAACTTCGATC : K Y I L S G E N R G Ii G C V D S K L V - TTTGCGTAGGTAGACAAGGAGGTGGAAACGTACTACAGCACCTACTAATCTCATCTCTGG 14041 τ + + „. + 14100 AAACGCATCCATCTGTTCCTCCACCTTTGCATGATG CGTGGATGATTAGAGTAGAGACC C V G R Q G G G L Q H L L I S S L G - ORF10 GTTAAAGCATCATGGACCTATCGTTTATTATTGTGCAGATCCTTTCCGCCTCGTACAATA 14101 4- 4- 4- + - 14160 CAATTTCGTAGTACCTGGATAGCAAATAATAACACGTCTAGGAAAGGCGGAGCATGTTAT * M D L S F I I V Q I L S A S Y N N - ATGACGTGACAGCACTTTACACTTTGATTAACGCGTATAATAGCGTTGATGATACGACGC 14161 4- 4- -r 4- 4- 4- 14220 TACTGCACTGTCGTGAAATGTGAAACTAATTGCGCATATTATCGCAACTACTATGCTGCG D V T A Y T I N A Y N S V D D T T R - GCTGGGCAGCGATAAACGATCCGCAAGCTGAGGTTAACGTCGTGAAGGCTTACGTAGCTA 14221 4- - 4- 4- 4- 4- 14280 CGACCCGTCGCTATTTGCTAGGCGTTCGACTCCAATTGCAGCACTTCCGAATGCATCGAT A A I N D P Q A E V N V V K A Y V A T - CTACAGCGACGACTGAGCTGCATAGAACAATTCTCATTGACAGTATAGACTCCGCCTTCG 14281 4- + 4- + 4- 4- 14340 GATGTCGCTGCTGACTCGACGTATCTTGTTAAGAGTAACTGTCATATCTGAGGCGGAAGC T A T T E L H R T I L I D S I D S A F A - CTTATGACCAAGTGGGGTGTTTGGTGGGCATAGCTAGAGGTTTGCTTAGACATTCGGAAG 14341 + 4- + 4- + 4- 14400 GAATACTGGTTCACCCCACAAACCACCCGTATCGATCTCCAAACGAATCTGTAAGCCTTC Y D Q V G C Ii V G I A R G L R H S E D - ATGTTCTGGAGGTCATCAAGTCGATGGAGTTATTCGAAGTGTGTCGTGGAAAGAGGGGAA 14401 4- 4- 4- 4- + 4- 14460 TACAAGACCTCCAGTAGTTCAGCTACCTCAATAAGCTTCACACAGCACCTTTCTCCCCTT V L E V I K S M E F Ξ V C R G K R G S - GCAAAAGATATCTTGGATACTTAAGTGATCAATGCACTAACAAATACATGATGCTAACTC 14461 4- + 4- 4- + - 14520 CGTTTTCTATAGAACCTATGAATTCACTAGTTACGTGATTGTTTATGTACTACGATTGAG K R Y G Y S D Q C T N K Y M M L T Q - AGGCCGGACTGGCCGCAGTTGAAGGAGCAGACATACTACGAACGAATCATCTAGTCAGTG 14521 4- 4- 4- 4- + + 14580 TCCG-GCCTGACCGGCGTO * ACT CCTCGTCTGTATGATGCTTGCTTAGTAGATCAGTCAC A G L A A V E G A D I L R T N H V S G - GTAATAAGTTCTCTCCAAATTTCGGGATCGCTAGGATGTTGCTCTTGACGCTTTGTTGCG 14581 4- 4- 4- 4- 4- - 14640 CATTATTCAAGAGAGGTTTAAAGCCCTAGCGATCCTACAACGAGAACTGCGAAACAACGC N F S P N F G I A R M L L L T C C G - GAGCACTATAAAAATGT ATGTTGTTCAGCCAGTGTCAAATT TCAAACGGGTTACAATT 14641 + 4- + 4- 4- - 14700 CTCGTGΛTATTTTTACAATACAACAAGTCGGTCACAGTTTAAAAGTTTGCCCAATGT AA A L * ATCGCTACTTATTTGCGCATGTTTGTTAGCGGTGCTAATTGTTAGCTTTTGTAGAAGGCG 14701 T + 4- -r 4- 4- 14760 TAGCGATGAATAAACGCGTACAAACAATCGCCACGATTAACAATCGAAAACATCTTCCGC ORF11 ATGAGGCACTTAGAAAAACCCATCAGAGTAGCGGTACACTATTGCGTCGTGCGAAGTGAC 14761 -- T -r -r 4- J- 14820 TACTCCGTGAATCTTTTTGGGTAGTCTCATCGCCATGTGATAACGCAGCACGCTTCACTG M R K L E K P 1 R V A V H Y C V V R S D GTTTGTGACGGGTGGGATGTATTTATAGGCGTAACGTTAATCGGTATGTTTATTAGTTAC 14821 4- 4- 4- 4- 4- 4- 14880 CAAACACTGCCCACCCTACATAAATATCCGCATTGCAATTAGCCATACAAATAATCAATG V C D G W D V F I G V T Ii l G M F I S Y TATTTATATGCTCTAATTAGCATATGTAGAAAAGGAGAAGGTTTAACAACCAGTAATGGG 14881 4- 4- 4- 4- 1- 4- 14940 ATAAATATACGAGATTAATCGTATACATCTTTTCCTCTTCCAAATTGTTGGTCATTACCC Y L Y A I S I C R K G E G T T S N G TAAAAATCCTTCAATAAATTTGAAATAAACAAAAGTAAGAAAAATGAAATAATTAGGCTA 14941 4- 4- + 4- + 4. 15000 ATTTTTAGGAAGTTATTTAAACTTTATTTGTTTTCATTCTTTTTACTTTATTAATCCGAT GTCTTTTTGTTCGTCTTTCGCTTTTGTAGAATAGGTTTTATTTCGAGGTAAGATGACTAA 15001 4- -i- 4- 4- 4- + 15060 CAGAAAAACAAGCAGAAAGCGAAAACATCTTATCCAAAATAAAGCTCCATTCTACTGATT ACTCTACCTCACGGTTTAATACTCTGATATTTGTAAAATTAGTCCGTAAAGTCAGATAGT 15061 4- 4- 4- 4- + 4- 15120 TGAGATGGAGTGCCAAATTATGAGACTATAAACATTTTAATCAGGCATTTCAGTCTATCA GATATTATATTAGTATAGTATAATAAACGCCAAAATCCAATCAAAGTTTGGGACCTAG-GC 15121 4- 4- 4- 4- 4- + 15180 CTATAATATAATCATATCATATTATTTGCGGTTTTAGGTTAGTTTCAAACCCTGGATCCG GGGCCTCTTATGAGGCTAACTTATCGACAATAAGTTAGGTCCGCCAC 15181 -r + + + 15227 CCCGGAGAATACTCCGATTGAATAGCTGTTATTCAATCCAGGCGGTG TABLE 5 Amino Acid Sequence Alignment for Helicases Encoded by GLRaV-3, BYV, CTV and LIYV. BYV_HEL CTV_HΞL GLRaV3_HEL LIYV_HEL CONSENSUS -Y-aPPGaG KTt d-f-k-v— 1 ]ς II_ BYV_HΞL EILAIVNRIV LD...EGDTP LQTRDRILTI DSYLMNNR.G LTCKVLYLDE CTV_HΞL EISQRISNEL MGPJLAAKYV TDAASRVFTV DSYLMNHL.R LTTQLLFIDE GLRaV3_HEL EDIN ... -A VKK DPN LEGLNSATTV NSRWNFIVR GMYKRVTΛTDE LIYV_HΞL ELIDKLKKDG XEKP ... EKY VKTYDSFLMN NDNXLEXV NLYCDE CONSENSUS -lev ■ ly-DE III BYV_HEL CFMVHAGAAV ACIΞFTKCDS AILFGDSRQI RYGRCSELDT AVLSDL RFV CTV_HEL CFMVHAGAIG AWEFTΞCKA WFFGDSKQI HYIHRNDLGV SFVADIDAFI GLRaV3_HEL VYMMHQGLLQ LGVFATGASE GLFFGDINQI PFINREKVFR MDCA..VFVP LIYV_HEL VFMMHAGHFL TLLTKIAYQN GYCYGDVNQI PFINRDPYTP AYLS..REFF CONSENSUS -fM-HaG c-- — ffGD--QI --i-r • f- IV BYV_HEL DDESRVYGEV SYRCPWDVCA WLSTF YPKTVAT TNLVSAGQSS CTV_HEL QPEHRIYGEV SYRCP DICE WLSEF YPRHVAT ANVGSIGKSS GLRaV3_HEL KKESWYTSK SYRCPLDVCY LLSSMTVRGT EKCYPEKWS GKDK.PWRS LIYV_HΞL RKQDLNYDTY TYRCPLDTCY LLSNLKDEMG NIIYAGGVKN VNEVYPTIRS CONSENSUS — e — Y sYRCP-DvC- -LS-f Yp--V — -n S BYV_KEL MQVREIESVD DVEYΞSΞFVY LTMLQSEKKD LLKSFGK..R SRSSVEKPTV CTV_HEL VSIEEINGCD DVPYDKAAKY IVYTQAEKND LQKHLGRLTV GRNKV.VPIV GLRaV3_HEL LSKRPIGTTD DVAEINADVY LCMTQLEKSD MKRSLKGKGK .ETP.....V LIYV_EEL LNLFGINWG EVPVΞYNAKY LTFTQDEKLN LQRHIDSQGG CRNA V CONSENSUS 1 1 d dV Y 1-- tQ-EK-d 1 1- V _Vi_ BYV_HEL LTVHEAQGΞT YRKVNLVRTK FQEDDPFRSE NHITVALSRH VESLTΥSVLS CTV_HEL NTVHEVQGET YKRVRLVRFK YQEDTPFSSK NHXWALTRH VOSLVYSVLT GLRaV3_HEL MTVHEAQGKT FSDWLFRTK KADDSLFTKQ PHILVGLSRH TRSLVYAALS LIYV_KEL STVNEAQGCT FΞEVNLVRLV QFDNPVMSDI NQFWAISRH TTTFKYFTPH CONSENSUS -TVϊiEaQG-T V-LvR-k d — f n i-ValsRH — -sl-Y — 1- BYV_HEL SKRDDAIAQA CTV_HEL SRRYDDTAT GLRaV3_KΞL SKLDDKVG Y LIYV HEL SRLNDRVΞNA CONSENSUS S D-v 135 TABLE 6 Helicase RdRp p5K HSP70 HSP90 CP Virus nt aa nt aa nt aa nt aa nt aa nt aa BYV 37.7 38.4 44.5 41.2 42.0 30.4 43.5 28.6 40.5 21.7 41.5 20.3 (58.1) (61.0) (47.8) (48.0) (51.0) (43.7) CTV 45.3 36.3 44.0 40.1 42.8 20.0 43.7 28.7 38.6 17.5 40.3 20.5 (55.2) (62.2) (48.9) (49.3) (43.5) (41.9) LIYV 44.9 32.4 46.2 35.9 45.8 17.9 43.9 28.2 39.3 16.7 36.3 17.8 (53.5) (56.4) (46.2) (46.9) (36.8) (41.1) Nucleotide (nt) and amino acid (aa) sequence similarity was calculated from perfect matches after aligning with the GCG program GAP; the percentages in parentheses are the percentages calculated by the GAP program, which employs a matching table based on evolutionary conservation of amino acids (Devereux et al. , Nucleic Acids Res.. 12:387-395 (1984) , which is hereby incorporated by reference) . The sources for the BYV, CTV, and LIYV sequences were, respectively, Agranovsky (1994) , Karasev (1995) , and Klaassen (1995) , which are hereby incorporated by reference. TABLE 7 Plus (4-) and Minus (-) represent positive and negative reactions, respectively. For ELISA an OD 405πι . that was at least twice higher than a healthy control, and more than 0.100 was regarded as positive. TABLE 8 Amino Ac^ d Seσuence Alignment of RNA-dependent RNA Polymerase (RdRP) of GLRaV-3 , BYV, CTV and LIYV. BYV_RdRp ITTFKLMVKR DAKVKLDSSC LVXHPPAQNI MFHRKAVNAI FSPCrDEFKN CTV_RdRp IΞNFKLMVKR DAKVKLDDΞS LSKHPAAQNI MFHKKFINAI FSPCFDEFKN GLRaV3_RdRp LTSYTLMVKA DVKPKLDNTP LSKYVTGQNI VYHDRCVTAL FSCIFTACVΞ LIYV RORD FKTL LMVKG ETKPKMDLΞT YDSYNAPANI VYYQQIVNLY FSPIFLΞCFA CONSENSUS f-LMVK- d-K-KlD-s- 1-k qNI —h vna- FSp-F-e- III rv_ BYV_RdRp RVTTCTNSNI VFFTEMTNST LAΞIAKEMLG .SEHVYNVGE IDFSKFDKSQ CTV_RdRp RVLSSLNDNI VFFTΞMTNAG LAEIIRRIIG .DDDNLFVGΞ VDFSKFDKSQ GLRaV3_RdRp RLKYWDERW LFYHGMDTAE LAXALRNNLG .DIRQYYTYE LDISKYDK3Q LIYV_RdRp RLTYCLSDKI VLYSGMNTDV LAELIΞSKLP LGLNAYHTLE IDFSKFDKSQ CONSENSUS R- -d-i vf M LA lg y E iDfSKfDKSQ BYV_RdRp DAFIKSFERT LYSAFGFDED LLD.VWMQGΞ Y ΞNATTLDG QLSFSVDNQR CTV_RdRp DLFIKEYERT LYSEFGFDTE LLD.V MEGE YRARATTLDG QLSFSVDGQR GLRaV3_RdRα SALMKQVEEL ILLTLGVDRE VLS.TFFCGΞ YDSWRTMTK ELVLSVGSQR LIYV_RdRp GTCFKLYEEM MYKMFGFΞPE LYDRDFKYTE YFCRAKA.TC GVDLELGTQR CONSENSUS __f_K-yE—- ly—fGfd-e lid gE Y a-tl—- -1—sv— R V VI. BYV_RdRp KSGASNTWIG NSIETLGILS MFYYTNRFKA LFVSGDDΞLI FSESPIRNSA CTV_RdRp RSGGSNTWIG NSLVTLGILS LYYDVSKFDL LLVSGDDSLI YSSΞKISNFΞ GLRaV3_RdRp RSGGANTWLG NSLVLCTLLS WLRGLDYSY IWSGDDSLI FSRQPLDIDT LIYV_RdRp RTGSPNTWLS NTLVTLGMML SSYDIDDIDL LLVSGDDSLI FΞRKHLPNKT CONSENSUS rsG—-NTW-G Nslvtlg-ls —y f— 11VSGDDSLI fS- VTI. VIII BYV_RdRp DAMCTELGFE TKFLTPSVPY FCSKFFVMTG HDVFFVPDPY KLLVKLGAS. CTV_RdRp SEICLETGFE TKFMSPSVPY FCSKFWQTG NKTCFVPDPY KLLVKLGAP. GLRaV3_RdRp SVLSDNFGFD VKIFNQAAPY FCSKFLVQVΞ DSLFFVPDPL KLFVK GAS. LIYV_RdRp QEINKNFGME AKYIEKSΞPY FCSKFIVELN GKLKVTPDPI RFFEKLSIPI CONSENSUS fGfe -Kf s-PY FCSKF-V fvPDP- kl-vKlga— BYV_RdRp ..KDEVDDEF LFEVFTSFRD LTKDLVDERV IΞLLTHLVHS KYGYESGDTY CTV_RdRp .. Q NKLTDVE LFELFTSFKD MTQDFGDQW LΞKLKLLVEA KYGFASGTTM GLRaV3_RdRp ..KTSDID.L LHEIFQSFVD LΞKGFNREDV IQELAKLVTR KYK.HSGWTY LIYV_RdRp R Q EDFVNGSV VXERFIΞFXD LMKEYDNDVA VTRIDEAVCY RYSIPVGCSY CONSENSUS d—- 1-E-F-SF-D 1-kdf--e-v i—-1—-IV— kY sG-ty BYV_RdRp AALCAIHCIR SNFSSFKKLY CTV_RdRp PALCAIKCVR SNFLSFΞRLF GLRaV3_RdRp SALCVLHVLS ANFSQFCRLY L YV_RdRo AALCYIKCCM SNFVSFRRIY CONSENSUS -ALC-iHc — sNF-sF-rly 137 TAB Ξ 9 Nucleotide Sequence Comparison of GLRaV-3 and LIYV in Vicinitv of Frameshift CI-RaV-3_HEL S P Q S V S D A L GLRaV-3_RdRp T S P R L V A F E V Y GLRaV- 3 ( nt ) TCg Cct AA TCa GTa tec GAo ncτ tTσ rTr-c Λe« egT teg cce ccg ctg gtT GCt TTc GAg GTa TAT LIYV ( nt ) TCa Cta CAA TCC GTt agt GAt *• * ■ ? Tr *-τ-τ,- Λm 9 acT ate act tta gac agT GCc TTC GAc GTg TAT LIYV_HEL S L Q S V S D F V L LIYV_RdRp K T I I L D S A F D V Y TABLZ 10 Amino Acid Sequence Alignment of Small Hyάroohobic Transmembrane Proteins of GLRaV-3 (p5k) and BYV (p6K) CTV (pSK) and LIYV (pSK) . tCTπ*ϊMinιιl ILXIJΛP 54 BYV_p7K MDCT RSΪLL LAFGcLICLF LFCXVVFI F VYKQILFRTT AQSNEARHMH STW LrYV_P5K TT.T. * - T , MΞXLVWi liϊ TT.XT.TirV-TTD SΞVNIPNKSR F* ... GLRaV3_p5K HDD FKQAILL DFVFVIILLI. VLTFWPRLQ QSSTIIJTG-ύR TV* .. CTV_pδK MDCTTQGFLT FLVGIAVFCA ERGLIIIVIT irRCTIKPVR SASFYGTIfflX V ... CONSENSUS f il-f lvi-i s TABLS 11 Amino Acid Sequence Alignment of ASP7Q -related protein of GLRaV-3 with BYV <p65K) , CTV (pSΞX) and LIYV (pS2K) . BYV_pό5 . .MWFGLDF GT FSSVCAY VGEΞLYLFXQ RDSAYIPTYV FLHSDTQEVA CTV_p65 . .MVLLGLDF GTTFSTVAMA TPSELVILXQ ΞNSSYIPTCL L KAEPNSVS GLRaV3_p59 . . . MEVGIDF GTTFSTICFS PSGVSGCTPV AGSVYVΞTQI FIPEGSSTYL IYV_pS2 MRDCXVGLDF GTTFSTVSTIi VNNSMYVLRL GDSAYIPTCI AITPGGEAI . CONSENSUS -G1DF GTTFStv 1—1— —S-YipTci f- . BYV_p65 FGYDAEVLSN DLSVRGGFYR DLKRWIGCDE ENYR YLE L KPHYKTELLX CTV_p65 YGYDAEYLAA S.GΞSGSFYX DLXRWVGCTA JOrrQ Y HK SPSYKVTVKΞ GLRaV3^p59 IG.KAAGXAY RDGVEGRLYV NPKRWVGVTR DNVERYVΞXL KPTY VKM.. IYV_pS2 IGGAAEVLSG DDTPHCFFY. DLKRWVGVDD NTFXFAMNKI RPKYVAELVE CONSENSUS -G—Ae-1— g-fY- dlKRWvG -ny—y -Kl -P-Y 1— BYV_p65 VAQΞS STVK LDCYSGTVPQ NATLPGLIAT FVKA ISTAS EAFXCQCTGV CTV_pS5 FGT SVPVPY LΞPLNNDLGL SVALPSLIAS YAKSILSDAE RVFNVSCTGV GLRaV3_p59 ...DSGGALL IGGLGSGPDT LLRWDVICL FLRALILECS RYTSTTVTAA LIYV_pS2 GEVY LTGINKGFSI KLSVKQLIKA YIETIVR A SSYS RVID CONSENSUS -II- BYV_p65 ICSVPANYNC QRΞFTESCV NLSGYPCVY VNEPSAAAXiS ACΞRI GATS CTV_p65 ICSVPAGYNT LQRAFTQQSX SMSGYSCVYI INEPSAAAYS TLPKLNΞADK GLRaV3_ 59 WTVPADYNS FKRSFWEAL KG GIPVRGV VNEPTAAA Y SLAKSRVEDL LIYV_p62 NQSVPADYKN AQRLAARSVL KALSFPCRRI INEPSAAAVY CVSRYPNYNY CONSENSUS i-sVPA-Yn- IqR-f gypc—-i -NEPsAAA- BYV_p65 PV VYDFGGG TFDVSVISAL NNTFWRASG GDMNLGGRDI DKAFVEHLYN CTV_p65 YLAVYDFGGG TFDVSIVΞVR LPTFAVRSSS GDMNLGGRDI DKKLSDKIYE GLRaV3_p59 LLAVFDFGGG TFDVSFVKXX GNILCVIFSV GDNFLGGRDI DRAIVEVIKQ LIYV_p62 FL.VYDFGGG TFΠVSLIGXY KSYVTVTDTΞ GDSFLGGRDI DKSIEDYLVG CONSENSUS -1-VyDFGGG TFDVS f- —s- GD—LGGRDI Dk- BYV_p65 KAQ...LPVN YKH3IS LX-- SLSKXVΞFLN FFWSΞQGVR VDVLVNVSEL CTV_pS5 MAD...FVPQ ΪCELNVSSLKE ALSLQTDPVK YT.VNHYG-<-S ETVSEDQTVL GLRaV3_ 59 KIXGXASDAK LGIFVΞSUKE DLSNNNAITQ HLIPVEGGVE V.VDLTSDEL LIYV_p62 KYNIKKVXP. .ATYLALIKE E.CNNTNKSI FTILFDDGSV QWEFSXSEL CONSENSUS vs-lKΞ -1s- f-i—e-G- -V- -eL BYV_pS5 AEVAAPFVER TI TV EVY. .ΞXYCSSMRL EPNVKAKLL VGGSSYLPGL CTV_p6Ξ REIASVFIm TIDILTQV.. ..KVXSSMPE SQSL..KLW VGGSSYLPGL GLRaV3_p59 DAIVAPFΞAR AVΞVFXTG?. .DNFYPDPVI A VM TGG3SALVKV LIYV_pS2 EXCVRPFVER ΞlrLINDVVV RNXLTSG IYM VGGSSLLQPV CONSENSUS —i~pFv-R -i-i — — —s vGGSS-L /22700 139 SYV_pό5 LSRLΞSIPFV DEC . L . VLPD ARAAVAGGCA LYSACLRNDS PMLLVDCAAK crv_ 65 LDALATVPFV SGI . V. PVED ARTAVARGCA LYSECLDGRS KALLIDCITH GLRaV3_ 59 RSDVANLPQI SKV. VFDSTD FRCSVACGAX VYCDTLAGNS GLRLVDTLTN LIYV_ o2 QDMVRSYAST KGLTLVADQD MRSAVSYGCS VLKK . LEDNK EIVYIDCNSK CONSENSUS π-v — D -R-aVa-Gc- -y L — 1-Dc — h BYV_ 65 NLSISS YCΞ SIVCVPAGSP IPFTGVRTVN MTGSNASAVY ΞAALFEGDFV CTV_pό5 HLSVTTFSAD SVWAAAGS? IPFEGΞR LT LRKCVSTSNY QARMFEGDYΞ GLRaV3_ 59 TLTDEWGLQ PWTFPKGΞ? IPCSYTHRYT V GGGDV VYGIFEGE.. LIYV_ 62 PLSDISFNCD PΞPI rCPMS IPYTHTVKMR KDRPLKT... IVNIYEGSNL CONSENSUS -Ls d -wi gsp Pf- -fEGd— _H_ BYV_p65 KCRLNKRIFF GDWLGNVGV TGSATRTVPL TLEINVSSVG TIΞFSLVGPT CTV_p65 KVFRNERIYA AΞVSLFTLGV NWSVPNDVEM TLVTKVDSMG KVΞFYLKGPΞ GLRaV3_p59 NNRAFL NEPTFRGVSX RRGDPVETDV A. QFNLSTDG TVSVIVNGEΞ LIYV_p62 F PENDWLIS SNINTTDFAK VGEEY SXVYEYDIDG IITLKIRNEV CONSENSUS N-r- f- — -l β- G f g — BYV_p65 GVKXLIGGNA AYDFSSYQLG ERWADLK H NSDKVKLIKA LTYQPFQRKK CTV_pS5 GΞLVNVQGTS HYDYAGMPHP TRKLVRLSDY NVNSAALVLA LTLTREXREX GLRaV3_p59 VKNEYLVPGT TNVLDSL VYKΞGRE DLEAKAIPEY LTTLNILHDK LIYV_p62 TGKMFTLPNS FTKSDNIXPI TFKLTQLSNT D.DLATLTΞL LGYHDKNFER CONSENSUS 1— —d—1— Lt- ■ e BYV_p65 LTDGDKALFL KRLTADYRRE ARKFSSY DDAV LNSSELLLGR CTV_p65 FLLRT...LF DTLLADLRKT A.SLSΞYSKK YPITRNDIDV VSSR...MGI GLRaV3_p59 AFTRRNLGNK DKGFSDLRIE ENFLXS AVDTDTI LNG* L YV_pS2 FYG L FNVPTILIXΞ IJDKLGGF TL YRRLKSHNAN F CONSENSUS f 1 dlr-β l~y v 1 BYV_ 65 IIPKILRGSR VE LDV* CTV_ 65 WSKVLRGSD LERIPL. GLRaV3_p59 LIYV_pS2 CONSENSUS TABLE 12 Amino Acid Sequence Alignment of HSP90-like Protein (p55) of GLRaV-3 with p61K of CTV, p59 of LIYV and PG4 of BYV. BYV_pS4 11.5 ^G SS^TLQSVTΣFVKΣlN SJVAΣPSLVEK<ΛSτjSNS GZLXNPK∑ySKRFV CTV_p61 108_VGCRFTIiNDVESYLMSRGEDFADLAAVEHS CLSNSCSRLLSSTEIDAN LIYV_P59 13 l_EGCSFTΞvQVVΞKYPQVDSLVAKIL YRVCNΞLGKLLDLXDFΞNKN GLRaV3_p55 114_VDSNLPKXDRDDIME- .ASRRLSPSDAAFCRAVSVQVGKYVDVTQNLEST CONSENSUS vgc-f v-e a — sns-g-1 d BYV_p6 SLIFXGXDLAEΞTDEAIVS .. SSYLDYLSHCLNLYΞTCNLSSNSGXKΞLY CTV_p61 TLVF.TKNFDSNISG..VT..TKLETYLΞYCISLYKKKCH.KDDDYFNLI LIYV_P59 IΞGFEINTΛQDSPTVADDN .. ES . NDFFRECVNDQRYYS3LSGSKLGKAK GLRaV3_p55 rVPLRV-ffilKj RGSAHVSLPK SAYVDFYT^QELLSDEVTRARTDTV CONSENSUS -yl — c-n.1- BYV_p64 DEFLKKVXDYX....ENΞDLEYRSPSDNPLVAGILYDMCFEYNTLKSTYLK CTV_ 61 LP FNCLMKVT ...ASLGLFΪΕX-HLADNPLLTGMLIEFCLENKVYYSTFKV LIYV_P59 LEANAYIFKILLXSAΞGΞFDIDRLSRNPLAISKFMNLYTNHVTDSETFXS GLRaV3_p55 SAYATDSMAFLVKMLPLT AREQ LKDVLGYLLVRRRPANFSYDV CONSENSUS -πpl 1 — lc BYV_p64 NIΞSFDCFLSLYLPLLSΞVFSMN ERPAPDVRLLFΞLDAAELLL VPTIN CTV_ 61 NLDNVRiFKS- s TVLI-VVLTVWDISEPDDPVDERVLIPFDPTDFVLDLPKI-N LIYV_P59 KFEALKSIKTPFAΞFIKKAFGIR LNFEDSKIFYALPKER GLRaV3_ 55 RVA VYDVXATLIOiVIRLFFNKDTPGGIKDLKPCVPIΞΞFDPFHELS ... CONSENSUS __ e i f d f d-f— lp BYV_ 6 MHDST FLYK-^KLRYLEΞYFEDDSNELIKVKVDSLL cτy_p6i IHDTM VWGNQIRQLEYWESDALDDLSQHVDLRL L YV_P59 QSDVLSDDM VES-ΛTRDAASFT'WSDNNYLPERVDRFV GLRa.V3_ 55 SYFSRLSYEMTTGKGGXICPEIAEKL CONSENSUS — -1 vd— 1 TABLE 13 Amino Acid Seσuence Alignment of the HSP90-related Protein of GLRaV-3 with BYV p64K, CTV p61K and LIYV p59K. BYV_p61 MTTRFSTPAN YΥWGELFRRF FGGQE KNL SE AASVSRPRYS CTV_p61 MSSH HVWGSLFRXF YGEAIW KEYLSE STRNFDERNV LIYV_P59 ..MLNDRIAV TCFQTLLKKS NVKHEMEQTN NYIVNNLADI NRNTFPALAG GLRaV3_p55 MDK YIYVTGI. -L NPNEARDEVF SWNKGYIG? GGRSFSNRGS CONSENSUS •If- - - -£— r- BYVjpδl S.DFRFSDGV ILSRXTFGES TGES..FVRE FSLLLTFPKT YEVCKLCGVA CTV_ 61 SLDHTLSSGV WRRQSLLNA PQGT..FENE LALLYNSWI NDFVELTG P LIYV_P59 SVRIDFNSDY YIΞGGQIWS PKDSNAYVKL LIVYLKYCYT N.YSAKTKYP GLRaV3_ 55 KYTW EN.. ..SAARISGF TSTSQSTIDA FAYFL LrGGLTTT CONSENSUS S f — s s— fv 11 BYV_p61 MELALNGMN. .RLSDYNVSE FN IV DVKTVGCKFN IQSVTΞFVKX CTV_p61 LKSLMTGIΞD RKVPD... -E LI SV DPHEVGCRFT LNDVEΞYL S LIYV_P59 PQSLLAVLDY DΞFKAK VKY LDKSLTDYLD DNKTEGCSFT EQQWEXYPQ GLRaV3_p55 LSNPINCENW VRSSXDLSAF FRTLIKGXIY ASRSVDSNLP KKDRDDIME. CONSENSUS 1 1 d vgc-f- v-e BYV_ 61 INGNVAEPSL VEHC SLSNS CGELINPKDT KRFVSLIFKG KDLAESTDEA CTV_ 61 RGEDFADLAA VEHΞWCLSNS CSRLLSSTEI DANKTLVF.T KNFDSNISG . LIYV_PS9 VDSLVAKIL YRVCNS LGXLLDLKDF ENKNISGFEI NTAQDΞPTVA GLRaV3_ 55 .ASRRLSPSD AAFCRAVSVQ VGXYVDVTQN LΞSTIVPLKV MEIKKRRGSA - CONSENSUS -sns -g-1- BYV_ Sl TVS .. SSYLD YLSHCLNLYE TCNLSSNSGX KSLYDEFLKH VIDYL ... EN CTV_ 61 .VT..TKLET YLSYCISLYK KHC . KDDDY FNLILPMFNC UCVL...AS LIYV_P59 DDN! * .ES.ND FFRECVNDQR YYSSLSGSXL GKAKLEANAY IFKILLKSAS GLRaV3_p55 HVSLPKWSA YVDFYTNLQE LLSDEVTRAR TDTVSAYATD SMAFLVKMLP CONSENSUS -v- yl — c-nl- BYV_ 61 SDLEYRSPSD NPLVAGILYD MCFEYNTLKS TYLKNIESFD CFLSLYLPLL CTV_p61 LGLFYEKHAD NPLLTGMLIE FCLENKVYYS TFKVNLDNVR LFKSKVLPW LIYV_P59 GEFDIDRLSR NPLAISKFMN LYTNHVTDSΞ TFKSXFEALK SIKTPFASFI GLR-iV3_p55 LT R EQWLKDVLGY LLVRRRPANF SYDVRVAWVY DVIATLKLVT CONSENSUS npl- lc- BYV_ 61 ≤EVFSMNWER PAPDVRLLFE LDAAELLLKV PTINMHDΞT. .. FLYKNKLR CTV_p61 LTVWDISΞPD DPVDERVLIP FDPTDFVLDL PKLNIHDT . .. VGNQI I V_P59 KKAFGIR LN FΞDSXIFYAL PKERQSDVLS DDMMVESIVR GLRaV3_ 55 RLFFNKDTPG GIXDLKPCVP IESFDPFHEL S SYFS CONSENSUS -d-f — 1 P- - BYV_p61 YLESYFEDDS NΞLIXVKVDS LLTRDNPΞL. . KLAQR V GFHCYYG CTV_p61 QLEYWΞSDA LDDLSQHVDL RLAADNPDL. .RVGLR A GMFVYYG LIYV_P59 DAASFTWΞD NNYLPERVDR FVTQLLLELF PKTKASFPNK IMFGFLHYFA GLRaV3 D55 RLSYEMTTGK GGXICPEIAE KLVRRLMEEN YKLRLT.PVM ALIIILVYYS CONSENSUS -1 — -el- — w — -g-l-Yy- .II BYV_p61 VFRTAQTRKV KRDAEYKLPP AL GE FVINMSGVΞΞ FF.EELQKKM CTV_p61 VYRCWDRAV ERPTLFRLPQ KLLSQDDGES CSLHMGSVEA LF.NLVQKVN LIYV_P59 LSTTNSKR FNDTQ ESTIΞIEGET LKISLKFITS YLRNAIQSQH GLRaV3_p55 IYGTNATRIK RRPDFLNVRI KGRVΞ KVSLRGVED .. RAFRISEK CONSENSUS vy-t R — -r f — i ve- -f q BYV_p61 PSI...ΞVRR RFCGSLSKEA FSVFKRFGVG FPPITRLNVP VKYΞYLNVDY CTV_p61 KDI...NVRR QFMGRHSΞVA LRLYRNLGLR FPPISSVRLP AHHGYLYVDF LIYV_P59 PDYADSNIVR LWCNKRSNLA LGYFXΞRNIQ LYLYS..KYP RLLNYMRFDY GLRaV3_p56 RGINAQRVLC RYYSDLTCLA RRHYGIRRNN WKTLSYVD.. GTLAYDTADC CONSENSUS — i v-r -fc s — A 1— f— -s — Yl— Dy BYV_p61 YRHVKRVGLT QDELTILSNI ΞFDVAEMCCE REVALQARRA QR GEKP CTV_p61 YKRVPDGAVT ADELESLRQL RSSVDVMCKD R.VSITPPPF NRLRRGSSRT LIYV_P59 FKGLDMGKLT DEERLSIQTL RCITEDRS.E GTLATHNDLN S ILRP.... GLRaV3_p55 ITSXVRNTIN TADHASIIHY IKTNENQVTG TTLPHQL* CONSENSUS y 1 -de — s e e BYV_ 61 FQGWKGTKNE IΞPHARSΞIR VKKNNDSLLN ILWKDVGARS QRRLNPLHRK CTV_p61 FRGR.GARGA SΞRHMSRDVA TSGFNLPYHG RLYSTS* LIYV_P59 GLRaV3_p55 CONSENSUS BYV_ 61 H* CTV_p61 LIYV_P59 GLRaV3_p55 CONSENSUS /22700 143 TABLE 14 Nucleotide and Deduced Amino Acid Sequences of the Partial HSP90-Related Gene of GLRaV-3 Adapted for Cloning into Plant Expression Vectors. (5 ' primer, 93-224) Ncol tacπtatc agaacj. ■ ATGGAAGCCAGTCGACGACTATCGCCATCGGACGCCGC TTTTGCAGAGCAGTGTCGGTT 9404 -i -i + + -*- + M E A S R R L S P S D A A F C R A V S V CAGG AGGGAAGTATGTGGACGTAACGCAGAATTTAGAAAGTACGATCGTGCCGTTAAGA Q V G K Y V D V T Q N L E S T I V P L R GTTATGGAAATAAAGAAAAGACGAGGATCAGCACATGTTAGTTTACCGAAGGTGGTATCC 1 1 π 1 -i V M E I K K R R G S A H V S L P K V V S GCTTACGTAGATTTΓTATACGAAC^TGCAGGAATTGCΓGTCGGATGAAGTAACTAGGGCC A Y V D F Y T N L Q E L L S D E V T R A AGAACGGATACAGTTTCGGCATACGCTACCGACTCTATGGCTTTCTTAGTTAAGATGTTA R T D T V S A Y A T D S M A F L V K M L CC CT^CTGCTCGTGAGCAGTGGTTAAAAGACGTGCTAGGATAT CTGCTGGTACGGAGA — — — !.--.— — — H H — -I — — — -t— +— — — P L -T A R E Q W L K D V L G Y L L V R R CGACCAGCAAATTTTTCCTACGACGTAAGAGTAGCTTGGGTATATGACGTGATCGCTACG R P A N F S Y D V R V A W V Y D V I A T CTCAAGCTGGTC^TAAGATTGTTRTTCAFTCAAGGACACACCCGCTGGGTA^ L K L V I R L F F N K D T P G G I K D L AAACCGTGTGTGCCTATAC^GTCATTCGACCCCTRTCACGAGCTRTCGTCCTATTTC C K P C V P I E S F D P F H E L S S Y F S AGGTTAAGTTACGAGATGACGACAGGTAAAGC^K-GAAAGATATC^CCGGAGATCGCCGAG R L S Y E M T T G K G G K I C P E I A E AAGTTGGTGCGCCGTCTAATGGAGGAAAAC'-ATAAGTTAAGATTGACCCCAGTGATGGCC K L V R R L M E E Y R L T P V M A TT AT ATTATACTGGTATACTACTCCATTTACGGCACAAACGCTACCAGGATTAAAAGA L I I I L V Y Y S I Y G T N A T R I R CGCCCGGAT TCCTCAATGTGAGGATAAAGGGAAGAGTCGAGAAGGTTTCGrrACGGGGG 4. +— 1 ► -I R P D F L N V R I K G R V E K V S L R G GTAGAAGATCGTGCCTTTAGAATATCAGAAAAGCGCGGGATAAACGCTCAACGTGTATTA 4. 1_ .( 4_ — V E D R A F R I Ξ E K R G I N A Q R V L GTAGGTACTATAGCGATCrCACATG C GGCTAGGCGACATTACGGCATTCGCAGGAAC C R Y Y S D L T C L A R R H Y G I R R N AAT GGAAGACGCTGAGTTATGTAGACGGGACGT AGCGTATGACACGGCTGATTGTATA N W K T L S Y V D G T Ii A Y D T A D C I ACTTCTAAGGTGAGAAATACGATCAACACCGCAGATCACGCTAGCAT ATACACTATATC T S K V R N T I N T A D H A S I I H Y I AAGACGAACGAAAACCAGGTTACCGGAACTACTCTACCACACCAGCTTTAAAGC GCGTG T N E N Q V T G T T P H Q L * TAGTATGCGACGATGTTTCT Ncol (3 ' primer, 93-225)

Claims: CLAIMS : 1. An isolated DNA molecule encoding a protein or polypeptide of a grapevine leafroll virus. 2. An isolated DNA molecule according to claim 1, wherein the protein or polypeptide is selected from a group consisting of a helicase, an RNA-dependent RNA polymerase, an hsp70-related, an hsp90-related, a coat protein or polypeptide, coat protein repeat, ORF8 (p21) , ORF9 (P20) , ORF10 (P20) and ORF11 (p7) . 3. An isolated DNA molecule according to claim 2, wherein the protein or polypeptide is a helicase having a molecular weight of from about 146 to about 151 kDa. 4. An isolated DNA molecule according to claim 3, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO:2. 5. An isolated DNA molecule according to claim 4, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO:l. 6. An isolated DNA molecule according to claim 2, wherein the protein or polypeptide is an RNA-dependent RNA polymerase having a molecular weight of from about 59 to about 63 kDa. 7. An isolated DNA molecule according to claim 6, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID N0:4. 8. An isolated DNA molecule according to claim 7, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO:3. 9. An isolated DNA molecule according to claim 2, wherein the protein or polypeptide is an hsp70-related protein or polypeptide having a molecular weight of from about 57 to about 61 kDa. 10. An isolated DNA molecule according to claim 9, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO:6. 11. An isolated DNA molecule according to claim 10, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO:5. 12. An isolated DNA molecule according to claim 2, wherein the protein or polypeptide is an hsp90-related protein or polypeptide having a molecular weight of from about 53 to about 57 kDa. 13. An isolated DNA molecule according to claim 12, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO: 8. 14. An isolated DNA molecule according to claim 13, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO:7. 15. An isolated DNA molecule according to claim 2, wherein the protein or polypeptide is a coat protein or polypeptide having a molecular weight of from about 33 to about 43 kDa. 16. An isolated DNA molecule according to claim 15, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO: 10. 17. An isolated DNA molecule according to claim 16, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO: 9. 18. An isolated DNA molecule according to claim 1, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO:12. 19. An isolated DNA molecule according to claim 18, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO:11. 20. An isolated DNA molecule according to claim 1, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO:14. 21. An isolated DNA molecule according to claim 20, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO: 13. 22. An isolated DNA molecule according to claim 1, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO:16. 23. An isolated DNA molecule according to claim 22, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO:15. 24. An isolated DNA molecule according to claim 1, wherein the protein or polypeptide comprises an amino acid sequence corresponding to SEQ ID NO:18. 25. An isolated DNA molecule according to claim 24, wherein the DNA molecule comprises a nucleotide sequence corresponding to SEQ ID NO-.17. 26. An expression system comprising a DNA segment corresponding to a DNA molecule according to any of claims 1 to 25 in a vector heterologous to the DNA molecule and wherein a nucleotide sequence encoding a protein or polypeptide of a grapevine leafroll virus is operatively linked to nucleotide sequences which direct the expression of said protein or polypeptide. 27. A host cell transformed with a heterologous expression system according to claim 26. 28. A host cell according to claim 27, wherein the host cell is selected from the group consisting of Agrobacterium vitis and Agrobacterium tumefaciens . 29. A host cell according to claim 28, wherein the host cell is a grape cell or a citrus cell. 30. A transgenic Vi tis scion cultivar or rootstock cultivar comprising a DNA sequence encoding a protein or a polypeptide of a grapevine leafroll virus according to any of claims 1-25. 31. A transgenic Vi tis scion cultivar or rootstock cultivar according to claim 30, wherein the Vi tis scion or rootstock cultivar is a scion cultivar selected from the group consisting of Vi tis vinifra, Alden, Almeria, Anab-E-Shahi, Autumn Black, Beauty Seedless, Black Corinth, Black Damascus, Black alvoisie, Black Prince, Blackrose, Bronx Seedless, Burgrave, Calmeria, Campbell Early, Canner, Cardinal, Catawba, Christmas, Concord, Dattier, Delight, Diamond, Dizmar, Duchess, Early Muscat, Emerald Seedless, Emperor, Exotic, Ferdinand de Lesseps, Fiesta, Flame seedless, Flame Tokay, Gasconade, Gold, Himrod, Hunisa, Hussiene, Isabella, Italia, July Muscat, Khandahar, Katta, Kourgane, Kishmishi, Loose Perlette, Malaga, Monukka, Muscat of Alexandria, Muscat Flame, Muscat Hamburg, New York Muscat, Niabell, Niagara, Olivette blanche, Ontario, Pierce, Queen, Red Malaga, Ribier, Rish Baba, Romulus, Ruby Seedless, Schuyler, Seneca, Suavis (IP 365) , Thompson seedless, Aleatico, Alicante Bouschet, Aligote, Alvarelhao, Aramon, Baco blanc (22A) , Burger, Cabernet franc, Cabernet, Sauvignon, Calzin, Carignane, Charbono, Chardonnay, Chasselas dore, Chenin blanc, Clairette blanche, Early Burgundy, Emerald Riesling, Feher Szagos, Fernao Pires, Flora, French Colombard, Fresia, Furmint, Ga ay, Gewurztraminer, Grand noir, Gray Riesling, Green Hungarian, Green Veltliner, Grenache, Grillo, Helena, Inzolia, agrein, Lambrusco de Salamino, Malbec, Malvasia bianca, Mataro, Melon, Merlot, Meunier, Mission, Montua de Pilas, Muscadelle du Bordelais, Muscat blanc, Muscat Ottonel, Muscat Saint-Vallier, Nebbiolo, Nebbiolo fino, Nebbiolo Lampia, Orange Muscat, Palomino, Pedro Ximenes, Petit Bouschet, Petite Sirah, Peverella, Pinot noir, Pinot Saint-George, Primitivo di Gioa, Red Veltliner, Refosco, Rkatsiteli, Royalty, Rubired, Ruby Cabernet, Saint-Emilion, Saint Macaire, Salvador, Sangiovese, Sauvignon blanc, Sauvignon gris, Sauvignon vert, Scarlet, Seibel 5279, Seibel 9110, Seibel 13053, Semillon, Servant, Shiraz, Souzao, Sultana Crimson, Sylvaner, Tannat, Teroldico, Tinta Madeira, Tinto cao, Touriga, Traminer, Trebbiano Toscano, Trousseau, Valdepenas, Viognier, Walschriesling, White Riesling, and Zinfandel. 32. A transgenic Vitis scion cultivar or rootstock cultivar according to claim 30, wherein the Vitis scion or rootstock cultivar is a rootstock cultivar selected from the group consisting of Couderc 1202, Couderc 1613, Couderc 1616, Couderc 3309, Dog Ridge, Foex 33 EM, Freedom, Ganzin 1 (A x R #1) , Harmony, Kober 5BB, LN33, Millardet & de Grasset 41B, Millardet & de Grasset 420A, Millardet & de Grasset 101-14, Oppenhei 4 (S04) , Paulsen 775, Paulsen 1045, Paulsen 1103, Richter 99, Richter 110, Riparia Gloire, Ruggeri 225, Saint- George, Salt Creek, Teleki 5A, Vitis rupestris Constantia, Vitis California , and Vitis girdiana . 33. A method of imparting grapevine leafroll virus resistance to a Vitis scion cultivar or rootstock cultivar comprising: transforming a Vitis scion cultivar or rootstock cultivar with a an expression system according to claim 26 wherein said vector is a plant transformation vector. 34. A method according to claim 33, wherein the Vi tis scion cultivar or rootstock cultivar is a scion cultivar selected from the group consisting of Vitis vinifra, Alden, Almeria, Anab-E-Shahi, Autumn Black, Beauty Seedless, Black Corinth, Black Damascus, Black Malvoisie, Black Prince, Blackrose, Bronx Seedless, Burgrave, Calmeria, Campbell Early, Canner, Cardinal, Catawba, Christmas, Concord, Dattier, Delight, Diamond, Dizmar, Duchess, Early Muscat, Emerald Seedless, Emperor, Exotic, Ferdinand de Lesseps, Fiesta, Flame seedless, Flame Tokay, Gasconade, Gold, Himrod, Hunisa, Hussiene, Isabella, Italia, July Muscat, Khandahar, Katta, Kourgane, Kishmishi, Loose Perlette, Malaga, Monukka, Muscat of Alexandria, Muscat Flame, Muscat Hamburg, New York Muscat, Niabell, Niagara, Olivette blanche, Ontario, Pierce, Queen, Red Malaga, Ribier, Rish Baba, Romulus, Ruby Seedless, Schuyler, Seneca, Suavis (IP 365) , Thompson seedless, Aleatico, Alicante Bouschet, Aligote, Alvarelhao, Aramon, Baco blanc (22A) , Burger, Cabernet franc, Cabernet, Sauvignon, Calzin, Carignane, Charbono, Chardonnay, Chasselas dore, Chenin blanc, Clairette blanche, Early Burgundy, Emerald Riesling, Feher Szagos, Fernao Pires, Flora, French Colombard, Fresia, Furmint, Gamay, Gewurztraminer, Grand noir, Gray Riesling, Green Hungarian, Green Veltliner, Grenache, Grillo, Helena, Inzolia, Lagrein, Lambrusco de Salamino, Malbec, Malvasia bianca, Mataro, Melon, Merlot, Meunier, Mission, Montua de Pilas, Muscadelle du Bordelais, Muscat blanc, Muscat Ottonel, Muscat Saint-Vallier, Nebbiolo, Nebbiolo fino, Nebbiolo Lampia, Orange Muscat, Palomino, Pedro Ximenes, Petit Bouschet, Petite Sirah, Peverella, Pinot noir, Pinot Saint- George, Primitivo di Gioa, Red Veltliner, Refosco, Rkatsiteli, Royalty, Rubired, Ruby Cabernet, Saint-Emilion, Saint Macaire, Salvador, Sangiovese, Sauvignon blanc, Sauvignon gris, Sauvignon vert, Scarlet, Seibel 5279, Seibel 9110, Seibel 13053, Semillon, Servant, Shiraz, Souzao, Sultana Crimson, Sylvaner, Tannat, Teroldico, Tinta Madeira, Tinto cao, Touriga, Traminer, Trebbiano Toscano, Trousseau, Valdepenas, Viognier, alschriesling, White Riesling, and Zinfandel. 35. A method according to claim 33, wherein the Vitis scion cultivar or rootstock cultivar is a rootstock cultivar selected from the group consisting of Couderc 1202, Couderc 1613, Couderc 1616, Couderc 3309, Dog Ridge, Foex 33 EM, Freedom, Ganzin 1 (A x R #1) , Harmony, Kober 5BB, LN33, Millardet & de Grasset 41B, Millardet & de Grasset 420A, Millardet & de Grasset 101-14, Oppenheim 4 (S04), Paulsen 775, Paulsen 1045, Paulsen 1103, Richter 99, Richter 110, Riparia Gloire, Ruggeri 225, Saint-George, Salt Creek, Teleki 5A, Vitis rupestris Constantia, Vitis California , and Vitis girdiana . 36. A method according to claim 33, wherein the grapevine leafroll virus is selected from the group consisting of GLRaV-1, GLRaV-2, GLRaV-3, GLRaV-4, GLRaV-5, and GLRaV-6. 37. A method according to claim 33, wherein said transforming is AgroJacterium-mediated. 38. A method according to claim 37, wherein said transforming comprises: contacting tissue of the Vitis scion cultivar or rootstock cultivar with an inoculum of bacterium of the genus Agrobacterium transformed with an expression construct according to claims 26 and regenerating a transformed plant. 39. A method according to claim 38, wherein the tissue is selected from the group consisting of leaf tissue, root tissue, meristems, zygotic and somatic embryos, and anthers. 40. A method according to claim 33, wherein said transforming comprises: propelling particles at grape plant cells under conditions effective for the particles to penetrate into the cell interior and introducing an expression vector comprising the DNA molecule into the cell interior. 41. A method according to claim 40, wherein the vector is associated with the particles, whereby the vector is carried into the cell interior together with the particles. 42. A method according to claim 41, wherein the vector surrounds the cell and is drawn into the cell by the particle's wake. 43. A transgenic citrus scion cultivar or rootstock cultivar transformed with an expression system according to claim 26, wherein said vector is a plant transformation vector. 44. A transgenic citrus scion cultivar or rootstock cultivar according to claim 43, wherein the citrus scion cultivar or rootstock cultivar is selected from the group consisting of lemon, lime, orange, grapefruit, pineapple, and tangerine. 45. A transgenic citrus scion cultivar or rootstock cultivar according to claim 43, wherein the citrus scion cultivar or rootstock cultivar is selected from the group consisting of Joppa, Maltaise Ovale, Parson (Parson Brown) , Pera, Pineapple, Queen, Shamouti, Valencia, Tenerife, Imperial Doblefina, Washington Sanguine, Moro, Sanguinello Moscato, Spanish Sanguinelli, Tarocco, Atwood, Australian, Bahia, Baiana, Cram, Dalmau, Eddy, Fisher, Frost Washington, Gillette, LengNavelina, Washington, Satsuma Mandarin, Dancy, Robinson, Ponkan, Duncan, Marsh, Pink Marsh, Ruby Red, Red Seedless, Smooth Seville, Orlando Tangelo, Eureka, Lisbon, Meyer Lemon' , Rough Lemon, Sour Orange, Persian Lime, West Indian Lime, Bearss, Sweet Lime, Troyer Citrange, and Citrus trifoliata. 46. A method for producing a virus-resistant citrus scion cultivar or rootstock cultivar comprising: transforming citrus tissue with an expression vector according to claim 26. 47. A method according to claim 46, wherein said transforming is AgroJbacterium-mediated. 48. A method according to claim 46, wherein the tissue is selected from the group consisting of leaf tissue, root tissue, meristems, zygotic and somatic embryos, and anthers. 49. The method of claim 46 wherein said expression vector is introduced into plant cells by a biolistic method. 50. An antibody or binding portion thereof or probe recognizing the protein or polypeptide encoded by the DNA molecule according to any of claims 1 to 25. 51. An isolated protein or polypeptide corresponding to a protein or polypeptide of a grapevine leafroll virus encoded by a DNA molecule according to any of claims 1-25. 52. A method for detection of grapevine leafroll virus in a sample, said method comprising: providing an antibody or binding portion thereof recognizing the encoded protein or polypeptide according to any of claims 1 to 25; contacting the sample with the antibody or binding portion thereof; and detecting any reaction which indicates that grapevine leafroll virus is present in the sample using an assay system. 53. A method according to claim 55, wherein the assay system is selected from the group consisting of an enzyme- linked immunosorbent assay, a radioimmunoassay, a gel diffusion precipitin reaction assay, an immunodiffusion assay, an agglutination assay, a fluorescent immunoassay, a protein A immunoassay, and an immunoelectrophoresis assay. 54. A method for detection of grapevine leafroll virus in a sample, said method comprising: providing a nucleotide sequence of the DNA molecule according to any of claims 1 to 25 as a probe in a nucleic acid hybridization assay; contacting the sample with the probe; and detecting any reaction which indicates that grapevine leafroll virus is present in the sample. 55. A method for detection of grapevine leafroll virus in a sample: providing a nucleotide sequence of the DNA molecule according to any of claims 1 to 25 as a probe in a gene amplification detection procedure; contacting the sample with the probe; and detecting any reaction which indicates that grapevine leafroll virus is present in the sample.

Inventors: GONSALVES DENNIS, LING KAI-SHU, GONSALVES, DENNIS, LING, KAI-SHU
Applicants: CORNELL RES FOUNDATION INC, CORNELL RESEARCH FOUNDATION, INC.
Application year: 1996
Main classification: C12N15
IPC codes: C07K14, C12N9, C12N15